IDEXX Laboratories (IDXX) 10-K 17 Feb 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Feb. 05, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	IDEXX LABORATORIES INC /DE
Entity Central Index Key	874,716
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Well-known Seasoned Issuer	Yes
Entity Common Stock, Shares Outstanding		89,638,022
Entity Public Float			$ 5,849,454,087

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 128,994	$ 322,536
Marketable securities	213,591
Accounts receivable, net of reserves of $5,128 in 2015 and $4,306 in 2014	188,318	152,380
Inventories	188,833	160,342
Deferred income tax assets	39,829	37,689
Other current assets	62,069	86,451
Total current assets	821,634	759,398
Long-Term Assets:
Property and equipment, net	333,026	303,587
Goodwill	178,934	184,450
Intangible assets, net	55,909	65,122
Other long-term assets	85,490	71,654
Total long-term assets	653,359	624,813
TOTAL ASSETS	1,474,993	1,384,211
Current Liabilities:
Accounts payable	52,648	44,743
Accrued liabilities	205,530	195,351
Line of credit	573,000	549,000
Current portion of deferred revenue	25,583	31,812
Total current liabilities	856,761	820,906
Long-Term Liabilities:
Deferred income tax liabilities	49,389	41,688
Long-term debt	597,085	350,000
Long-term deferred revenue, net of current portion	27,055	21,665
Other long-term liabilities	28,698	32,363
Total long-term liabilities	702,227	445,716
Total liabilities	$ 1,558,988	$ 1,266,622
Commitments and Contingencies (Note 14)
Stockholders’ Equity (Deficit):
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 102,237 and 101,947 shares in 2015 and 2014, respectively	$ 10,258	$ 10,195
Additional paid-in capital	940,534	888,293
Deferred stock units: Outstanding: 240 and 235 units in 2015 and 2014, respectively	5,409	5,066
Retained earnings	318,356	1,675,299
Accumulated other comprehensive loss	(42,265)	(8,071)
Treasury stock, at cost: 12,242 and 54,574 shares in 2015 and 2014, respectively	(1,316,417)	(2,453,266)
Total IDEXX Laboratories, Inc. stockholders’ equity (deficit)	(84,125)	117,516
Noncontrolling interest	130	73
Total stockholders’ equity (deficit)	(83,995)	117,589
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$ 1,474,993	$ 1,384,211

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Consolidated Balance Sheets [Abstract]
Accounts receivable, reserves	$ 5,128	$ 4,306
Common stock, par value	$ 0.10	$ 0.10
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	102,237,000	101,947,000
Deferred stock units, outstanding	240,000	235,000
Treasury stock, shares	12,242,000	54,574,000

Consolidated Statements Of Inco

Consolidated Statements Of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue:
Product revenue	$ 974,933	$ 899,412	$ 854,531
Service revenue	626,959	586,395	522,527
Total revenue	1,601,892	1,485,807	1,377,058
Cost of Revenue:
Cost of product revenue	360,208	335,046	318,685
Cost of service revenue	351,414	334,645	302,255
Total cost of revenue	711,622	669,691	620,940
Gross profit	890,270	816,116	756,118
Expenses:
Sales and marketing	299,955	283,708	243,492
General and administrative	182,510	173,890	157,861
Research and development	99,681	98,263	88,003
Impairment charge	8,212
Income from operations	299,912	260,255	266,762
Interest expense	(29,239)	(15,429)	(5,386)
Interest income	2,468	1,729	1,885
Income before provision for income taxes	273,141	246,555	263,261
Provision for income taxes	81,006	64,604	75,467
Net income	192,135	181,951	187,794
Less: Net income (loss) attributable to noncontrolling interest	57	45	(6)
Net income attributable to IDEXX Laboratories, Inc. stockholders	$ 192,078	$ 181,906	$ 187,800
Earnings per Share:
Basic	$ 2.07	$ 1.82	$ 1.77
Diluted	$ 2.05	$ 1.79	$ 1.74
Weighted Average Shares Outstanding:
Basic	92,601	100,094	106,318
Diluted	93,649	101,503	107,970

Consolidated Statements Of Comp

Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Consolidated Statements Of Comprehensive Income [Abstract]
Net income	$ 192,135	$ 181,951	$ 187,794
Other comprehensive income, net of tax:
Foreign currency translation adjustments	(30,718)	(29,126)	(4,502)
Unrealized gain on net investment hedge	1,894
Unrealized gain (loss) on investments, net of tax expense (benefit) of ($93), ($63) and $165 in 2015, 2014, and 2013, respectively	(226)	(107)	279
Unrealized gain (loss) on derivative instruments:
Unrealized gain, net of tax expense of $3,736, $4,073 and $1,555 in 2015, 2014 and 2013, respectively	8,839	9,542	3,781
Less: reclassification adjustment for gains included in net income, net of tax expense of $5,853, $756 and $679 in 2015, 2014 and 2013, respectively	(13,983)	(2,002)	(1,890)
Unrealized gain (loss) on derivative instruments	(5,143)	7,540	1,891
Other comprehensive loss, net of tax	(34,194)	(21,693)	(2,332)
Comprehensive income	157,941	160,258	185,462
Less: comprehensive income (loss) attributable to noncontrolling interest	57	45	(6)
Comprehensive income attributable to IDEXX Laboratories, Inc.	$ 157,884	$ 160,213	$ 185,468

Consolidated Statements Of Com6

Consolidated Statements Of Comprehensive Income (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Consolidated Statements Of Comprehensive Income [Abstract]
Unrealized gain (loss) on investments, tax expense (benefit)	$ (93)	$ (63)	$ 165
Unrealized gain, tax expense	3,736	4,073	1,555
Reclassification adjustment for gains included in net income, tax expense	$ 5,853	$ 756	$ 679

Consolidated Statements Of Stoc

Consolidated Statements Of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Deferred Stock Units [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]	Total
Balance, value at Dec. 31, 2012	$ 10,016	$ 757,214	$ 4,630	$ 1,305,593	$ 15,954	$ (1,457,184)	$ 34	$ 636,257
Balance, shares at Dec. 31, 2012	100,160,000
Comprehensive Income:
Net income (loss)				187,800			(6)	187,794
Other comprehensive loss, net					(2,332)			(2,332)
Repurchases of common stock						(372,194)		(372,194)
Common stock issued under stock plans, including excess tax benefit, value	$ 103	51,861	(38)					51,926
Common stock issued under stock plans, including excess tax benefit, shares	1,028,000
Deferred stock units activity		(259)	448					189
Share-based compensation cost		16,504	70					16,574
Balance, value at Dec. 31, 2013	$ 10,119	825,320	5,110	1,493,393	13,622	(1,829,378)	28	518,214
Balance, shares at Dec. 31, 2013	101,188,000
Comprehensive Income:
Net income (loss)				181,906			45	181,951
Other comprehensive loss, net					(21,693)			(21,693)
Repurchases of common stock						(623,888)		(623,888)
Common stock issued under stock plans, including excess tax benefit, value	$ 76	45,162						45,238
Common stock issued under stock plans, including excess tax benefit, shares	759,000
Deferred stock units activity		(218)	(114)					(332)
Share-based compensation cost		18,029	70					18,099
Balance, value at Dec. 31, 2014	$ 10,195	888,293	5,066	1,675,299	(8,071)	(2,453,266)	73	$ 117,589
Balance, shares at Dec. 31, 2014	101,947,000							101,947,000
Comprehensive Income:
Net income (loss)				192,078			57	$ 192,135
Other comprehensive loss, net					(34,194)			(34,194)
Repurchases of common stock						(412,172)		(412,172)
Stock split enacted through stock dividend				(1,518,264)		1,518,264
Shares retired, value				(30,757)		30,757
Shares retired, shares	(346,000)
Common stock issued under stock plans, including excess tax benefit, value	$ 63	32,700						32,763
Common stock issued under stock plans, including excess tax benefit, shares	636,000
Deferred stock units activity		(258)	258
Share-based compensation cost		19,799	85					19,884
Balance, value at Dec. 31, 2015	$ 10,258	$ 940,534	$ 5,409	$ 318,356	$ (42,265)	$ (1,316,417)	$ 130	$ (83,995)
Balance, shares at Dec. 31, 2015	102,237,000							102,237,000

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash Flows from Operating Activities:
Net income	$ 192,135	$ 181,951	$ 187,794
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	68,956	58,888	54,596
Amortization on marketable securities, net	1,432
Impairment charge	8,212
Provision for uncollectible accounts	2,200	2,035	1,601
Provision for deferred income taxes	5,143	830	2,073
Share-based compensation expense	19,884	18,099	16,539
Other	(472)	(160)	614
Tax benefit from share-based compensation arrangements	(11,315)	(16,078)	(14,158)
Changes in assets and liabilities:
Accounts receivable	(50,142)	(3,626)	(15,946)
Inventories	(34,969)	(38,310)	(1,347)
Accounts payable	(2,468)	6,703	(4,399)
Deferred revenue	(319)	14,195	6,442
Other assets and liabilities	18,087	11,319	12,187
Net cash provided by operating activities	216,364	235,846	245,996
Cash Flows from Investing Activities:
Purchases of property and equipment	(82,921)	(60,523)	(77,612)
Purchase of marketable securities	(271,958)
Proceeds from the sale and maturities of marketable securities	56,775
Proceeds from disposition of pharmaceutical product lines			3,500
Proceeds from sale of equity investment		5,400
Acquisitions of intangible assets		(175)	(1,024)
Acquisitions of a businesses, net of cash acquired	(10,302)	(25,115)	(10,923)
Net cash used by investing activities	(308,406)	(80,413)	(86,059)
Cash Flows from Financing Activities:
Borrowings on revolving credit facilities, net	24,000	272,000	65,000
Issuance of senior notes	250,097	200,000	150,000
Debt issue costs	(1,380)	(1,406)	(976)
Payment of notes payable		(1,394)	(1,107)
Repurchases of common stock	(401,981)	(618,158)	(367,761)
Proceeds from exercises of stock options and employee stock purchase plans	22,397	29,442	38,235
Tax benefit from share-based compensation arrangements	11,315	16,078	14,158
Net cash used by financing activities	(95,552)	(103,438)	(102,451)
Net effect of changes in exchange rates on cash	(5,948)	(8,517)	(2,414)
Net increase (decrease) in cash and cash equivalents	(193,542)	43,478	55,072
Cash and cash equivalents at beginning of period	322,536	279,058	223,986
Cash and cash equivalents at end of period	128,994	322,536	279,058
Supplemental Disclosures of Cash Flow Information:
Interest paid	27,187	12,284	5,024
Income taxes paid	$ 54,877	$ 60,239	$ 67,721

Nature Of Business, Basis Of Pr

Nature Of Business, Basis Of Presentation And Principles Of Consolidation	12 Months Ended
	Dec. 31, 2015
Nature Of Business, Basis Of Presentation And Principles Of Consolidation [Abstract]
Nature Of Business, Basis Of Presentation And Principles Of Consolidation	NOTE 1. NATURE OF BUSINESS, BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION The accompanying consolidated financial statements of IDEXX Laboratories, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and with the requirements of Regulation S-X. These statements include the accounts of IDEXX Laboratories, Inc. and our wholly-owned and majority-owned subsidiaries (“IDEXX,” the “Company,” “we” or “our”). We do not have any variable interest entities for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation. We develop, manufacture and distribute products and provide services for the veterinary, bioresearch, water, livestock, poultry and dairy markets. We also sell a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Our principal line of business, which we refer to as our Companion Animal Group (“CAG”) operating segment, provides diagnosti c capabilities and information management solutions for the veterinary market as well as and biological materials testing and services for the bioresearch market. Our principal markets for these products and services are the United States (“U.S.”) and Europe, but we also sell to customers and distributors in many other countries around the world. Ou r Water operating segment provides innovative testing solutions for the quality and safety of water in our principal markets the U.S. and Europe, but we also sell to customers in many other countries around the world. Our Livestock, Poultry and Dairy (“LPD”) operating segment provides diagnostic tests and related instrumentation and performs services that are used to manage the health status of livestock and poultry, to improve bovine reproductive efficiency, and to ensure the quality and safety of milk and food. Our principal market s for these products and services is Europe, China and Australia but we also sell to customers in many other countries around the world. We also operate a smaller operating segment that comprises products for the human point-of-care medical diagnostics market (“OPTI Medical”). Financial information about the OPTI Medical operating segment is combined and presented with our pharmaceutical product line and out-licensing arrangements remaining from our pharmaceutical business in an “Other” category because they do not meet the quantitative or qualitative thresholds for reportable segments. See Note 15 for additional information regarding our reportable operating segments, products and services and geographical areas. Stock Split On May 6, 2015, we announced a two -for-one split of our outstanding shares of common stock which was effected through a stock dividend that was paid through the issuance of treasury shares. The stock split entitled each stockholder of record at the close of business on May 18, 2015 to receive one additional share of common stock for each outstanding share of common stock held. The additional shares of our common stock paid pursuant to the stock split were distributed by the Company’s transfer agent on June 15, 2015. All share and per share amounts in the consolidated balance sheets, consolidated statement of operations and notes to the consolidated financial statements retroactively reflect the effect of the stock split unless otherwise noted. Reclassificatio ns Certain prior year amounts have been reclassified to conform with the current year presentation. Reclassifications had no material impact on previously reported results of operations, financial position or cash flows.

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) Estimates The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate these estimates, including those related to reserves for accounts receivable; goodwill and other intangible assets; income taxes; inventory valuation; revenue recognition, product returns, customer programs and multiple element arrangements; share-based compensation; warranty reserves; self-insurance reserves; fair value measurements and loss contingencies. We accrue contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. ( b ) Cash and Cash Equivalents We consider all highly liquid investments with original maturities of ninety days or less to be cash equivalents. Cash and cash equivalents consist primarily demand dep osits, money market funds and short duration agency bonds and commercial paper as described above. There is no restricted cash on our consolidated balance sheet for the years ended December 31, 2015 and 2014. (c) Marketable Securities During the year ended December 31, 2015, we purchased marketable debt securities, which are classified as available-for-sale and carried at fair valu e in the accompanying consolidated balance sheets on a trade date basis. We have classified our investments with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. Unrealized holding gains and losses are deferred within accumulated other comprehensive income (“AOCI”), net of applicable taxes, except for when an impairment is determined to be other-than-temporary or the security is divested prior to maturity. Wi thin the accompanying consolidated statements of operations, interest earned and amortization of premiums or discounts on marketable securities are included in interest income, realized gains and losses on the sale of our marketable securities are included in other income. (d ) Inventories Inventories, which are stated at the lower of cost (first-in, first-out) or market, include material, conversion costs and inbound freight charges. We write down the carrying value of inventory for estimated obsolescence by an amount equal to the difference between the cost of inventory and the estimated market value when warranted based on assumptions of future demand, market conditions, remaining shelf life, or product functionality. If actual market conditions or results of estimated functionality are less favorable than those we estimated, additional inventory write-downs may be required, which would have a negative effect on results of operations. (e ) Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation and amortization. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to expense as incurred. When an item is sold or retired, the cost and related accumulated depreciation is relieved, and the resulting gain or loss, if any, is recognized in the consolidated statements of income. We provide for depreciation and amortization primarily using the straight-line method by charges to income in amounts that allocate the cost of property and equipment over their estimated useful lives as follows: Asset Classification Estimated Useful Life Land improvements 15 to 20 years Buildings and improvements 15 to 40 years Leasehold improvements Shorter of remaining lease term or useful life of improvements Machinery and equipment 3 to 8 years Office furniture and equipment 3 to 7 years Computer hardware and software 3 to 7 years We capitalize interest on the acquisition and construction of significant assets that require a substantial period of time to be made ready for use. The capitalized interest is included in the cost of the completed asset and depreciated over the asset’s estimated useful life. The amount of interest capitalized during the years ended December 31, 2015 and 2014 was not material. We capitalize certain costs incurred in connection with developing or obtaining software designated for internal use based on three distinct stages of development. Qualifying costs incurred during the application development stage, which consist primarily of internal payroll and direct fringe benefits and external direct project costs, including labor and travel, are capitalized and amortized on a straight-line basis over the estimated useful life of the asset. Costs incurred during the preliminary project and post-implementation and operation phases are expensed as incurred. These costs are general and administrative in nature and relate primarily to the determination of performance requirements, data conversion and training. Software developed to deliver hosted services to our customers has been designated as internal use. See Note 7 for further information regarding costs capitalized in connection with software developed for internal use. (f ) Goodwill and Other Intangible Assets A significant portion of the purchase price for acquired businesses is generally assigned to intangible assets. Intangible assets other than goodwill are initially valued at fair value. If a quoted price in an active market for the identical asset is not readily available at the measurement date, the fair value of the intangible asset is estimated based on discounted cash flows using market participant assumptions, which are assumptions that are not specific to IDEXX. The selection of appropriate valuation methodologies and the estimation of discounted cash flows require significant assumptions about the timing and amounts of future cash flows, risks, appropriate discount rates, and the useful lives of intangible assets. When material, we utilize independent valuation experts to advise and assist us in determining the fair values of the identified intangible assets acquired in connection with a business acquisition and in determining appropriate amortization methods and periods for those intangible assets. Goodwill is initially valued based on the excess of the purchase price of a business combination over the fair value of acquired net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Our business combinations regularly include contingent consideration arrangements that require additional consideration to be paid based on the achievement of established objectives, most commonly surrounding the retention of customers during the post-combination period. We assess contingent consideration to determine if it is part of the business combination or if it should be accounted for separately from the business combination in the post-combination period. Contingent consideration is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved, with changes in fair value recognized in earnings. Changes in fair value of contingent consideration and differences arising upon settlement were not material during the years ended December 31, 2015, 2014 and 2013. See Note 3 for additional information regarding contingent consideration arising from recent business acquisitions. We provide for amortization primarily using the straight-line method by charges to income in amounts that allocate the intangible assets over their estimated useful lives as follows: Asset Classification Estimated Useful Life Patents 13 years Product rights (1) 5 to 15 years Customer-related intangible assets (2) 5 to 17 years Noncompete agreements 3 to 5 years (1) Product rights comprise certain technologies, intellectual property, licenses and trade names acquired from third parties. (2) Customer-related intangible assets comprise customer lists and customer relationships acquired from third parties. We assess goodwill for impairment annually, at the reporting unit level, in the fourth quarter and whenever events or circumstances indicate impairment may exist. In evaluating goodwill for impairment, we have the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. The more-likely-than-not threshold is defined as having a likelihood of more than 50 percent. If, after assessing the totality of events or circumstances, we determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, we would then perform step one of the two-step impairment test; otherwise, no further impairment test would be required. In contrast, we can opt to bypass the qualitative assessment for any reporting unit in any period and proceed directly to step one of the two-step impairment test. Doing so does not preclude us from performing the qualitative assessment in any subsequent period. In the fourth quarters of 2015 and 2014, we elected to bypass the qualitative approach and instead proceeded directly to step one of the two-step impairment test to assess the fair value of all of our reporting units. As part of step one of the two-step impairment test, we estimate the fair values of applicable reporting units using an income approach based on discounted forecasted cash flows. We make significant assumptions about the extent and timing of future cash flows, growth rates and discount rates. Model assumptions are based on our projections and best estimates, using appropriate and customary market participant assumptions. In addition, we make certain assumptions in allocating shared assets and liabilities to individual reporting units in determining the carrying value of each reporting unit. Changes in forecasted cash flows or the discount rate would affect the estimated fair values of our reporting units and could result in a goodwill impairment charge in a future period. No goodwill impairments were identified during the years ended December 31, 2015, 2014 or 2013. We assess the realizability of intangible assets other than goodwill whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If an impairment review is triggered, we evaluate the carrying value of intangible assets based on estimated undiscounted future cash flows over the remaining useful life of the primary asset of the asset group and compare that value to the carrying value of the asset group. The cash flows that are used contain our best estimates, using appropriate and customary assumptions and projections at the time. If the net carrying value of an intangible asset exceeds the related estimated undiscounted future cash flows, an impairment to write the intangible asset to its fair value would be reported as a non-cash charge to earnings. If necessary, we would calculate the fair value of an intangible asset using the present value of the estimated future cash flows to be generated by the intangible asset, and applying a risk-adjusted discount rate. Impairments of our intangible assets during the years ended December 31, 2015, 2014 and 2013 were not material. See Note 9 for further information regarding our goodwill and intangible assets. (g ) Warranty Reserves We provide a standard twelve month warranty on all instruments sold. We recognize the cost of instrument warranties in cost of product revenue at the time revenue is recognized based on the estimated cost to repair the instrument over its warranty period. Cost of product revenue reflects not only estimated warranty expense for instruments sold in the current period, but also any changes in estimated warranty expense for the portion of the aggregate installed base that is under warranty. Estimated warranty expense is based on a variety of inputs, including historical instrument performance in the customers’ environment, historical costs incurred in servicing instruments and projected instrument reliability. Should actual service rates or costs differ from our estimates, revisions to the estimated warranty liability would be required. The liability for warranties is included in accrued liabilities in the accompanying consolidated balance sheets. ( h ) Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the estimated future tax effects of temporary differences between book and tax treatment of assets and liabilities and carryforwards to the extent they are realizable. We record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. While we consider future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for a valuation allowance, in the event we were to determine that we would be able to realize our deferred tax assets in the future in excess of the net recorded amount, a reduction of the valuation allowance would increase income in the period such determination was made. Likewise, should we determine that we would not be able to realize all or part of our net deferred tax asset in the future, a reduction to the deferred tax asset would be charged to income in the period such determination was made. We record a liability for uncertain tax positions that do not meet the more likely than not standard as prescribed by the authoritative guidance for income tax accounting. We record tax benefits for only those positions that we believe will more likely than not be sustained. Unrecognized tax benefits are the differences between tax positions taken, or expected to be taken, in tax returns, and the benefits recognized for accounting purposes. Significant judgment is required in determining our worldwide provision for income taxes and our income tax filings are regularly under audit by tax authorities. Any audit result differing from amounts recorded would increase or decrease income in the period that we determine such adjustment is likely. Interest expense and penalties associated with the underpayment of income taxes are included in income tax expense. See Note 12 for additional information regarding income taxes. (i ) Taxes Remitted to Governmental Authorities by IDEXX on Behalf of Customer We calculate, collect from our customers, and remit to governmental authorities sales, value-added and excise taxes assessed by governmental authorities in connection with revenue-producing transactions with our customers. We report these taxes on a net basis and do not include these tax amounts in revenue or cost of product or service revenue. ( j ) Revenue Recognition We recognize revenue when four criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. Revenue-generating transactions generally fall into one of the following categories of revenue recognition: · We recognize revenue from the sales of consumables, rapid assay test kits and other diagnostic products when the product is delivered to the customer, except as noted below. · We recognize revenue from the sales of instruments, non-cancelable software licenses and hardware systems upon installation and the customer’s acceptance of the instrument or system as we have no significant further obligations after this point in time. · We recognize service revenue at the time the service is performed. · We recognize revenue associated with extended maintenance agreements (“EMAs”) and our software-as-a-service subscriptions over the life of the contracts using the straight-line method, which approximates the expected timing in which applicable services are performed. Amounts collected in advance of revenue recognition are recorded as current or long-term deferred revenue based on the time from the balance sheet date to the future date of revenue recognition. · We recognize revenue on certain instrument systems under rental programs over the life of the rental agreement using the straight-line method. Amounts collected in advance of revenue recognition are recorded as current or long-term deferred revenue based on the time from the balance sheet date to the future date of revenue recognition. · We recognize revenue on practice management systems sales, where the system includes software that is considered more than incidental, either by allocating the revenue to each element of the sale based on relative fair values of the elements, including post-contract support when fair value for all elements is available, or by use of the residual method when only the fair value of the post-contract support is available. We recognize revenue for the system upon installation and customer acceptance and recognize revenue equal to the fair value of the post-contract support over the support period. · Shipping costs reimbursed by the customer are included in revenue. These same costs are also included in cost of product revenue. Multiple Element Arrangements (“MEAs”) . Arrangements to sell products to customers frequently include multiple deliverables. Our most significant MEAs include the sale of one or more of the instruments from the IDEXX VetLab suite of analyzers, di agnostic imaging systems or practice management software, combined with one or more of the following products: EMAs, consumables and reference laboratory diagnostic and consulting services. Practice management software is frequently sold with post-contract customer support and implementation services. Delivery of the various products or performance of services within the arrangement may or may not coincide. Delivery of our IDEXX VetLab instruments, di agnostic imaging systems, and practice management software generally occurs at the onset of the arrangement. EMAs, consumables, and reference laboratory diagnostic and consulting services typically are delivered over future periods, generally one to six years . In certain arrangements, revenue recognized is limited to the amount invoiced or received that is not contingent on the delivery of products and services in the future. W e allocate revenue to each element based on the relative selling price and recognize revenue when the elements have standalone value and the four criteria for revenue recognition, as discussed above, have been met for each element. If available, we establish the selling price of each element based on vendor-specific objective evidence (“VSOE”), which represents the price charged for a deliverable when it is sold separately. We use third-party evidence (“TPE”) if VSOE is not available or best estimate of selling price if neither VSOE nor TPE is available. When these arrangements include a separately-priced EMA, we recognize revenue related to the EMA at the stated contractual price on a straight-line basis over the life of the agreement to the extent the separately stated price is substantive. If there is no stated contractual price for an EMA, or the separately stated price is not substantive, we allocate revenue to each element based on the relative selling price and recognize revenue when the elements have standalone value and the four criteria for revenue recognition, as discussed above, have been met for each element . When arrangements within the scope of software revenue recognition guidance include multiple elements, we allocate revenue to each element based on relative fair value, when VSOE exists for all elements, or by using the residual method when there is VSOE for the undelivered elements but no such evidence for the delivered elements. Under the residual method, the fair value of the undelivered elements is deferred and the residual revenue is allocated to the delivered elements. Revenue is recognized on any delivered elements when the four criteria for revenue recognition have been met for each element. If VSOE does not exist for the undelivered element, all revenue from the arrangement is deferred until the earlier of the point at which such sufficient VSOE does exist or all elements of the arrangement have been delivered. We determine fair value based on amounts charged separately for the delivered and undelivered elements to similar customers in standalone sales of the specific elements. Certain arrangements with customers include discounts on future sales of products and services. We apply judgment in determining whether future discounts are significant and incremental. When the future discount offered is not considered significant and incremental, we do not account for the discount as an element of the original arrangement. If the future discount is significant and incremental, we recognize that discount as an element of the original arrangement and allocate the discount to the other elements of the arrangement based on relative selling price. To determine whether a discount is significant and incremental, we look to the discount provided in comparison to standalone sales of the same product or service to similar customers, the level of discount provided on other elements in the arrangement, and the significance of the discount to the overall arrangement. If the discount in the MEA approximates the discount typically provided in standalone sales, that discount is not considered incremental. Customer Programs . We record reductions to revenue related to customer marketing and incentive programs, which include end-user rebates and other volume-based incentives. Incentives may be provided in the form of IDEXX Points, credits or cash and are earned by end users upon achieving defined volume purchases or utilization levels or upon entering an agreement to purchase products or services in future periods. Our most significant customer programs are categorized as follows: Customer Loyalty Programs . Our customer loyalty programs offer customers the opportunity to earn incentives on a variety of IDEXX products and services as those products and services are purchased and utilized. Revenue reductions related to customer loyalty programs are recorded based on the actual issuance of incentives, incentives earned but not yet issued and estimates of incentives to be earned in the future. Up-Front Customer Loyalty Programs . Our up-front loyalty programs provide incentives to customers in the form of cash payments or IDEXX Points upon entering multi-year agreements to purchase annual minimum amounts of future products or services. If a customer breaches its agreement, it is required to refund all or a portion of the up-front cash or IDEXX Poin ts, or make other repayments, remedial actions or both . These incentives are considered to be customer acquisition costs and are capitalized within other current assets and other long-term assets and are subsequently recognized as a reduction to revenue over the term of the customer agreement. If these up-front incentives are subsequently utilized to purchase I DEXX VetLab instruments, diagnostic imaging systems or Cornerstone practice management systems, product revenue and cost is deferred and recognized over the term of the customer agreement as products and services are provided to the customer. We monitor customer purchases over the term of their agreement to assess the realizability of our capitalized customer acquisition costs. For the years ended December 31, 2015, 2014 and 2013, impairments of customer acquisition costs were immaterial. IDEXX Instrument Marketing Programs . Our instrument marketing programs require the customer to enroll at the time of instrument purchase and offer customers the opportunity to earn incentives in future periods based on the volume of the products they purchase and utilize over the term of the program. These arrangements are considered MEAs in accordance with our revenue recognition policy stated above. Revenue reductions related to instrument marketing programs are recorded based on an estimate of customer purchase and utilization levels and the incentive the customer will earn over the term of the program. Our estimates are based on historical experience and the specific terms and conditions of the marketing program and require us to apply judgment to estimate future product purchases and utilization. Differences between our estimates and actual incentives earned are accounted for as a change in estimate. These differences were not material for the years ended December 31, 2015, 2014 and 2013. Reagent Rental Programs . Our reagent rental programs provide our customers the right to use our instruments in consideration for multi-year agreements to purchase annual minimum amounts of consumables. No instrument revenue is recognized at the time of instrument installation. We recognize a portion of the revenue allocated to the instrument concurrent with the future sale of consumables. We determine the amount of revenue allocated from the consumable to the instrument based on relative selling prices and determine the rate of instrument revenue recognition in proportion to the customer’s minimum volume commitment. The cost of the instrument is capitalized within property and equipment, and is charged to cost of product revenue on a straight-line basis over the term of the minimum purchase agreement. IDEXX Points may be applied against the purchase price of IDEXX products and s ervices or applied to trade receivables due to us. IDEXX Points that have not yet been used by customers are classified as a liability until use or expiration occurs. We estimate the amount of IDEXX Points expected to expire, or breakage, based on historical expirations and we recognize the estimated benefit of breakage in proportion to actual redemptions of IDEXX Points by customers. On November 30 of each year, unused IDEXX Points earned before January 1 of the prior year generally expire and any variance from the breakage estimate is accounted for as a change in estimate. This variance was not material for the years ended December 31, 2015, 2014 and 2013. Future market conditions and changes in product offerings may cause us to change marketing strategies to increase or decrease customer incentive offerings, possibly resulting in incremental reductions of revenue in future periods as compared to reductions in the current or prior periods. Additionally, certain customer programs require us to estimate, based on historical experience, and apply judgment to predict the number of customers who will actually redeem the incentive. In determining estimated revenue reductions we utilize data collected directly from end users, which includes the volume of qualifying products purchased and the number of qualifying tests run as reported to us by end users via IDEXX SmartService , a secure i nternet link that enables us to extract data and provide diagnostic service and support for certain IDEXX VetLab instruments through remote access. Differences between estimated and actual customer participation in programs may impact the amount and timing of revenue recognition. Doubtful Accounts Receivable . We recognize revenue when collection from the customer is reasonably assured. We maintain allowances for doubtful accounts for potentially uncollectible receivables. We base our estimates on a detailed analysis of specific customer situations and a percentage of our accounts rece ivable by aging category. Additional allowances may be required if either the financial condition of our customers were to deteriorate or a strengthening U.S. dollar impacts the ability of foreign customers to make payments to us on their U.S. denominated purchases . Account balances are charged off against the allowance when we believe it is probable the receivable will not be recovered. We do not have any off-balance sheet credit exposure related to our customers. We have no significant customers that accounted for greater than 10% of our consolidated revenues for the year ended December 31, 2015. Similarly, we have no concentration of credit risk as of December 31, 2015. (k ) Research and Development Costs Research and development costs, which consist of salaries, employee benefits, materials and external consulting and product development costs, are expensed as incurred. We evaluate our software research and development costs for capitalization after the technological feasibility of software and products containing software has been established. No costs were capitalized during the years ended December 31, 2015, 2014 and 2013. (l ) Advertising Costs Advertising costs, which are recognized as sales and marketing expense in the period in which they are incurred, were $ 1.2 million for each of the years ended December 31, 2015 and 2014 and $ 1.5 million for the year ended December 31, 2013. (m ) Legal Costs Legal costs are considered period costs and accordingly are expensed in the year services are provided. (n ) Share-Based Compensation We provide for various forms of share-based compensation awards to our employees and non-employee directors. With the exception of stock options, the fair value of our awards is equal to the closing stock price of IDEXX common stock on the date of grant. We calculate the fair value of our stock option awards using the Black-Scholes-Merton option-pricing model. Share-based compensation expense is recognized net of estimated forfeitures, on a straight-line basis over the requisite service period of the award. See Note 4 for additional information regarding share-based compensation. (o ) Self-Insurance Accruals We self-insure costs associated with workers’ compensation and health and general welfare claims incurred by our U.S. and Canadian employees up to certain limits. The insurance company provides insurance for claims above these limits. Claim liabilities are recorded for estimates of the loss that we will ultimately incur on reported claims, as well as estimates of claims that have been incurred but not yet reported. Such liabilities are based on individual coverage, the average time from when a claim is incurred to the time it is paid and judgments about the present and expected levels of claim frequency and severity. Estimated claim liabilities could be significantly affected if future occurrences and claims differ from these assumptions and historical trends. Estimated claim liabilities are included in accrued liabilities in the accompanying consolidated balance sheets. (p ) Leases The m ajority of our facilities are occupied under operating lease arrangements with various expiration dates through 2030 . W e are responsible for the real estate taxes and operating expenses related to these facilities. Additional ly , we enter into operating leases for certain vehicles and office equipment in the normal course of business . We determine the expected term of any executed agreements using the noncancelable lease term plus any renewal options by which the failure to renew imposes a penalty in such amount that renewal is reasonably assured. The derived expected term is then used in the determination of a capital or operating lease and in the calculation of straight-line rent expense. Rent escalations are considered in the calculation of minimum lease payments in our capital lease tests and in determining straight-line rent expense for operating leases. ( q ) Earnings per Share Basic earnings per share is computed by dividing net income attributable to IDEXX Laboratories, Inc. stockholders by the weighted average number of shares of common stock and vested deferred stock units outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and assumed issuance of unvested restricted stock units and unvested deferred stock units using the treasury stock method unless the

Acquisitions And Disposition Of

Acquisitions And Disposition Of Strategic Investment	12 Months Ended
	Dec. 31, 2015
Acquisitions And Disposition Of Strategic Investments [Abstract]
Acquisitions And Disposition of Strategic Investment	NOTE 3. ACQUISITIONS AND DISPOSITION OF STRATEGIC INVESTMENT We believe that our acquisitions of businesses and other assets enhance our existing businesses by either ex panding our geographic range and customer base or expanding our existing product lines. During the year ended December 31, 2015, we paid an aggregate of $7.5 million in cash and recorded contingent consideration of $3.2 million to acquire the assets of two reference laboratory diagnostic and consulting businesses, each accounted for as a separate business combination. As part of these business acquisitions, we recognized $5.2 million in customer list amortizable intangible assets, $5.0 million in goodwill, $1.1 million in working capital, $0.3 million in fixed assets and a deferred tax liability of $0.9 million. The customer lists were each assigned useful lives of 15 years. Goodwill is calculated as the consideration in excess of net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. The goodwill recorded from these business acquisitions is not deductible for income tax purposes. All assets acquired in connection with these business acquisitions were assigned to our CAG segment. One of the businesses acquired is located outside of the U.S. and, as such, the assets and liabilities recorded are subject to impacts of changes in foreign currency exchange rates. The results of operations of these acquired businesses have been included since the acquisition date. Pro forma information has not been presented for these business acquisitions because such information is not material to the financial statements. During the year ended December 31, 2014, we paid an aggregate of $25.1 million, to acquire seven businesses, each accounted for as separate business combinations. We paid an aggregate of $18.7 million in cash and recorded contingent consideration of $4.2 million upon the acquisition of substantially all outstanding shares of a business and the assets of two other businesses, all of which comprise cloud-based veterinary practice software. As part of the business acquisitions, we recorded $11.7 million in amortizable intangible assets and $12.4 million in goodwill. Amortizable intangible assets primarily consisted of customer lists and software which were assigned weighted average useful lives of 16.4 years and 7.0 years, respectively. The weighted average useful life of all recognized amortizable intangible assets wa s 11.4 years. Of the total goodwill and amortizable assets acquired, $5.6 million of a mortizable intangible assets are deductible for income tax purposes. All assets acquired in connection with these business combinations were assigned to our CAG segment. Two out of three businesses acquired are located outside of the U.S. and, as such, the assets and liabil ities recorded are subject to impacts of changes in foreign currency exchange rates. T he results of operations of these acquired business es have been included since the acquisition date. Pro forma information has not been p resented for these business acquisitions because such information is not material to the financial statements. We paid an aggregate of $6.2 million in cash and recorded contingent consideration of $1.5 million upon the acquisition of all outstanding shares of two veterinary reference laboratory testing businesses and to acquire the assets of two veterinary reference laboratory testing businesses. The purchase price in these business acquisitions was allocated primarily to customer list intangible assets, which were assigned a weighted average useful life of 13.3 years . $4.9 million of amortizable intangible assets associated with these acquisitions are deductible for income tax purposes. All assets acquired in connection with these business acquisitions were assigned to our CAG segment. Certain of these business acquisitions were of businesses located outside of the U.S. and, as such, the assets and liabilities recorded are subject to impacts of changes in foreign currency exchange rates. The results of operation s of these acquired business es have been included since the acquisition date. Pro forma information has not been presented for these business acquisitions because such information is not material to the financial statements. In June 2014, we divested our investment in a company that owns and operates veterinary hospitals. Upon the closing date, we received proceeds of $5.4 million in exchange for two outstanding promissory notes of the company and its subsidiaries and our 11% equity interest in the company. This investment has been accounted for under the equity method of accounting since acquisition in the fourth quarter of 2010. Upon the disposition of this strategic investment, we realized a $0.7 million gain, which has been reflected as a reduction to general and administrative. During the year ended December 31, 2013, we paid an aggregate of $10.8 million in cash to acquire all outstanding shares of a distributor of certain of our bovine and dairy test products, as well as other food safety testing products, in Brazil. As part of this business acquisition, we recorded $4.8 million in amortizable intangible assets other than goodwill and $6.5 million in goodwill. The amortizable assets acquired consisted of a customer list, non-compete agreement and a trademark, which were assigned useful lives of 10 , 5 , and 15 years, respectively. The weighted average useful life of all recognized amortizable intangible assets was 9.9 years. Additionally, we recorded $0.7 million of cash and cash equivalents, $1.0 million in working capital, $0.5 million of fixed assets , $2.1 million in other assets and net deferred tax liabilities of $1.7 million . W e deemed certain pre-acquisition contingent liabilities probable and recorded $3.1 million in other liabilities at December 31, 2013. The goodwill and amortizable intangible assets recorded from this business acquisition are not deductible for income tax purposes. All assets acquired in connection with this business acquisition were assigned to our LPD segment. The results of operation s of this acquired business have been included since the acquisition date. Pro forma information has not been presented for this business acquisition because such information is not material to the financial statements.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2015
Share-Based Compensation [Abstract]
Share-Based Compensation	NOTE 4. SHARE-BASED COMPENSATION Share-Based Awards Our share-based compensation plans allow for the issuance of a mix of stock options, restricted stock, stock appreciation rights, employee stock purchase rights and other stock unit awards. Other stock unit awards include restricted stock units (“RSUs”) and deferred stock units (“DSUs”). Stock options permit a holder to buy IDEXX stock upon vesting at the stock’s price on the date the option was granted. An RSU is an agreement to issue shares of IDEXX stock at the time of vesting. DSUs are granted under our Executive Deferred Compensation Plan (the “Executive Plan”) and non-employee Director Deferred Compensation Plan (the “Director Plan”) . DSUs may or may not have vesting conditions depending on the plan under w hich they are issued. We did no t issue any restricted stock or stock appreciation rights during t he years ended December 31, 2015 , 2014 and 2013 no r were any restricted stock or stock appreciation rights outstanding as of those years ended. There were no material modifications to the terms of outstanding options, RSUs or DSUs during t he years ended December 31, 2015, 2014 or 2013 . We primarily issue shares of common stock to satisfy stock option exercises and employee stock purchase rights and to settle RSUs and DSUs. We issue shares of treasury stock to settle certain RSU s and upon the ex ercise of certain stock options, which were not material for the years ended December 31, 2015, 2014 and 2013 . The number of shares of common stock and treasury stock issued are equivalent to the number of awards exercised or settled. With the exception of employee stock purchase rights, equity awards are issued to employees and non-employee directors under the 2009 Stock Incentive Pla n (the “2009 Stock Plan”). Our Board of D irectors has authorized the issuance of 19,900,000 shares of our common stock under this share-based incentive plan. Any shares that are subject to awards of stock options or stock appreciation rights will be counted against the share limit as one share for every share granted. Any shares that are issued other than stock options and stock appreciation rights will be counted against the share limit as two shares for every share granted. If any shares issued under our prior plans are forfeited, settled for cash or expire, these shares, to the extent of such forfeiture, cash settlement or expiration, will again be available for issuance under the 2009 Stock Plan. As of December 31, 2015, there were 12,538,049 remaining shares available for issuance under the 2009 Stock Plan. Employee stock purchase rights are issued under the 1997 Employee Stock Purchase Plan, under which we reserved and may issue up to an aggregate of 4,700,000 shares of common stock in periodic offerings. Under this plan, stock is sold to employees at a 15 % discount off the closing price of the stock on the last day of each quarter. The dollar value of t his discount is equal to the fair value of purchase rights recognized as share-based compensation. We issue d 105,000 , 93,000 and 110,000 shares of common stock in connection with the Employee Stock Purchase Plan during the years ended December 31, 201 5 , 201 4 and 201 3 , respectively. As of December 31, 201 5 , there were 1,393, 760 remainin g shares available for issuance under the 1997 Employee Stock Purchase Plan. Share-Based Compensation Share-based compensation costs are classified in our consolidated financial statements consistent with the classification of cash compensation paid to the employees receiving such share-based compensation. The following is a summary of share-based compensation costs and related tax benefits recorded in our consolidated statements of income for t he years ended December 31, 2015, 2014 and 2013 (in thousands) : For the Years Ended December 31, 2015 2014 2013 Share-based compensation expense included in cost of revenue $ 2,138 $ 1,937 $ 1,841 Share-based compensation expense included in operating expenses 17,746 16,162 14,733 Total share-based compensation expense included in consolidated statements of income 19,884 18,099 16,574 Income tax benefit resulting from share-based compensation arrangements (6,229 ) (6,107 ) (5,584 ) Net impact of share-based compensation on net income $ 13,655 $ 11,992 $ 10,990 Share-based compensation expense is reduced for an estimate of the number of awards that are expected to be forfeited. We use historical data and other factors to estimate expected employee terminations and to evaluate whether particular groups of employees have significantl y different forfeiture expectations . The total unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensation awards at December 31, 201 5 was $ 37. 8 million, which will be recognized over a weighted average period of approximately 1.6 years. Stock Options Option awards are granted with an exercise price equal to the closing market price of our common stock at the date of grant. Options granted to employees primarily vest ratably over five years on each anniversary of the date of grant and options granted to non-employee directors vest fully on the first anniversary of the date of grant. Vesting of option awards issued is conditional based on continuous service. Options granted after May 8, 2013 have a contractual term of ten years, options granted between January 1, 2006 and May 8, 2013 have contractual terms of seven years and options granted prior to January 1, 2006 have contractual terms of ten years. Upon any change in control of the company, 25% of the unvested stock options then outstanding will vest and become exercisable. However, if the acquiring entity does not assume outstanding options, then all options will vest immediately prior to the change in control. We use the Black-Scholes-Merton option-pricing model to determine the fair value of options granted. Option-pricing models require the input of highly subjective assumptions, particularly for the expected stock price volatility and the expected term of options. Changes in the subjective input assumptions can materially affect the fair value estimate. Our expected stock price volatility assumptions are based on the historical volatility of our stock over periods that are similar to the expected terms of grants and other relevant factors. We derive the expected term based on historical experience and other relevant factors concerning expected employee behavior with regard to option exercise. The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected term calculated at the date of grant. We have never paid any cash dividends on our common stock and we have no intention to pay a dividend at this time; therefore, we assume that no dividends will be paid over the expected terms of option awards. We determine the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at those grant dates. As such, we may use different assumptions for options granted throughout the year. The weighted averages of the valuation assumptions used to determine the fair value of each option award on the date of grant and the weighted average estimated fair values were as follows: For the Years Ended December 31, 2015 2014 2013 Expected stock price volatility 23 % 28 % 32 % Expected term, in years 5.6 5.7 4.9 Risk-free interest rate 1.5 % 1.5 % 1.0 % Weighted average fair value of options granted $ 19.72 $ 18.07 $ 13.59 A summary o f the status of options granted under our share-based compensation plans at December 31, 201 5 , and changes during the year then ended, are presented in the table below: Number of Options (000) Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value ($000) Outstanding as of December 31, 2014 3,560 $ 40.08 Granted 611 78.08 Exercised (675) 23.65 Forfeited (112) 53.64 Expired - Outstanding as of December 31, 2015 3,384 $ 49.76 4.8 $ 81,936 Fully vested as of December 31, 2015 1,748 $ 39.67 3.0 $ 58,132 Fully vested and expected to vest as of December 31, 2015 3,276 $ 49.41 4.7 $ 80,453 The total fair value of options vested during the years ended December 31, 201 5 , 201 4 and 201 3 wa s $ 8 .7 million, $ 7.8 million and $ 8 .4 million, respectively . Intrinsic value of stock options exercised represents the amount by which the market price of the common stock exceeded the exercise price, before applicable inc ome taxes. During the years ended December 31, 201 5 , 201 4 and 201 3 the total intrinsic value of stock options exercised was $35. 1 million, $51.2 million and $ 49. 0 million, respectively. Restricted Stock Units The majority of RSUs granted to employees vest ratably over five years on each ann iversary of the date of grant. RSUs granted to non-employee directors vest fully on the first anniversary of the date of grant. Vesting as it relates to RSUs issued is conditional based on continuous service . Upon any change in control of the company, 25% of the unvested RSUs then outstanding will vest, provided, however, that if the acquiring entity does not assume the RSUs, then all such units will vest immediately prior to the change in control. A summary of the status of RSUs granted under our share-based compensation plans at December 31, 201 5 , and changes during the period then ended, are presented in the table below: Number of Units (000) Weighted Average Grant-Date Fair Value Nonvested as of December 31, 2014 578 $ 47.98 Granted 153 78.46 Vested (196) 43.14 Forfeited (37) 56.01 Nonvested as of December 31, 2015 498 $ 58.94 Expected to vest as of December 31, 2015 456 $ 58.52 The total fair value of RSUs vested during the years ended December 31, 201 5 , 201 4 and 201 3 was $ 15. 3 million, $ 15. 4 million and $ 12. 7 million, respectively. The aggregate intrinsic value of nonvested RSUs as of December 31, 201 5 is equal to the fair value of IDEXX’s common stock as of December 31, 201 5 multiplied by the number of nonvested units as of December 31, 201 5 . Deferred Stock Units Under our Director Plan, non-employee directors may defer a portion of their cash fees in the form of vested DSUs. Prior to 2014, certain members of our management could elect to defer a portion of their cash compensation in the form of vested deferred stock units under our Executive Plan. Each DSU represents the right to receive one unissued share of our common stock. These recipients receive a number of DSUs equal to the amount of cash fees or compensation deferred divided by the closing sale price of the common stock on the date of deferral. Also under the Director Plan, non-employee directors are awarded annual grants of DSUs that vest fully on the first anniversary of the date of grant. Vesting for these annual DSU grants is conditional based on continuous service. DSUs are exchanged for a fixed number of shares of common stock, upon vesting if vesting criteria apply, subject to the limitations of the Director and Executive Plans and applicable law. There were approximately 240,000 and 235,000 vested DSUs outstanding under our share-based compensation plans as of December 31, 2015 and 2014 , respectively. Unvested DSUs as of December 31, 201 5 and 201 4 were not material.

Marketable Securities

Marketable Securities	12 Months Ended
	Dec. 31, 2015
Marketable Securities [Abstract]
Marketable Securities	NOTE 5 . MARKETABLE SECURITIES The amortized cost and fair value of marketable securities were as follows ( in thousands ): As of December 31, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Corporate bonds $ 177,810 $ 24 $ (221) $ 177,613 U.S. government bonds 12,881 - (10) 12,871 Agency bonds 12,068 - (3) 12,065 Certificates of deposit 3,500 - - 3,500 Commercial paper 3,491 - - 3,491 International government bonds 1,462 - (3) 1,459 Municipal bonds 1,400 - (1) 1,399 Treasury bill 1,192 1 - 1,193 Total marketable securities $ 213,804 $ 25 $ (238) $ 213,591 No marketable securities have been in a continuous unrealized loss position for more than twelve months. Our portfolio of marketable securities had an average AA- credit rating as of December 31, 2015. There were no marketable securities that we consider to be other-than-temporarily impaired as of December 31, 2015. Remaining contractual maturities of marketable securities were as follows ( in thousands ): As of December 31, 2015 Amortized Cost Fair Value Due in one year or less $ 147,735 $ 147,626 Due after one through two years 66,069 65,965 $ 213,804 $ 213,591

Inventories

Inventories	12 Months Ended
	Dec. 31, 2015
Inventories [Abstract]
Inventories	NOTE 6 . INVENTORIES The components of inventories are as follows (in thousands) : December 31, December 31, 2015 2014 Raw materials $ 31,184 $ 26,908 Work-in-process 18,698 16,859 Finished goods 138,951 116,575 Total inventories $ 188,833 $ 160,342

Property And Equipment, Net

Property And Equipment, Net	12 Months Ended
	Dec. 31, 2015
Property And Equipment, Net [Abstract]
Property And Equipment, Net	NOTE 7 . PROPERTY AND EQUIPMENT, NET Property and equipment, net, consisted of the following ( in thousands ) : December 31, December 31, 2015 2014 Land and improvements $ 7,357 $ 7,417 Buildings and improvements 162,146 159,298 Leasehold improvements 40,526 45,655 Machinery and equipment 224,100 183,575 Office furniture and equipment 39,334 35,696 Computer hardware and software 169,615 151,404 Construction in progress 35,546 20,890 678,624 603,935 Less accumulated depreciation and amortization 345,598 300,348 Total property and equipment, net $ 333,026 $ 303,587 Depreciation and amortization expense of property and equipment was $ 57. 0 million, $ 48.8 million and $ 42. 8 million for the years ended Dece mber 31, 2015, 2014 and 2013 , respectively. During the yea rs ended December 31, 2015, 2014 and 201 3 , we capitalized $19.1 million, $ 11.9 million and $ 10.9 million, respectively, related to computer software developed for internal use. We recorded an $8.2 million impairment charge related to internally-developed software not yet placed into service within Unallocated Amounts operating expenses during the year ended December 31, 2015 as a result of a strategic shift to refocus our development efforts within our information management business. Unpaid property and equipment reflected within accounts payable and accrued liabilities in our consolidated balance sheets at December 31, 2015, 2014, and 2013 totaled $8.5 million, $6.5 million, and $2.2 million, respectively.

Other Current and Noncurrent As

Other Current and Noncurrent Assets	12 Months Ended
	Dec. 31, 2015
Other Current and Noncurrent Assets [Abstract]
Other Noncurrent Assets	NOTE 8 . OTHER CURRENT AND NONCURRENT ASSETS Other current assets consisted of the following (in thousands) : December 31, December 31, 2015 2014 Prepaid expenses $ 27,244 $ 32,672 Taxes receivable 11,792 28,926 Customer acquisition costs, net 16,412 11,262 Other assets 6,621 13,591 Total other current assets $ 62,069 $ 86,451 Other noncurrent assets consisted of the following (in thousands) : December 31, December 31, 2015 2014 Investment in long-term product supply arrangements $ 12,165 $ 10,765 Customer acquisition costs, net 43,570 28,165 Other assets 29,755 32,724 Total other long-term assets $ 85,490 $ 71,654

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets, Net [Abstract]
Goodwill And Intangible Assets, Net	NOTE 9 . GOODWILL AND INTANGIBLE ASSETS, NET Intangible assets other than goodwill consisted of the following (in thousands) : December 31, 2015 December 31, 2014 Cost Accumulated Amortization Cost Accumulated Amortization Patents $ 2,192 $ 1,907 $ 4,871 $ 4,308 Product rights (1) 35,318 22,976 36,912 20,657 Customer-related intangible assets (2) 86,806 44,232 88,494 40,933 Noncompete agreements 1,413 705 1,125 382 $ 125,729 $ 69,820 $ 131,402 $ 66,280 (1) Product rights comprise certain technologies, licenses and trade names acquired from third parties. (2) Customer-related intangible assets are comprised of customer lists and customer relationships acquired from third parties. Amortization expense of intangible assets other than goodwill was $ 10.4 mi llion, $ 9.8 million and $ 9.7 million for the years ended December 31, 201 5 , 201 4 and 201 3 , respectively. The decrease in intangible assets other than goodwill during the twelve months ended December 31, 2015 was driven by amortization expense and changes in foreign currency exchange rates, partly offset by intangibles recognized in connection with the acquisition of businesses. At December 31, 2015 , the aggregate amortization expense associated with intangible assets is estimated to be as follows for each of the next five years and thereafter ( in thousands ): Amortization Expense 2016 $ 9,952 2017 9,144 2018 7,854 2019 6,541 2020 5,123 Thereafter 17,295 $ 55,909 The decrease in goodwill during the twelve months ended December 31, 2015 resulted from changes in foreign currency exchange rates, partly offset by goodwill recognized in connection with the acquisition of businesses. See Note 3 for information regarding goodwill and other intangible assets recognized in connection with the acquisition of businesses and other assets during the years ended December 31, 201 5 , 201 4 and 201 3 . The changes in the carrying amount of goodwill for t he years ended December 31, 2015, 2014, and 2013 were as follows ( in thousands ): CAG Water LPD Other Consolidated Total Balance as of December 31, 2012 $ 143,155 $ 14,179 $ 11,129 $ 6,531 $ 174,994 Business Combinations 250 - 6,491 - 6,741 Impact of Changes in Foreign Currency Exchange Rates (1,997) 336 447 - (1,214) Balance as of December 31, 2013 $ 141,408 $ 14,515 $ 18,067 $ 6,531 $ 180,521 Business Combinations 13,077 - - - 13,077 Impact of Changes in Foreign Currency Exchange Rates (6,334) (826) (1,988) - (9,148) Balance as of December 31, 2014 $ 148,151 $ 13,689 $ 16,079 $ 6,531 $ 184,450 Business Combinations 5,047 - - - 5,047 Impact of Changes in Foreign Currency Exchange Rates (8,007) (651) (1,905) - (10,563) Balance as of December 31, 2015 $ 145,191 $ 13,038 $ 14,174 $ 6,531 $ 178,934

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2015
Accrued Liabilities [Abstract]
Accrued Liabilities	NOTE 10 . ACCRUED LIABILITIES Accrued liabilities consisted of the following ( in thousands ): December 31, December 31, 2015 2014 Accrued expenses $ 65,665 $ 55,655 Accrued employee compensation and related expenses 77,027 75,232 Accrued taxes 18,963 28,439 Accrued customer programs 43,875 36,025 Total accrued liabilities $ 205,530 $ 195,351

Debt

Debt	12 Months Ended
	Dec. 31, 2015
Debt [Abstract]
Debt	NOTE 1 1 . DEBT Credit Facility In December 201 5 , we refinanced our existing $ 700 million unsecured revolving credit facility by entering into a second amended and restated credit agreement relating to a five-year unsecured revolving credit facility in the principal amount of $ 850 million with a syndicate of multinational banks, which matures on December 4, 2020 (the new credit facility and the prior credit facility are referred to collectively as the “Credit Facility”) and requires no scheduled prepayments before that date. Alt hough the Credit Facility does not mature until December 4 , 20 20 , all individual borrowings under the terms of the Credit Facility have a stated term between 30 and 180 days. At the end of each term, the obligation is either repaid or rolled over into a new borrowing. The Credit Facility contains a subjective material adverse event clause, which allows the debt holders to call the loans under the Credit Facility if we fail to provide prompt written notice to the syndicate of such an event. Based on the stated term and the existence of the subjective material adverse event clause, this Credit Facility is reflected in the current liabilities section of our consolidated balance sheets. At December 31, 2015 and 2014, we had $ 573.0 million and $ 549.0 million, respectively, outstanding under the Credit Facility with weighted average effective interest rates of 1.9 % and 1.5 %, respectively. The funds available under the Credit Facility at December 31, 2015 and December 31, 2014 reflect a further reduction due to the issuance of a letter of credit for $ 1.0 million, which was issued in connection with our workers’ compensation policy. Applicable interest rates on borrowings under the Credit Facility generally range from 0.875 to 1.375 percentage points (“Credit Spread”) above the London interbank offered rate, based on our leverage ratio, or the prevailing prime rate plus a maximum spread of up to 0.375 %, based on our leverage ratio. We have entered into forward fixed interest rate swap agreements to manage the economic effect of the first $ 80 million of variable interest rate borrowings. As such, we continue to designate the existing interest rate swaps as cash flow hedges. See Note 17 for a discussion of our derivative instruments and hedging activities. Under the Credit Facility, we pay quarterly commitment fees of 0.075 % to 0.25 %, based on our leverage ratio, on any unused commitment. Th e obligations under the Credit Facility may be accelerated upon the occurrence of an event of default under the Credit Facility, which includes customary events of default including payment defaults, defaults in the performance of the affirmative, negative and financial covenants, the inaccuracy of representations or warranties, bankruptcy and insolvency related defaults, defaults relating to judgments, certain events related to employee pension benefit plans under the Employee Retirement Income Security Act of 1974, the failure to pay specified indebtedness, cross-acceleration to specified indebtedness and a change of control default. The Credit Facility contains affirmative, negative and financial covenants customary for financings of this type. The negative covenants include restrictions on liens, indebtedness of subsidiaries of the Company, fundamental changes, investments, transactions with affiliates and certain restrictive agreements. The sole financial covenant is a consolidated leverage ratio test that requires our ratio of debt to earnings before interest, taxes, depreciation, amortization and share-based compensation defined as the consolidated leverage ratio under the terms of the Credit Facility, not to exceed 3.5 -to-1. At December 31, 2015, we were in compliance with the covenants of the Credit Facility. Senior Notes In December 2013, we issued and sold through a private placement an aggregate principal amount of $ 150 million of unsecured senior notes consisting of $75 million of 3.94% Series A Senior Notes due December 11, 2023 (the “2023 Notes”) and $75 million of 4.04% Series B Senior Notes due December 11, 2025 (the “2025 Notes” and together with the 2023 Notes, the “December Notes”) under a Note Purchase Agreement among the Company , New York Life Insurance Company and the accredited institutional purch asers named therein (the “December 2013 Note Agreement”). In July 2014, we issued and sold through a private placement an aggregate principal amount of $125 million of unsecured senior notes consisting of $75 million of 3.76% Series B Senior Notes due July 21, 2024 (the “2024 Notes”) and $50 million of 3.32% Series A Senior Notes due July 21, 2021 (the “2021 Notes” and together with the 2024 Notes, the “Prudential Notes”) under a Note Purchase and Private Shelf Agreement among the Company, Prudential Investment Management, Inc. (“Prudential”) and the accredited institutional purchasers named therein (the “July 2014 Note Agreement”). In September 2014, we issued and sold through a private placement an aggregate principal amount of $75 million of unsecured 3.72% senior notes due September 4, 2026 (the “2026 Notes”) under a Note Purchase Agreement dated as of July 22, 2014 among the Company, New York Life Insurance Company and the accredited institutional purchasers named therein (the “September 2014 Note Agreement”). In December 2014, we entered into a Multi -C urrency Note Purchase and Private Shelf Agreement among the Company, Metropolitan Life Insurance Company (“MetLife”) , and the accredited institutional purchasers named therein pursuant to which the Compan y agreed to issue and sell $75 million of its unsecured 3.25% Series A Senior Notes having a seven -year term , and $75 million of its unsecured 3.72% Series B Senior Notes having a twelve -year term. The issuance, sale and purchase of the se notes occurred in February 2015 (the “MetLife Notes”) . The agreement (the “December 2014 Note Agreement”) also provides for an uncommitted shelf facility by which the Company may request that MetLife purchase, over the subsequent three years, up to $50 million of additional senior promissory notes of the Company at a fixed interest rate to be determined at the time of purchase and with a maturity date not to exceed fifteen years. In June 2015, we entered into an Amended and Restated Multi-Currency Note Purchase and Private Shelf Agreement (the “Amended Agreement”), among the Company, Prudential Investment Management, Inc. and the accredited institutional purchasers named therein, which amends and restates the Note Purchase and Private Shelf Agreement dated July 21, 2014. We refer to the Amended Agreement together with the December 2013 Note Agreement, September 2014 Note Agreement, and December 2014 Note Agreement collectively as the “Senior Note Agreements”). Pursuant to the Amended Agreement, we issued and sold through a private placement a principal amount of €88 .9 million (approximately $100 million) of unsecured 1.785% Series C Senior Notes due June 18, 2025 (the “2025 Notes”). We refer to the 2025 Notes together with the Prudential Notes, December Notes, MetLife Notes and the 2026 Notes, collectively, as the “Senior Notes”) . We used the net proceeds from this issuance and sale of the 2025 Notes for general corporate purposes, including repaying amounts outstanding under our Credit Facility. The Amended Agreement also provides for an uncommitted shelf facility by which we may request that Prudential purchase, over the next three years, up to $75 million (or the foreign currency equivalent) of additional senior promissory notes of the Company at a fixed interest rate and with a maturity date not to exceed twelve years (the “Shelf Notes”). Prudential is under no obligation to purchase any of the Shelf Notes. The interest rate of any series of Shelf Notes will be determined at the time of purchase. The proceeds of any series of Shelf Notes are able to be used for general corporate purposes. The Senior Note Agreement s contain affirmative, negative and financial covenants customary for agreements of this type. The negative covenants include restrictions on liens, indebtedness of our subsidiaries, priority indebtedness, fundamental changes, investments, transactions with affiliates, certain restrictive agreements and violations of laws and regulations. The sole financial covenant is a consolidated leverage ratio test that requires our ratio of debt to earnings before i nterest, taxes, depreciation, amortization and share-based compensation , as defined in the Senior Note Agreement s , not to exceed 3.5 -to-1. At December 31, 2015 , we were in compliance with the covenants of the Senior Note Agreement s . Should we elect to prepay the Senior Notes, such aggregate prepayment will include the applicable make-whole amount(s), as defined within the applicable Senior Note Agreements. Additionally, in the event of a change in control of the Company or upon the disposition of certain assets of the Company the proceeds of which are not reinvested (as defined in the Senior Note Agreements), we may be required to prepay all or a portion of the Senior Notes. The obligations under the Senior Notes may be accelerated upon the occurrence of an event of default under the applicable Senior Note Agreement, each of which includes customary events of default including payment defaults, defaults in the performance of the affirmative, negative and financial covenants, the inaccuracy of representations or warranties, bankruptcy and insolvency related defaults, defaults relating to judgments, certain events related to employee pension benefit plans under the Employee Retirement Income Security Act of 1974, the failure to pay specified indebtedness and cross-acceleration to specified indebtedness. A nnual principal payments on long-term debt at December 31, 201 5 are as follows (in thousands ): Years Ending December 31, Amount 2016 $ - 2017 - 2018 - 2019 - 2020 - Thereafter 597,085 $ 597,085

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Taxes [Abstract]
Income Taxes	NOTE 1 2 . INCOME TAXES Earnings before income taxes were as follows ( in thousands ): For the Years Ended December 31, 2015 2014 2013 Domestic $ 187,200 $ 148,510 $ 184,086 International 85,941 98,045 79,175 $ 273,141 $ 246,555 $ 263,261 The provision (benefit) for income taxes comprised the following ( in thousands ): For the Years Ended December 31, 2015 2014 2013 Current Federal $ 52,966 $ 39,713 $ 50,999 State 5,353 4,692 5,639 International 17,681 20,213 16,657 76,000 64,618 73,295 Deferred Federal 5,762 2,301 3,203 State 526 33 329 International (1,282) (2,348) (1,360) 5,006 (14) 2,172 $ 81,006 $ 64,604 $ 75,467 The provision for income taxes differs from the amounts computed by applying the statutory federal income tax rate as follows: For the Years Ended December 31, 2015 2014 2013 U.S. federal statutory rate 35.0 % 35.0 % 35.0 % State income tax, net of federal tax benefit 1.6 1.5 1.5 International income taxes (5.3) (7.0) (4.6) Domestic manufacturing exclusions (1.5) (1.2) (1.4) Research and development credit (1.2) (1.3) (2.3) Other, net 1.1 (0.8) 0.5 Effective tax rate 29.7 % 26.2 % 28.7 % Our effective income tax rate was 29.7 % for the year ended December 31, 201 5 and 26.2 % for the year ended December 31, 201 4. The increase in our effective income tax rate for the year ended December 31, 2015, as compared to the year ended December 31, 2014, was related to lower relative earnings subject to international tax rates that are lower than domestic tax rates, including the impact of foreign currency exchange rates, as well as a non-recurring benefit recognized during period ended December 31, 2014 related to the deferral of inter-company profits that were included in prior year tax provisions in error, which is not material to prior interim or annual periods. Our effective income tax rate was 26.2 % for the year ended December 31, 201 4 and 28.7 % for the year ended December 31, 2013 . The decrease in our effective income tax rate for the year ended December 31, 2014, as compared to the year ended December 31, 2013, was related to higher relative earnings subject to international tax rates that are lower than domestic tax rates, a non-recurring benefit related to the deferral of intercompany profits that were included in prior year tax provisions in error, which is not material to current or prior interim or annual periods, and the resolution of domestic and international tax audits, which resulted in a net reduction in our provision for uncertain tax positions. These favorable factors were partly offset by a reduction in the benefit from the U.S. research and development (“R&D”) tax credit. During the three months ended March 31, 2013, legislation in the U.S. retroactively allowed the R&D tax credit for all of 2012 and extended the R&D tax credit through the year ended December 31, 2013. As a result, in the year ended December 31, 2013 we recorded the benefit of two years of R&D tax credit as compared to the year ended December 31, 2014 in which we have recorded only the benefit related to that year’s activities. We have business operations in Switzerland and the Netherlands and have been granted tax rulings by each jurisdiction. Our tax rulings in Switzerland expired December 31, 2015 and the Netherlands ruling is set to expire on December 31, 2022 . As a result of the tax rulings, our net income was higher by $ 8.5 million, $ 8.5 million and $ 6.5 million for the years ended December 31, 2015, 2014 and 201 3 , respectively. The benefit from these tax rulings is reflected within the overall benefit received from international income taxes in the table above. We consider the majority of the operating earnings of non-U.S. subsidiaries to be indefinitely invested outside the U.S. The cumulative earnings of these subsidiaries were $ 493.3 million at December 31, 2015. No provision has been made for U.S. federal and state, or international taxes that may result from future remittances of the undistributed earnings of non-U.S. subsidiaries. Should we repatriate these earnings in the future, we would have to adjust the income tax provision in the period in which the decision to repatriate earnings is made. A determination of the related tax liability that would be paid on these undistributed earnings if repatriated is not practicable for several reasons including the complexity of laws and regulations in the various jurisdictions where we operate, the varying tax treatment of potential repatriation scenarios and the timing of any future repatriation. For the operating earnings not considered to be indefinitely invested outside the U.S., we have accounted for the tax impact on a current basis. The components of the net deferred tax assets (liabilities) included in the accompanying consolidated balance sheets are as follows ( in thousands ): December 31, 2015 December 31, 2014 Current Long-Term Current Long-Term Assets Accrued expenses $ 23,298 $ 5,329 $ 20,377 $ 7,824 Accounts receivable reserves 2,973 - 2,591 - Deferred revenue 7,392 3,656 8,697 3,084 Inventory basis differences 3,292 293 3,154 347 Property-based differences - 1,524 - 1,601 Share-based compensation 2,565 10,580 2,490 8,936 Other 234 361 171 255 Net operating loss carryforwards 65 4,059 65 4,368 Unrealized losses on foreign currency exchange contracts, interest rate swaps and investments - 53 - - Total assets 39,819 25,855 37,545 26,415 Valuation allowance (507) (3,939) (457) (4,221) Total assets, net of valuation allowance 39,312 21,916 37,088 22,194 Liabilities Deferred instrument costs - (16,090) - (10,149) Property-based differences - (35,079) - (33,978) Intangible asset basis differences - (17,109) - (16,882) Other (550) (1,460) (610) (517) Unrealized gains on foreign currency exchange contracts, interest rate swaps and investments (882) - (2,603) - Total liabilities (1,432) (69,738) (3,213) (61,526) Net deferred tax assets (liabilities) $ 37,880 $ (47,822) $ 33,875 $ (39,332) We record a liability for uncertain tax positions that do not meet the more likely than not standard as prescribed by the authoritative guidance for income tax accounting. We record tax benefits for only those positions that we believe will more likely than not be sustained. Unrecognized tax benefits are the differences between tax positions taken, or expected to be taken, in tax returns, and the benefits recognized for accounting purposes. We classify certain uncertain tax positions as long-term liabilities. The total amount of unrecognized tax benefits at December 31, 201 5 a nd December 31, 201 4 was $ 7 . 2 million and $ 5 . 9 million, respectively. Of the total unrecognized tax benefits at December 31, 201 5 and 201 4 , $ 5.9 million and $ 5.0 million, respectively, comprise unrecognized tax positions that woul d, if recognized, affect our effective tax rate. The ultimate deductibility of the remaining unrecognized tax positions is highly certain but there is uncertainty about the timing of such deductibility. Because of the impact of deferred tax accounting, other than interest and penalties, the disallowance of the shorter deductibility period would not affect the annual effective tax rate but would accelerate the payment of cash to the taxing authority to an earlier period. During each of the years ended December 31, 201 5 , 201 4 and 201 3 , we recorded interest expense and penalties of $ 0.3 million as income tax expense in our consolidated statement of income. At December 31, 201 5 and 201 4 , we had $ 0.6 million and $ 0.5 million, respectively, of estimated interest expense and penalties accrued in our consolidated balance sheets. The following table summarizes the changes in unrecognized tax benefits during the years ended December 31, 201 5 , 201 4 and 201 3 ( in thousands ): For the Years Ended December 31, 2015 2014 2013 Total amounts of unrecognized tax benefits, beginning of period $ 5,942 $ 6,325 $ 5,906 Gross increases in unrecognized tax benefits as a result of tax positions taken during a prior period 47 432 8 Gross increases in unrecognized tax benefits as a result of tax positions taken in the current period 1,569 1,789 1,954 Decreases in unrecognized tax benefits relating to settlements with taxing authorities - (2,242) (317) Decreases in unrecognized tax benefits as a result of a lapse of the applicable statutes of limitations (354) (362) (1,226) Total amounts of unrecognized tax benefits, end of period $ 7,204 $ 5,942 $ 6,325 In the ordinary course of our business, our income tax filings are regularly under audit by tax authorities. While we believe we have appropriately provided for all uncertain tax positions, amounts asserted by taxing authorities could be greater or less than our accrued position. Accordingly, additional provisions on income tax matters, or reductions of pre viously accrued provisions, could be recorded in the future as we revise our estimates due to changing facts and circumstances or the underlying matters are settled or otherwise resolved. W e are currently under tax examinations by various state and international tax authorities. We anticipate that these examinations will be concluded within the next year. We are no longer subject to U.S. federal examinations for tax years before 2013 . With few exceptions, we are no longer subject to income tax examinations in any state and local, or international jurisdictions in which we conduct significant taxable activities for years before 2007 . At December 31, 201 5 , we had net operating loss carryforwards in certain state and international jurisdictions of approximately $ 31.5 million available to offset future taxable income. Most of these net operating loss carryforwards will expire at various dates through 2018 and the remainder have indefinite lives. We have recorded a valuation allowance of $ 4.4 million against certain deferred tax assets related to temporary differences including net operating loss carryforwards, as it is more likely than not that they will not be realized or utilized within the carryforward period.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share	NOTE 13 . EARNINGS PER SHARE The following is a reconciliation of shares outstanding for basic and diluted earnings per share for the years ended December 31, 2015, 2014 and 2013 ( in thousands ): For the Years Ended December 31, 2015 2014 2013 Shares outstanding for basic earnings per share: 92,601 100,094 106,318 Shares outstanding for diluted earnings per share: Shares outstanding for basic earnings per share 92,601 100,094 106,318 Dilutive effect of share-based payment awards 1,048 1,409 1,652 93,649 101,503 107,970 C ertain options to acquire shares have been excluded from the calculation of shares outstanding for dilutive earnings per share because they were anti-dilutive. The following table presents information concerning those anti-dilutive options for the years ended December 31, 2015, 2014 and 2013 (in thousands ): For the Years Ended December 31, 2015 2014 2013 Weighted average number of shares underlying anti-dilutive options 644 644 1,054

Commitments, Contingencies And

Commitments, Contingencies And Guarantees	12 Months Ended
	Dec. 31, 2015
Commitments, Contingencies And Guarantees [Abstract]
Commitments, Contingencies And Guarantees	NOTE 14 . COMMITMENTS, CONTINGENCIES AND GUARANTEES Commitments Rent expense charged to operations under operating leases was approximate ly $ 20.5 million, $ 17.2 mi llion and $ 15.8 million for the years ended December 31, 201 5 , 201 4 and 201 3 , respectively. Minimum annual rental payments under these agreements are estimated as follows ( in thousands ): Years Ending December 31, Amount 2016 $ 16,222 2017 14,005 2018 10,719 2019 7,321 2020 5,607 Thereafter 11,006 $ 64,880 We have various minimum royalty payments due through 2027 of $ 3.1 million. If these obligations are not satisfied, the related license arrangements may be terminated, resulting in either a loss in ex clusivity or the right to use the technology. We are required to annually purchase a minimum amount of inventory from certain suppliers. Through 2022, we have a total of $ 15.2 million in minimum purchase commitments under these arrangements. Contingencies We are subject to claims that arise in the ordinary course of business, including with respect to actual and threatened litigation and other matters. We accrue for loss contingencies when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. However, our actual losses with respect to these contingencies could exceed our accruals. Under our worker s ’ compensation insurance policies for U.S. employees, we have retained the first $300,000 , $300,000 and $250,000 in claim liability per incident with aggregate maximum claim liabilities per year of $3.5 million , $2.3 million and $2.0 million for the years ended December 31, 2015, 2014 and 2013, respectively. Workers’ compensation expense recognized during the years ended December 31, 2015, 2014 and 2013 and our respective liability for such claims as of December 31, 2015, 2014, and 2013 was not material. Claims incurred during the years ended December 31, 201 5 and 201 4 are relatively undeveloped as of December 31, 201 5 . Therefore, it is possible that we could incur additional healthcare and wage indemnification costs beyond those previously recognized up to our aggregate liability for each of the respective claim years. For the years ended on or prior to December 31, 201 3 , based on our retained claim liability per incident and our aggregate claim liability per year, our maximum liability in excess of the amounts deemed probable and previously recognized is not material as of December 31, 201 5 . As of December 31, 201 5 , we had outstanding letters of credit totaling $ 1.3 million to the insurance companies as security for these claims in connection with these policies. Under our current employee healthcare insurance policy for U.S. employees, we retain claims liability risk up to $ 425,000 , $ 375,000 and $325,000 per incident per year in 2015, 2014 and 2013, respectively. We recognized employee healthcare claim expense of $ 34.6 million, $ 32.0 million and $ 29.2 million during the years ended December 31, 2015, 2014 and 2 013, respectively, which represent s actual claims paid and an estimate of our liability for the uninsured portion of employee healthcare obligations that have been incurred but not paid. Should employee health insurance claims exceed our estimated liability, we would have further obligations. Our estimated liability for healthcare claims that have been incurred but not paid as of December 31, 2015 and 2014 was $ 4.8 million and $ 4.1 million, respectively. We have entered into an employment agreement with our chief executive officer whereby payment may be required if we terminate his employment without cause other than following a change in control. The amount payable is based upon the executive’s salary at the time of termination and the cost to us of continuing to provide certain benefits. Had this officer been terminated without cause at December 31, 201 5 , other t han following a change in control, we would have had an obligation for salaries and benefits of approximately $ 1.6 million u nder such agreement. In addition, the agreement provides for continued vesting of his outstanding equity awards for a period of two years . We have entered into employment agreements with each of our officers that require us to make certain payments in the event the officer’s employment is terminated under certain circumstances within a certain period following a change in control. The amount payable by us under each of these agreements is based on the officer’s salary and bonus history at the time of termination and the cost to us of continuing to provide certain benefits. Had all of our officers been terminated in qualifying terminations following a change in control at December 31, 2015, we would have had aggregate obligations of approximately $ 26.4 million under these agreements. These agreements also provide for the acceleration of the vesting of all stock options and restricted stock units upon any qualifying termination following a change in control. At this time, we believe the likelihood of terminations as a result of the scenarios described is remote, and therefore, we have not accrued for such loss contingencies. We have total contingent consideration liabilities outstanding of up to $ 11.4 million primarily related to the achievement of certain revenue milestones. We have recorded $5.9 and $6.3 million of contingent consideration liabilities on our consolidated balance sheets at December 31, 2015 and 2014, respecti vely. We have not accrued for $5.5 million of contingent consideration liabilities, related to the acquisition of an intangible asset in 2008, as we do not deem the achievement of associated revenue milestones to be probable of occurring as of December 31, 2015. From time to time, we have received notices alleging that our products infringe third-party proprietary rights, although we are not aware of any pending litigation with respect to such claims. Patent litigation frequently is complex and expensive, and the outcome of patent litigation can be difficult to predict. There can be no assurance that we will prevail in any infringement proceedings that may be commenced against us. If we lose any such litigation, we may be stopped from selling certain products and/or we may be required to pay damages as a result of the litigation. Guarantees We enter into agreements with third parties in the ordinary course of business under which we are obligated to indemnify such third parties for and against various risks and losses. The precise terms of such indemnities vary with the nature of the agreement. In many cases, we limit the maximum amount of our indemnification obligations, but in some cases those obligations may be theoretically unlimited. We have not incurred material expenses in discharging any of these indemnification obligations, and based on our analysis of the nature of the risks involved, we believe that the fair value of these agreements is minimal. Accordingly, we have recorded no liabilities for these obligations at December 31, 201 5 and 201 4 . When acquiri ng a business, we sometimes assume liability for certain events or occurrences that took place prior to the date of acquisition. We have recor ded $ 1.4 millio n and $2.5 million of probable pre-acquisition liabilities in the accompanying consolidated balance sheets at December 31, 201 5 and 2014 , respectively.

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segment Reporting	NOTE 15 . SEGMENT REPORTING We operate primarily through three business segments: diagnostic and information technology-based products and services for the veterinary market, which we refer to as CAG; water quality products (“Water”); and diagnostic products and services for livestock and poultry health and to ensure the quality and safety of milk and food, which we refer to as LPD. Our Other operating segment combines and presents products for the human point-of-care medical diagnostics market with our pharmaceutical product line and our out-licensing arrangements because they do not meet the quantitative or qualitative thresholds for reportable segments. Prior to January 1, 2015, our CAG segment included certain livestock testing services processed within our CAG Reference Laboratories. We have transitioned the responsibility for these diagnostic services from our CAG segment to our LPD segment to more effectively align our business with the nature and customers of these livestock services. Segment revenue and income from operations for years ended December 31, 2014 and 2013 have been retrospectively revised in this Annual Report on Form 10-K to reflect this change in the composi tion of our reportable segments. Revenue related to these livestock diagnostic services was $13.8 million and $9.9 million for the years ended December 31, 2014 and 2013, respectively. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-maker is our Chief Executive Officer. Our operating segments include: CAG, Water, LPD, and Other. Assets are not allocated to segments for internal reporting purposes. CAG develops, designs, manufactures and distributes products and performs services for veterinarians and the bioresearch market, primarily related to diagnostics and information management. Water develops, designs, manufactures and distributes a range of products used in the detection of various microbiological parameters in water. LPD develops, designs, manufactures and distributes diagnostic tests and related instrumentation and performs services that are used to manage the health status of livestock and poultry, to improve bovine reproductive efficiency, and to ensure the quality and safety of milk and food . OPTI Medical develops, designs, manufactures and distributes point-of-care electrolyte and blood gas analyzers and related consumable products for the human medical diagnostics market. The accounting policies of our segments are the same as those described in the summary of significant accounting policies in Note 2 except for inventories, as discussed below. Intersegment revenues, which are not included in the table below, were not material for the years ended December 31, 201 5, 2014 and 201 3 . Certain costs are not allocated to our oper a ting segments and are instead reported under the caption “Unallocated Amounts.” Our business segments generally have limited control over the timing and amount of these expenses. The major categories of these costs include: Gross Profit: · The capitalization of variances between standard and actual manufacturing costs to adjust the timing of expense recognition from when the variance is created to the period in which the related inventory is sold. Operating Expenses : · Costs that do not align with one of our existing operating segments or are cost prohibitive to allocate, primarily our R&D function, regional or country expenses and certain foreign currency revaluation gains/losses on monetary balances in currencies other than our subsidiaries’ functional currency. · Corporate support function costs (such as information technology, facilities, human resources, finance and legal), health benefits and incentive compensation, which are charged to our business segments at pre-determined budgeted amounts or rates. Differences from pre-determined budgeted amounts or rates are captured within our Unallocated Segment. · Unusual or extraordinary items. Below is our segment information ( in thousand s): For the Years Ended December 31, CAG Water LPD Other Unallocated Amounts Consolidated Total 2015 Revenue $ 1,356,287 $ 96,884 $ 127,143 $ 21,578 $ - $ 1,601,892 Income (loss) from operations $ 231,642 $ 44,584 $ 24,397 $ 156 $ (867) $ 299,912 Interest expense, net (26,771) Income before provision for income taxes 273,141 Provision for income taxes 81,006 Net income 192,135 Less: Net income attributable to noncontrolling interest 57 Net income attributable to IDEXX Laboratories, Inc. stockholders $ 192,078 Depreciation and amortization $ 60,715 $ 3,188 $ 4,367 $ 686 $ - $ 68,956 Expenditures for long-lived assets (1) $ 69,371 $ 2,781 $ 9,110 $ 1,659 $ - $ 82,921 2014 Revenue $ 1,223,064 $ 94,725 $ 141,179 $ 26,839 $ - $ 1,485,807 Income (loss) from operations $ 203,536 $ 39,262 $ 33,788 $ 2,479 $ (18,810) $ 260,255 Interest expense, net (13,700) Income before provision for income taxes 246,555 Provision for income taxes 64,604 Net income 181,951 Less: Net income attributable to noncontrolling interest 45 Net income attributable to IDEXX Laboratories, Inc. stockholders $ 181,906 Depreciation and amortization $ 48,740 $ 2,553 $ 5,144 $ 2,451 $ - $ 58,888 Expenditures for long-lived assets (1) $ 49,270 $ 2,499 $ 4,025 $ 4,729 $ - $ 60,523 2013 Revenue $ 1,140,292 $ 87,959 $ 123,688 $ 25,119 $ - $ 1,377,058 Income (loss) from operations $ 212,558 $ 37,321 $ 20,246 $ 2,405 $ (5,768) $ 266,762 Interest expense, net (3,501) Income before provision for income taxes 263,261 Provision for income taxes 75,467 Net income 187,794 Less: Net loss attributable to noncontrolling interest (6) Net income attributable to IDEXX Laboratories, Inc. stockholders $ 187,800 Depreciation and amortization $ 45,079 $ 2,470 $ 4,906 $ 2,141 $ - $ 54,596 Expenditures for long-lived assets (1) $ 66,134 $ 3,254 $ 5,569 $ 2,655 $ - $ 77,612 __________ (1) Expenditures for long-lived assets exclude expenditures for intangible assets. See Note 3 for information regarding acquisitions of intangible assets during the years ended December 31, 2015, 2014 and 2013. Revenue by product and service categories was as follows ( in thousands ): For the Years Ended December 31, 2015 2014 2013 CAG segment revenue: CAG Diagnostics recurring revenue: $ 1,146,527 $ 1,039,252 $ 964,009 VetLab consumables 396,526 341,407 312,457 VetLab service and accessories 55,176 53,006 50,675 Rapid assay products 182,670 165,647 169,547 Reference laboratory diagnostic and consulting services 512,155 479,192 431,330 CAG Diagnostics capital instruments 99,001 79,993 83,492 Customer information management and diagnostic imaging systems 110,759 103,819 92,791 CAG segment revenue 1,356,287 1,223,064 1,140,292 Water segment revenue 96,884 94,725 87,959 LPD segment revenue 127,143 141,179 123,688 Other segment revenue 21,578 26,839 25,119 Total revenue $ 1,601,892 $ 1,485,807 $ 1,377,058 Revenue by principal geographic area, based on customers’ domiciles, was as follows ( in thousands ): For the Years Ended December 31, 2015 2014 2013 Americas United States $ 980,281 $ 848,928 $ 802,345 Canada 69,303 69,743 69,947 Latin America 34,725 34,086 26,893 1,084,309 952,757 899,185 Europe, the Middle East and Africa Germany 73,395 85,189 78,109 United Kingdom 74,879 74,131 65,027 France 46,972 53,322 49,093 Italy 25,903 28,794 26,443 Spain 19,998 21,566 20,194 Switzerland 15,631 14,544 12,246 Netherlands 11,645 10,643 9,352 Other 79,910 78,201 66,221 348,333 366,390 326,685 Asia Pacific Region Australia 49,274 58,448 53,063 Japan 43,171 44,132 44,869 China 40,619 34,674 29,044 Other 36,186 29,406 24,212 169,250 166,660 151,188 Total $ 1,601,892 $ 1,485,807 $ 1,377,058 Net long-lived assets, consisting of net property and equipment, are subject to geographic risks because they are generally difficult to move and to effectively utilize in another geographic area in a reasonable time period and because they are relatively illiquid. Net long-lived assets by principal geographic areas were as follows (in thousands) : December 31, December 31, 2015 2014 Americas United States $ 285,391 $ 262,475 Brazil 8,404 3,206 Canada 1,796 2,270 295,591 267,951 Europe, the Middle East and Africa United Kingdom 13,269 14,366 Germany 5,159 4,836 Netherlands 4,425 3,456 France 2,679 3,172 Switzerland 2,831 2,631 Other 2,047 1,674 30,410 30,135 Asia Pacific Region Japan 2,210 2,204 Australia 2,135 1,789 Other 2,680 1,508 7,025 5,501 Total $ 333,026 $ 303,587

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2015
Fair Value Measurements [Abstract]
Fair Value Measurements	NOTE 16 . FAIR VALUE MEASUREMENTS The following table sets forth our assets and liabilities that were measured at fair value on a recurring basis at December 31, 201 5 and at December 31, 2014 by level within the fair value hierarchy ( in thousands ): Quoted Prices Significant in Active Other Significant Markets for Observable Unobservable Identical Assets Inputs Inputs Balance at As of December 31, 2015 (Level 1) (Level 2) (Level 3) December 31, 2015 Assets Money market funds (1) $ 15,490 $ - $ - $ 15,490 Agency bonds - 1,999 - 1,999 Commercial paper - 1,800 - 1,800 Marketable securities Corporate bonds - 177,613 - 177,613 U.S. government bonds - 12,871 - 12,871 Agency bonds - 12,065 - 12,065 Certificates of deposit - 3,500 - 3,500 Commercial paper - 3,491 - 3,491 International government bonds - 1,459 - 1,459 Municipal bonds - 1,399 - 1,399 Treasury bills - 1,193 - 1,193 Total marketable securities - 213,591 - 213,591 Equity mutual funds (2) 2,264 - - 2,264 Foreign currency exchange contracts (3) - 4,876 - 4,876 Liabilities Foreign currency exchange contracts (3) - 1,365 - 1,365 Deferred compensation (4) 2,264 - - 2,264 Interest rate swaps (5) - 384 - 384 Quoted Prices Significant in Active Other Significant Markets for Observable Unobservable Identical Assets Inputs Inputs Balance at As of December 31, 2014 (Level 1) (Level 2) (Level 3) December 31, 2014 Assets Money market funds (1) $ 204,743 $ - $ - $ 204,743 Equity mutual funds (2) 2,654 - - 2,654 Foreign currency exchange contracts (3) - 12,226 - 12,226 Liabilities Foreign currency exchange contracts (3) - 1,323 - 1,323 Deferred compensation (4) 2,654 - - 2,654 Interest rate swaps (5) - 1,117 - 1,117 __________ (1) Money market funds, agency bonds and commercial paper with an original maturity of less than ninety days are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of December 31, 2015 and December 31, 2014 consisted of demand deposits. Commercial paper with an original maturity of over ninety days is included within marketable securities. (2) Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other long-term assets, net. See number (4) below for a discussion of the related deferred compensation liability. (3) Foreign currency exchange contracts are included within other current assets, net; other long-term assets, net; accrued liabilities; or other long-term liabilities depending on the gain (loss) position and anticipated settlement date. (4) A deferred compensation plan assumed as part of a previous business combination is included within other long-term liabilities. The fair value of our deferred compensation plan is indexed to the performance of the underlying equity mutual funds discussed in number (2) above. (5) Interest rate swaps are included within accrued liabilities. We did not have any transfers between Level 1 and Level 2 or transfers in or out of Level 3 of the fair value hierarchy during the years ended December 31, 2015 and 2014 . The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate carrying value due to their short maturity. See Note 2 for additional information regarding valuation methodology for assets and liabilities for which fair value is measured on a recurring basis and for information regarding the fair values of our unsecured revolving cr edit facility and long-term debt .

Hedging Instruments

Hedging Instruments	12 Months Ended
	Dec. 31, 2015
Hedging Instruments [Abstract]
Hedging Instruments	Note 17 . HEDGING Instruments Disclosure within this footnote is presented to provide transparency about how and w hy we use derivative and non-derivative instruments (collectively “hedging instruments”) and how the hedging instruments and related hedged items affect our financial position, results of operations, and cash flows. See Note 2 fo r a discussion surrounding our hedging instrument s and hedging accounting policies, Note 16 for additional information regarding the fair value of our derivative instruments and Note 1 9 for additional information regarding the effect of derivative instruments designated as cash flow hedges on the consolidated statement of operations. We are exposed to certain risks related to our ongoing business operations. The primary risks th at we manage by using hedging instruments are foreign currency exchange risk and interest rate risk. Our subsidiaries enter into foreign currency exchange contracts to manage the exchange risk associated with their forecasted intercompany inventory purchases and sales for the next year. From time to time, we may also enter into other foreign currency exchange contracts or foreign-denominated debt issuances to minimize the impact of foreign currency fluctuations associated with specific balance sheet exposures, including net investments in certain foreign subsidiaries . We enter into interest rate swaps to minimize the impact of interest rate fluctuations associated with borrowings under our variable-rate Credit Facility . The primary purpose of our foreign currency hedging activities is to protect against the volatility associated with foreign currency transactions, includi ng transactions denominated in e uro, British pound, Japanese yen, Canadian dollar, Australian dollar and Swiss franc. We also utilize natural hedges to mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of allowable hedging activity. We enter into foreign currency exchange contracts with well-capitalized multinational financial institutions , and we do not hold or engage in t ransactions involving hedging instruments for purposes other than risk management. Our accounting policies for these contracts are based on our designation of such instruments as hedging transactions. Cash Flow Hedges We have designated our foreign currency exchange contracts and variable-to-fixed interest rate swaps as cash flow hedges as these derivative instruments mitigate the exposure to variability in the cash flows of forecasted transactions attributable to foreign currency exchange and interest rates. Unless noted otherwise, we have also designated our derivative instruments as qualifying for hedge accounting treatment. We did not de-designate any instruments from hedge accounting treatment during t he years ended December 31, 2015 , 2014 and 2013 . Gains or losses related to hedge ineffectiveness recognized in earnings during the years ended December 31, 201 5 , 201 4 and 201 3 were not material . At December 31, 201 5 , the estimated amount of net gains, net of income tax expense, which are expected to be reclassified out of AOCI and into earnings within the next twelve months is $ 2.3 million if exchange and interest rates do not fluctuate from the levels at December 31, 201 5 . We hedge approximately 85% of the estimated exposure from intercompany product purchases and sales denominated in the euro, British pound, Canadian dollar, Japanese yen, Australian dollar and Swiss franc. We have additional unhedged foreign currency exposures related to foreign services and emerging markets where it is not practical to hedge. We primarily utilize foreign currency exchange contracts with durations of less than 24 months . Quarterly, we enter into contracts to hedge incremental portions of anticipated foreign currency transactions for the current and following year. As a result, our risk with respect to foreign currency exchange rate fluctuations and the notional value of foreign currency exchange contracts may vary throughout the year. The U.S. dollar is the currency purchased or sold in all of our foreign currency exchange contracts. The notional amount of foreign currency exchange contracts to hedge forecasted intercompany inventory purch ases and sales totaled $ 1 76.1 million and $186.7 million at December 31, 201 5 and December 31, 201 4 , respectively . We have entered into forward fixed interest rate swap agreements to manage the economic effect of variable interest obligations on amounts borrowed under the terms of our Credit Facility. Beginning on March 30, 2012, the variable interest rate associated with $ 40 million of borrowings outstanding under the Credit Facility became effectively fixed at 1.36 % plus the range of applicable interest rate fixed credit spreads (“ Credit Spread ”) through June 30, 2016. Beginning on March 28, 2013, the variable interest rate associated with an additional $ 40 million of borrowings outstanding under the Credit Facility became effectively fixed at 1.64 % plus the Credit Spread through June 30, 2016. Net Investment Hedge In June 2015, we issued and sold our 2025 Notes through a private placement an aggregate principal amount of €88.9 million (approximately USD $100 million). We have designated these euro-denominated notes as a hedge of our euro net investment in certain foreign subsidiaries to reduce the volatility in stockholders’ equity caused by changes in foreign currency exchange rates in the euro relative to the U.S. dollar. As a result of this designation, gains and losses from the change in translated U.S. dollar value of these euro-denominated notes are recorded in AOCI rather than to earnings. We recorded a $1.9 million gain, net of income tax, within AOCI as a result of this net investment hedge for the year ended December 31, 2015. This unrealized gain recorded at December 31, 2015 will not be reclassified in earnings until the complete or substantially complete liquidation of the net investment i n the hedged foreign operations or all or a portion of the hedge no longer qualifies for hedge accounting treatmen t. See Note 11 to the consolidated financial statements included in this Annual Report on Form 10-K for further information regarding the issuance of these 2025 Notes . Fair Values of Hedging Instruments Designated as Hedges in Consolidated Balance Sheets The fair values of hedging instruments, and their respective classification on the consolidated balance sheets and amounts subject to offset under master netting arrangements consisted of the following (in thousands) : Hedging Assets December 31, December 31, 2015 2014 Derivatives designated as hedging instruments Balance Sheet Classification Foreign currency exchange contracts Other current assets $ 4,876 $ 12,226 Gross amounts subject to master netting arrangements not offset on the balance sheet 1,268 1,323 Net amount $ 3,608 $ 10,903 Hedging Liabilities December 31, December 31, 2015 2014 Derivatives designated as hedging instruments Balance Sheet Classification Foreign currency exchange contracts Accrued liabilities $ 1,365 $ 1,323 Interest rate swaps Accrued liabilities 384 1,117 Total derivative instruments presented as cash flow hedges on the balance sheet 1,749 2,440 Foreign currency borrowings designated as net investment hedge on the balance sheet Long-term debt 97,085 - Total hedging instruments presented on the balance sheet 98,834 2,440 Gross amounts subject to master netting arrangements not offset on the balance sheet 1,268 1,323 Net amount $ 97,566 $ 1,117 The effect of derivative instruments designated as cash flow hedges on the consolidated balance sheets for the years ended December 31, 201 5 , 201 4 and 201 3 consisted of the following (in thousands) : Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion) For Year Ended December 31, Derivative instruments 2015 2014 2013 Foreign currency exchange contracts, net of tax $ (5,604) $ 7,098 $ 1,350 Interest rate swaps, net of tax 461 442 541 Total derivative instruments, net of tax $ (5,143) $ 7,540 $ 1,891

Repurchases Of Common Stock

Repurchases Of Common Stock	12 Months Ended
	Dec. 31, 2015
Repurchases Of Common Stock [Abstract]
Repurchases Of Common Stock	NOTE 18 . REPURCHASES OF COMMON STOCK Our Board of D irectors has authorized the repurchase of up to 65,000,000 shares of our common stock in the open market or in negotiated transactions pursuant to the Company’s share repurchase program. We believe that the repurchase of our common stock is a favorable means of returning value to our shareholders, and we also repurchase to offset the dilutive effect of our share-based compensation programs. Repurchases of our common stock may vary d epending upon the level of other investing activities and the shar e price. As of December 31, 2015 , there are 6,806,152 re maining shares available for repurchase under this authorization. We primarily acquire shares by means of repurchases in the open market. However, we also acquire shares that are sur rendered by employees in payment for the minimum required withholding taxes due on the vesting of restricted stock units and the settlement of deferred stock units, otherwise referred to herein as employee surrenders. The following is a summary of our open market common stock repurchases and shares acquired through employee surrender for the years ended December 31, 201 5 , 201 4 and 201 3 ( in thousands, except per share amounts ): For the Years Ended December 31, 2015 2014 2013 Share repurchases during the period (1) 5,659 9,761 7,903 Shares acquired through employee surrender (1) 69 92 99 Total shares repurchased (1) 5,728 9,853 8,002 Cost of share repurchases during the period $ 406,430 $ 618,158 $ 367,762 Cost of employee surrenders 5,457 5,809 4,548 Total cost of shares repurchased $ 411,887 $ 623,967 $ 372,310 Average cost per share $ 71.90 $ 63.32 $ 46.53 (1) Shares repurchased and acquired through employee surrender for payment of minimum required withholding taxes on and before June 15, 2015 and the associated average cost per share have been adjusted to reflect the June 2015 two-for-one stock split. Actual shares repurchased were approximately 4,313,000 , 4,927,000 and 4,001,000 for the years ended December 31, 2015, 2014, and 2013, respectively.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	12 Months Ended
	Dec. 31, 2015
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income	NOTE 1 9 . ACCUMULATED OTHER COMPREHENSIVE INCOME The changes in a ccumulated other comprehensive income , net of tax, for the years ended December 31, 2015 and 2014 consisted of the following (in thousands) : Unrealized gain (loss) on investments, net of tax Unrealized gain (loss) on derivatives instruments, net of tax Unrealized gain on net investment hedge, net of tax Cumulative translation adjustment Total Balance as of December 31, 2013 $ 108 $ (179) $ - $ 13,693 $ 13,622 Other comprehensive income (loss) before reclassifications (107) 9,542 - (29,126) (19,691) Gains reclassified from accumulated other comprehensive income - (2,002) - - (2,002) Balance as of December 31, 2014 1 7,361 - (15,433) (8,071) Other comprehensive income (loss) before reclassifications (226) 8,839 1,894 (30,718) (20,211) Gains reclassified from accumulated other comprehensive income - (13,983) - - (13,983) Balance as of December 31, 2015 $ (225) $ 2,217 $ 1,894 $ (46,151) $ (42,265) The following is a summary of reclassifications out of accumulated other comprehensive income for the years ended December 31, 2015, 2014 and 2013 ( in thousands ): Amounts Reclassified from Accumulated Other Affected Line Item in the Comprehensive Income Details about Accumulated Other Statement Where For the Years Ended December 31, Comprehensive Income Components Net Income in Presented 2015 2014 2013 Gains (losses) on derivative instruments included in net income: Foreign currency exchange contracts Cost of revenue $ 20,878 $ 3,822 $ 3,469 Interest rate swaps Interest expense (1,042) (1,064) (900) Total gains before tax 19,836 2,758 2,569 Tax expense 5,853 756 679 Gains, net of tax $ 13,983 $ 2,002 $ 1,890

Preferred Stock

Preferred Stock	12 Months Ended
	Dec. 31, 2015
Preferred Stock [Abstract]
Preferred Stock	NOTE 20 . PREFERRED STOCK Our Board of D irectors is authorized, subject to any limitations prescribed by law, without further stockholder approval, to issue from time to time up to 500,000 shares of Preferred Stock, $ 1.00 par value per share (“Preferred Stock”), in one or more series. Each such series of Preferred Stock shall have such number of shares, designations, preferences, voting powers, qualifications and special or relative rights or privileges as shall be determined by the Board of D irectors, which may include, among others, dividend rights, voting rights, redemption and sinking fund provisions, liquidation preferences, conversion rights and preemptive rights. There are no shares of Preferred Stock outstanding as of December 31, 2015 .

IDEXX Retirement And Incentive

IDEXX Retirement And Incentive Savings Plan	12 Months Ended
	Dec. 31, 2015
IDEXX Retirement And Incentive Savings Plan [Abstract]
IDEXX Retirement And Incentive Savings Plan	NOTE 21 . IDEXX RETIREMENT AND INCENTIVE SAVINGS PLAN We have established the IDEXX Retirement and Incentive Savings Plan (the “401(k) Plan”). U.S. e mployees eligible to participate in the 401(k) Plan may contribute specified percentages of their salaries. We match a portion of these contributions, not to exceed 4% of participants’ eligible compensation . We matched $ 11.5 million, $ 8.8 million and $ 7.8 million for the years ended December 31, 201 5 , 201 4 and 201 3 , respectively. In addition, we may make contributions to the 401(k) Plan at the discretion of the Board of D irectors. There were no discretionary contributions in 201 5 , 201 4 or 201 3 . We also have established defined contribution plans for regional employees in Europe and in Canada. With respect to these plans, we contributed $ 3.5 million, $ 3.7 million and $ 3.1 million for the years ended December 31, 201 5 , 201 4 and 201 3 , respectively.

Summary Of Quarterly Data

Summary Of Quarterly Data	12 Months Ended
	Dec. 31, 2015
Summary Of Quarterly Data [Abstract]
Summary Of Quarterly Data	NOTE 22 . SUMMARY OF QUARTERLY DATA (UNAUDITED) A summary of quarterly data (1) follows ( in thousands, except per share data ): For the Three Months Ended March 31, June 30, September 30, December 31, 2015 Revenue $ 382,477 $ 413,343 $ 406,387 $ 399,685 Gross profit 215,544 232,757 224,274 217,695 Operating income 72,803 88,303 71,895 66,911 Net income attributable to IDEXX Laboratories, Inc. stockholders 46,594 56,912 44,223 44,349 Earnings per share: Basic $ 0.49 $ 0.61 $ 0.48 $ 0.49 Diluted $ 0.49 $ 0.60 $ 0.48 $ 0.48 2014 Revenue $ 360,203 $ 390,122 $ 383,523 $ 351,959 Gross profit 202,097 218,518 213,336 182,165 Operating income 70,046 83,219 72,189 34,801 Net income attributable to IDEXX Laboratories, Inc. stockholders 46,585 57,218 52,142 25,961 Earnings per share: Basic $ 0.45 $ 0.56 $ 0.52 $ 0.27 Diluted $ 0.45 $ 0.55 $ 0.52 $ 0.27 (1) Amounts presented may not recalculate to full-year totals due to rounding.

Valuation And Qualifying Accoun

Valuation And Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Valuation and Qualifying Accounts [Abstract]
Valuation And Qualifying Accounts	SCHEDULE II IDEXX LABORATORIES, INC. AND SUBSIDIARIES VALUATION AND QUALIFYING ACCOUNTS ( in thousands ) Balance at Beginning of Year Charges to Costs and Expenses Charges to Other Accounts (1) Write-Offs/Cash Payments Foreign Currency Translation Balance at End of Year Reserves for doubtful accounts receivable: December 31, 2013 $ 2,632 $ 1,601 $ - $ (762) $ 62 $ 3,533 December 31, 2014 3,533 2,035 - (1,146) (116) 4,306 December 31, 2015 4,306 2,200 - (817) (561) 5,128 Valuation allowance for deferred tax assets: December 31, 2013 $ 4,547 $ 735 $ 742 $ (701) $ (122) $ 5,201 December 31, 2014 5,201 799 - (1,042) (280) 4,678 December 31, 2015 4,678 634 - (468) (398) 4,446 (1) Amount relates to net operating losses obtained through acquisitions where uncertainty exists as to our ability to use the tax attribute.

Summary Of Significant Accoun32

Summary Of Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2015
Summary Of Significant Accounting Policies [Abstract]
Estimates	(a) Estimates The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate these estimates, including those related to reserves for accounts receivable; goodwill and other intangible assets; income taxes; inventory valuation; revenue recognition, product returns, customer programs and multiple element arrangements; share-based compensation; warranty reserves; self-insurance reserves; fair value measurements and loss contingencies. We accrue contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
Cash And Cash Equivalents	( b ) Cash and Cash Equivalents We consider all highly liquid investments with original maturities of ninety days or less to be cash equivalents. Cash and cash equivalents consist primarily demand dep osits, money market funds and short duration agency bonds and commercial paper as described above. There is no restricted cash on our consolidated balance sheet for the years ended December 31, 2015 and 2014.
Marketable Securities	(c) Marketable Securities During the year ended December 31, 2015, we purchased marketable debt securities, which are classified as available-for-sale and carried at fair valu e in the accompanying consolidated balance sheets on a trade date basis. We have classified our investments with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. Unrealized holding gains and losses are deferred within accumulated other comprehensive income (“AOCI”), net of applicable taxes, except for when an impairment is determined to be other-than-temporary or the security is divested prior to maturity. Wi thin the accompanying consolidated statements of operations, interest earned and amortization of premiums or discounts on marketable securities are included in interest income, realized gains and losses on the sale of our marketable securities are included in other income.
Inventories	Inventories Inventories, which are stated at the lower of cost (first-in, first-out) or market, include material, conversion costs and inbound freight charges. We write down the carrying value of inventory for estimated obsolescence by an amount equal to the difference between the cost of inventory and the estimated market value when warranted based on assumptions of future demand, market conditions, remaining shelf life, or product functionality. If actual market conditions or results of estimated functionality are less favorable than those we estimated, additional inventory write-downs may be required, which would have a negative effect on results of operations.
Property And Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation and amortization. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to expense as incurred. When an item is sold or retired, the cost and related accumulated depreciation is relieved, and the resulting gain or loss, if any, is recognized in the consolidated statements of income. We provide for depreciation and amortization primarily using the straight-line method by charges to income in amounts that allocate the cost of property and equipment over their estimated useful lives as follows: Asset Classification Estimated Useful Life Land improvements 15 to 20 years Buildings and improvements 15 to 40 years Leasehold improvements Shorter of remaining lease term or useful life of improvements Machinery and equipment 3 to 8 years Office furniture and equipment 3 to 7 years Computer hardware and software 3 to 7 years We capitalize interest on the acquisition and construction of significant assets that require a substantial period of time to be made ready for use. The capitalized interest is included in the cost of the completed asset and depreciated over the asset’s estimated useful life. The amount of interest capitalized during the years ended December 31, 2015 and 2014 was not material. We capitalize certain costs incurred in connection with developing or obtaining software designated for internal use based on three distinct stages of development. Qualifying costs incurred during the application development stage, which consist primarily of internal payroll and direct fringe benefits and external direct project costs, including labor and travel, are capitalized and amortized on a straight-line basis over the estimated useful life of the asset. Costs incurred during the preliminary project and post-implementation and operation phases are expensed as incurred. These costs are general and administrative in nature and relate primarily to the determination of performance requirements, data conversion and training. Software developed to deliver hosted services to our customers has been designated as internal use. See Note 7 for further information regarding costs capitalized in connection with software developed for internal use.
Goodwill And Other Intangible Assets	Goodwill and Other Intangible Assets A significant portion of the purchase price for acquired businesses is generally assigned to intangible assets. Intangible assets other than goodwill are initially valued at fair value. If a quoted price in an active market for the identical asset is not readily available at the measurement date, the fair value of the intangible asset is estimated based on discounted cash flows using market participant assumptions, which are assumptions that are not specific to IDEXX. The selection of appropriate valuation methodologies and the estimation of discounted cash flows require significant assumptions about the timing and amounts of future cash flows, risks, appropriate discount rates, and the useful lives of intangible assets. When material, we utilize independent valuation experts to advise and assist us in determining the fair values of the identified intangible assets acquired in connection with a business acquisition and in determining appropriate amortization methods and periods for those intangible assets. Goodwill is initially valued based on the excess of the purchase price of a business combination over the fair value of acquired net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Our business combinations regularly include contingent consideration arrangements that require additional consideration to be paid based on the achievement of established objectives, most commonly surrounding the retention of customers during the post-combination period. We assess contingent consideration to determine if it is part of the business combination or if it should be accounted for separately from the business combination in the post-combination period. Contingent consideration is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved, with changes in fair value recognized in earnings. Changes in fair value of contingent consideration and differences arising upon settlement were not material during the years ended December 31, 2015, 2014 and 2013. See Note 3 for additional information regarding contingent consideration arising from recent business acquisitions. We provide for amortization primarily using the straight-line method by charges to income in amounts that allocate the intangible assets over their estimated useful lives as follows: Asset Classification Estimated Useful Life Patents 13 years Product rights (1) 5 to 15 years Customer-related intangible assets (2) 5 to 17 years Noncompete agreements 3 to 5 years (1) Product rights comprise certain technologies, intellectual property, licenses and trade names acquired from third parties. (2) Customer-related intangible assets comprise customer lists and customer relationships acquired from third parties. We assess goodwill for impairment annually, at the reporting unit level, in the fourth quarter and whenever events or circumstances indicate impairment may exist. In evaluating goodwill for impairment, we have the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. The more-likely-than-not threshold is defined as having a likelihood of more than 50 percent. If, after assessing the totality of events or circumstances, we determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, we would then perform step one of the two-step impairment test; otherwise, no further impairment test would be required. In contrast, we can opt to bypass the qualitative assessment for any reporting unit in any period and proceed directly to step one of the two-step impairment test. Doing so does not preclude us from performing the qualitative assessment in any subsequent period. In the fourth quarters of 2015 and 2014, we elected to bypass the qualitative approach and instead proceeded directly to step one of the two-step impairment test to assess the fair value of all of our reporting units. As part of step one of the two-step impairment test, we estimate the fair values of applicable reporting units using an income approach based on discounted forecasted cash flows. We make significant assumptions about the extent and timing of future cash flows, growth rates and discount rates. Model assumptions are based on our projections and best estimates, using appropriate and customary market participant assumptions. In addition, we make certain assumptions in allocating shared assets and liabilities to individual reporting units in determining the carrying value of each reporting unit. Changes in forecasted cash flows or the discount rate would affect the estimated fair values of our reporting units and could result in a goodwill impairment charge in a future period. No goodwill impairments were identified during the years ended December 31, 2015, 2014 or 2013. We assess the realizability of intangible assets other than goodwill whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If an impairment review is triggered, we evaluate the carrying value of intangible assets based on estimated undiscounted future cash flows over the remaining useful life of the primary asset of the asset group and compare that value to the carrying value of the asset group. The cash flows that are used contain our best estimates, using appropriate and customary assumptions and projections at the time. If the net carrying value of an intangible asset exceeds the related estimated undiscounted future cash flows, an impairment to write the intangible asset to its fair value would be reported as a non-cash charge to earnings. If necessary, we would calculate the fair value of an intangible asset using the present value of the estimated future cash flows to be generated by the intangible asset, and applying a risk-adjusted discount rate. Impairments of our intangible assets during the years ended December 31, 2015, 2014 and 2013 were not material. See Note 9 for further information regarding our goodwill and intangible assets.
Warranty Reserves	Warranty Reserves We provide a standard twelve month warranty on all instruments sold. We recognize the cost of instrument warranties in cost of product revenue at the time revenue is recognized based on the estimated cost to repair the instrument over its warranty period. Cost of product revenue reflects not only estimated warranty expense for instruments sold in the current period, but also any changes in estimated warranty expense for the portion of the aggregate installed base that is under warranty. Estimated warranty expense is based on a variety of inputs, including historical instrument performance in the customers’ environment, historical costs incurred in servicing instruments and projected instrument reliability. Should actual service rates or costs differ from our estimates, revisions to the estimated warranty liability would be required. The liability for warranties is included in accrued liabilities in the accompanying consolidated balance sheets.
Income Taxes	Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the estimated future tax effects of temporary differences between book and tax treatment of assets and liabilities and carryforwards to the extent they are realizable. We record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. While we consider future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for a valuation allowance, in the event we were to determine that we would be able to realize our deferred tax assets in the future in excess of the net recorded amount, a reduction of the valuation allowance would increase income in the period such determination was made. Likewise, should we determine that we would not be able to realize all or part of our net deferred tax asset in the future, a reduction to the deferred tax asset would be charged to income in the period such determination was made. We record a liability for uncertain tax positions that do not meet the more likely than not standard as prescribed by the authoritative guidance for income tax accounting. We record tax benefits for only those positions that we believe will more likely than not be sustained. Unrecognized tax benefits are the differences between tax positions taken, or expected to be taken, in tax returns, and the benefits recognized for accounting purposes. Significant judgment is required in determining our worldwide provision for income taxes and our income tax filings are regularly under audit by tax authorities. Any audit result differing from amounts recorded would increase or decrease income in the period that we determine such adjustment is likely. Interest expense and penalties associated with the underpayment of income taxes are included in income tax expense. See Note 12 for additional information regarding income taxes.
Taxes Remitted To Governmental Authorities By IDEXX On Behalf Of Customer	Taxes Remitted to Governmental Authorities by IDEXX on Behalf of CustomerWe calculate, collect from our customers, and remit to governmental authorities sales, value-added and excise taxes assessed by governmental authorities in connection with revenue-producing transactions with our customers. We report these taxes on a net basis and do not include these tax amounts in revenue or cost of product or service revenue.
Revenue Recognition	( j ) Revenue Recognition We recognize revenue when four criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. Revenue-generating transactions generally fall into one of the following categories of revenue recognition: · We recognize revenue from the sales of consumables, rapid assay test kits and other diagnostic products when the product is delivered to the customer, except as noted below. · We recognize revenue from the sales of instruments, non-cancelable software licenses and hardware systems upon installation and the customer’s acceptance of the instrument or system as we have no significant further obligations after this point in time. · We recognize service revenue at the time the service is performed. · We recognize revenue associated with extended maintenance agreements (“EMAs”) and our software-as-a-service subscriptions over the life of the contracts using the straight-line method, which approximates the expected timing in which applicable services are performed. Amounts collected in advance of revenue recognition are recorded as current or long-term deferred revenue based on the time from the balance sheet date to the future date of revenue recognition. · We recognize revenue on certain instrument systems under rental programs over the life of the rental agreement using the straight-line method. Amounts collected in advance of revenue recognition are recorded as current or long-term deferred revenue based on the time from the balance sheet date to the future date of revenue recognition. · We recognize revenue on practice management systems sales, where the system includes software that is considered more than incidental, either by allocating the revenue to each element of the sale based on relative fair values of the elements, including post-contract support when fair value for all elements is available, or by use of the residual method when only the fair value of the post-contract support is available. We recognize revenue for the system upon installation and customer acceptance and recognize revenue equal to the fair value of the post-contract support over the support period. · Shipping costs reimbursed by the customer are included in revenue. These same costs are also included in cost of product revenue. Multiple Element Arrangements (“MEAs”) . Arrangements to sell products to customers frequently include multiple deliverables. Our most significant MEAs include the sale of one or more of the instruments from the IDEXX VetLab suite of analyzers, di agnostic imaging systems or practice management software, combined with one or more of the following products: EMAs, consumables and reference laboratory diagnostic and consulting services. Practice management software is frequently sold with post-contract customer support and implementation services. Delivery of the various products or performance of services within the arrangement may or may not coincide. Delivery of our IDEXX VetLab instruments, di agnostic imaging systems, and practice management software generally occurs at the onset of the arrangement. EMAs, consumables, and reference laboratory diagnostic and consulting services typically are delivered over future periods, generally one to six years . In certain arrangements, revenue recognized is limited to the amount invoiced or received that is not contingent on the delivery of products and services in the future. W e allocate revenue to each element based on the relative selling price and recognize revenue when the elements have standalone value and the four criteria for revenue recognition, as discussed above, have been met for each element. If available, we establish the selling price of each element based on vendor-specific objective evidence (“VSOE”), which represents the price charged for a deliverable when it is sold separately. We use third-party evidence (“TPE”) if VSOE is not available or best estimate of selling price if neither VSOE nor TPE is available. When these arrangements include a separately-priced EMA, we recognize revenue related to the EMA at the stated contractual price on a straight-line basis over the life of the agreement to the extent the separately stated price is substantive. If there is no stated contractual price for an EMA, or the separately stated price is not substantive, we allocate revenue to each element based on the relative selling price and recognize revenue when the elements have standalone value and the four criteria for revenue recognition, as discussed above, have been met for each element . When arrangements within the scope of software revenue recognition guidance include multiple elements, we allocate revenue to each element based on relative fair value, when VSOE exists for all elements, or by using the residual method when there is VSOE for the undelivered elements but no such evidence for the delivered elements. Under the residual method, the fair value of the undelivered elements is deferred and the residual revenue is allocated to the delivered elements. Revenue is recognized on any delivered elements when the four criteria for revenue recognition have been met for each element. If VSOE does not exist for the undelivered element, all revenue from the arrangement is deferred until the earlier of the point at which such sufficient VSOE does exist or all elements of the arrangement have been delivered. We determine fair value based on amounts charged separately for the delivered and undelivered elements to similar customers in standalone sales of the specific elements. Certain arrangements with customers include discounts on future sales of products and services. We apply judgment in determining whether future discounts are significant and incremental. When the future discount offered is not considered significant and incremental, we do not account for the discount as an element of the original arrangement. If the future discount is significant and incremental, we recognize that discount as an element of the original arrangement and allocate the discount to the other elements of the arrangement based on relative selling price. To determine whether a discount is significant and incremental, we look to the discount provided in comparison to standalone sales of the same product or service to similar customers, the level of discount provided on other elements in the arrangement, and the significance of the discount to the overall arrangement. If the discount in the MEA approximates the discount typically provided in standalone sales, that discount is not considered incremental. Customer Programs . We record reductions to revenue related to customer marketing and incentive programs, which include end-user rebates and other volume-based incentives. Incentives may be provided in the form of IDEXX Points, credits or cash and are earned by end users upon achieving defined volume purchases or utilization levels or upon entering an agreement to purchase products or services in future periods. Our most significant customer programs are categorized as follows: Customer Loyalty Programs . Our customer loyalty programs offer customers the opportunity to earn incentives on a variety of IDEXX products and services as those products and services are purchased and utilized. Revenue reductions related to customer loyalty programs are recorded based on the actual issuance of incentives, incentives earned but not yet issued and estimates of incentives to be earned in the future. Up-Front Customer Loyalty Programs . Our up-front loyalty programs provide incentives to customers in the form of cash payments or IDEXX Points upon entering multi-year agreements to purchase annual minimum amounts of future products or services. If a customer breaches its agreement, it is required to refund all or a portion of the up-front cash or IDEXX Poin ts, or make other repayments, remedial actions or both . These incentives are considered to be customer acquisition costs and are capitalized within other current assets and other long-term assets and are subsequently recognized as a reduction to revenue over the term of the customer agreement. If these up-front incentives are subsequently utilized to purchase I DEXX VetLab instruments, diagnostic imaging systems or Cornerstone practice management systems, product revenue and cost is deferred and recognized over the term of the customer agreement as products and services are provided to the customer. We monitor customer purchases over the term of their agreement to assess the realizability of our capitalized customer acquisition costs. For the years ended December 31, 2015, 2014 and 2013, impairments of customer acquisition costs were immaterial. IDEXX Instrument Marketing Programs . Our instrument marketing programs require the customer to enroll at the time of instrument purchase and offer customers the opportunity to earn incentives in future periods based on the volume of the products they purchase and utilize over the term of the program. These arrangements are considered MEAs in accordance with our revenue recognition policy stated above. Revenue reductions related to instrument marketing programs are recorded based on an estimate of customer purchase and utilization levels and the incentive the customer will earn over the term of the program. Our estimates are based on historical experience and the specific terms and conditions of the marketing program and require us to apply judgment to estimate future product purchases and utilization. Differences between our estimates and actual incentives earned are accounted for as a change in estimate. These differences were not material for the years ended December 31, 2015, 2014 and 2013. Reagent Rental Programs . Our reagent rental programs provide our customers the right to use our instruments in consideration for multi-year agreements to purchase annual minimum amounts of consumables. No instrument revenue is recognized at the time of instrument installation. We recognize a portion of the revenue allocated to the instrument concurrent with the future sale of consumables. We determine the amount of revenue allocated from the consumable to the instrument based on relative selling prices and determine the rate of instrument revenue recognition in proportion to the customer’s minimum volume commitment. The cost of the instrument is capitalized within property and equipment, and is charged to cost of product revenue on a straight-line basis over the term of the minimum purchase agreement. IDEXX Points may be applied against the purchase price of IDEXX products and s ervices or applied to trade receivables due to us. IDEXX Points that have not yet been used by customers are classified as a liability until use or expiration occurs. We estimate the amount of IDEXX Points expected to expire, or breakage, based on historical expirations and we recognize the estimated benefit of breakage in proportion to actual redemptions of IDEXX Points by customers. On November 30 of each year, unused IDEXX Points earned before January 1 of the prior year generally expire and any variance from the breakage estimate is accounted for as a change in estimate. This variance was not material for the years ended December 31, 2015, 2014 and 2013. Future market conditions and changes in product offerings may cause us to change marketing strategies to increase or decrease customer incentive offerings, possibly resulting in incremental reductions of revenue in future periods as compared to reductions in the current or prior periods. Additionally, certain customer programs require us to estimate, based on historical experience, and apply judgment to predict the number of customers who will actually redeem the incentive. In determining estimated revenue reductions we utilize data collected directly from end users, which includes the volume of qualifying products purchased and the number of qualifying tests run as reported to us by end users via IDEXX SmartService , a secure i nternet link that enables us to extract data and provide diagnostic service and support for certain IDEXX VetLab instruments through remote access. Differences between estimated and actual customer participation in programs may impact the amount and timing of revenue recognition. Doubtful Accounts Receivable . We recognize revenue when collection from the customer is reasonably assured. We maintain allowances for doubtful accounts for potentially uncollectible receivables. We base our estimates on a detailed analysis of specific customer situations and a percentage of our accounts rece ivable by aging category. Additional allowances may be required if either the financial condition of our customers were to deteriorate or a strengthening U.S. dollar impacts the ability of foreign customers to make payments to us on their U.S. denominated purchases . Account balances are charged off against the allowance when we believe it is probable the receivable will not be recovered. We do not have any off-balance sheet credit exposure related to our customers. We have no significant customers that accounted for greater than 10% of our consolidated revenues for the year ended December 31, 2015. Similarly, we have no concentration of credit risk as of December 31, 2015.
Research And Development Costs	Research and Development Costs Research and development costs, which consist of salaries, employee benefits, materials and external consulting and product development costs, are expensed as incurred. We evaluate our software research and development costs for capitalization after the technological feasibility of software and products containing software has been established. No costs were capitalized during the years ended December 31, 2015, 2014 and 2013.
Advertising Costs	Advertising Costs Advertising costs, which are recognized as sales and marketing expense in the period in which they are incurred, were $ 1.2 million for each of the years ended December 31, 2015 and 2014 and $ 1.5 million for the year ended December 31, 2013.
Legal Costs	Legal Costs Legal costs are considered period costs and accordingly are expensed in the year services are provided.
Share-Based Compensation	Share-Based Compensation We provide for various forms of share-based compensation awards to our employees and non-employee directors. With the exception of stock options, the fair value of our awards is equal to the closing stock price of IDEXX common stock on the date of grant. We calculate the fair value of our stock option awards using the Black-Scholes-Merton option-pricing model. Share-based compensation expense is recognized net of estimated forfeitures, on a straight-line basis over the requisite service period of the award. See Note 4 for additional information regarding share-based compensation.
Self-Insurnace Accruals	(o ) Self-Insurance Accruals We self-insure costs associated with workers’ compensation and health and general welfare claims incurred by our U.S. and Canadian employees up to certain limits. The insurance company provides insurance for claims above these limits. Claim liabilities are recorded for estimates of the loss that we will ultimately incur on reported claims, as well as estimates of claims that have been incurred but not yet reported. Such liabilities are based on individual coverage, the average time from when a claim is incurred to the time it is paid and judgments about the present and expected levels of claim frequency and severity. Estimated claim liabilities could be significantly affected if future occurrences and claims differ from these assumptions and historical trends. Estimated claim liabilities are included in accrued liabilities in the accompanying consolidated balance sheets.
Leases	(p ) Leases The m ajority of our facilities are occupied under operating lease arrangements with various expiration dates through 2030 . W e are responsible for the real estate taxes and operating expenses related to these facilities. Additional ly , we enter into operating leases for certain vehicles and office equipment in the normal course of business . We determine the expected term of any executed agreements using the noncancelable lease term plus any renewal options by which the failure to renew imposes a penalty in such amount that renewal is reasonably assured. The derived expected term is then used in the determination of a capital or operating lease and in the calculation of straight-line rent expense. Rent escalations are considered in the calculation of minimum lease payments in our capital lease tests and in determining straight-line rent expense for operating leases.
Earnings Per Share	Earnings per Share Basic earnings per share is computed by dividing net income attributable to IDEXX Laboratories, Inc. stockholders by the weighted average number of shares of common stock and vested deferred stock units outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and assumed issuance of unvested restricted stock units and unvested deferred stock units using the treasury stock method unless the effect is anti-dilutive. The treasury stock method assumes that proceeds, including cash received from the exercise of employee stock options, the total unrecognized compensation expense for unvested share-based compensation awards and the excess tax benefits resulting from share-based compensation tax deductions in excess of the related expense recognized for financial reporting purposes, would be used to purchase our common stock at the average market price during the period. Vested deferred stock units outstanding are included in shares outstanding for basic and diluted earnings per share because the associated shares of our common stock are issuable for no cash consideration, the number of shares of our common stock to be issued is fixed and issuance is not contingent. See Note 4 for additional information regarding deferred stock units.
Foreign Currency	Foreign Currency The functional currency of all but three of our subsidiaries is their local currency. Assets and liabilities of these foreign subsidiaries are translated to the U.S. dollar using the exchange rate in effect at the balance sheet date. Revenue and expense accounts are translated to the U.S. dollar using the exchange rate at the date which those elements are recognized, and where it is impractical to do so, an average exchange rate in effect during the period is used to translate those elements. Cumulative translation gains and losses are shown in the accompanying consolidated balance sheets as a separate component of accumulated other comprehensive income (“AOCI”) . Revenues and expenses denominated in a currency other than the respective subsidiary’s functional currency are recorded at the current exchange rate when the transaction is recognized. Monetary assets and liabilities denominated in a currency other than the respective subsidiary’s functional currency are remeasured at each balance sheet date using the exchange rate in effect at each balance sheet date. These foreign currency gains and losses are included in general and administrative expenses. We recognized aggregate foreign currency losses of $ 0.2 million, $ 2. 0 million and $ 0.1 million for the years ended December 31, 2015, 2014 and 2013, respectively.
Hedging Instruments	Hedging Instruments We recognize all derivative and non-derivative instruments (collectively “hedging instruments”) on the balance sheet at fair value at the balance sheet date. Instruments that do not qualify for hedge accounting treatment must be recorded at fair value through earnings. To qualify for hedge accounting treatment, cash flow and net investment hedges must be highly effective in offsetting changes to expected future cash flows or fair value on hedged transactions. If the instrument qualifies for hedge accounting, c hanges in the fair value of the hedging instrument from the effective portion of the hedge are deferred in AOCI, net of tax, and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. We immediately record in earnings the extent to which a hedging instrument is not effective in achieving offsetting changes in fair value. We de-designate hedging instruments from hedge accounting when the likelihood of the hedged transaction occurring becomes less than probable. For de-designated instruments, the gain or loss from the time of de-designation through maturity of the instrument is recognized in earnings. Any gain or loss in AOCI at the time of de-designation is reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. We enter into master netting arrangements with the counterparties to our derivative transactions which permit certain outstanding receivables and payables to be offset in the event of default. Our derivative contracts do not require either party to post cash collateral. We elect to present our derivative assets and liabilitie s in the accompanying consolidated balance sheets on a gross basis. All cash flows related to our foreign currency exchange contracts and interest rate swaps are classified as operating cash flows, which is consistent with the cash flow treatment of the underlying items being hedged.
Fair Value Measurements	Fair Value Measurements U.S. GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. U.S. GAAP requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The Company has certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and liabilities that may be measured at fair value on a non - recurring basis and certain financial assets and liabilities that are not measured at fair value in our consolidated balance sheets but for which we disclose the fair value. The fair value disclosures of these assets and liabilities are based on a three-level hierarchy, which is defined as follows: Level 1 Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Our foreign currency exchange contracts and interest rate swap agreements are measured at fair value on a recurring basis in our accompanying consolidated balance sheets. We measure the fair value of our foreign currency exchange contracts classified as derivative instruments using an income approach, based on prevailing market forward rates less the contract rate multiplied by the notional amount. The product of this calculation is then adjusted for counterparty risk. We measure the fair value of our interest rate swaps classified as derivative instruments using an income approach, utilizing a discounted cash flow analysis based on the terms of the contract and the interest rate curve adjusted for counterparty risk. The amount outstanding under our unsecured revolving credit facility and long-term debt are measured at carrying value in our accompanying consolidated balance sheets though we disclose the fair value of these financial instruments. We determine the fair value of the amount outstanding under our credit facility and long-term debt using an income approach, utilizing a discounted cash flow analysis based on current market interest rates for debt issues with similar remaining years to maturity, adjusted for applicable credit risk. Our credit facility and long-term debt are valued using Level 2 inputs. The estimated fair value of our credit facility approximates its carrying value. At December 31, 2015, the estimated fair value and carrying value of our long-term debt were $593.7 million and $597.1 million, respectively. At December 31, 2014, the estimated fair value and carrying value of our long-term debt were $367.3 million and $350.0 million, respectively.
Comprehensive Income	Comprehensive Income We report all changes in equity, including net income and transactions or other events and circumstances from non-owner sources during the period in which they are recognized. We have chosen to present comprehensive income, which encompasses net income, foreign currency translation adjustments , gains and losses on our net investment hedge and the difference between the cost and the fair market value of investments in debt and equity securities, forward currency exchange contracts and interest rate swap agreements, in the consolidated statements of comprehensive income. S ee Note 19 for information about the effects on net income of significant amounts reclassified out of each component of AOCI for the years ended December 31, 2015 and 2014. We consider the foreign currency cumulative translation adjustment to be permanently invested and, therefore, have not provided income taxes on those amounts.
Concentrations Of Risk	Concentrations of Risk Financial Instruments . Financial instruments that potentially subject us to concentrations of credit risk are principally cash, cash equivalents , accounts receivable and derivatives. To mitigate such risk with respect to cash and cash equivalents, we place our cash with highly-rated financial institutions, in non-interest bearing accounts that are insured by the U.S. government and money market funds invested in government securities. Concentration of credit risk with respect to accounts receivable is limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our most significant customers and monitor the amounts owed to us, taking appropriate action when necessary. As a result, we believe that accounts receivable credit risk exposure is limited. We maintain an allowance for doubtful accounts, but historically have not experienced any material losses related to an individual customer or group of customers in any particular industry or geographic area. To mitigate concentration of credit risk with respect to derivatives we enter into transactions with highly-rated financial institutions, enter into master netting arrangements with the counterparties to our derivative transactions and frequently monitor the credit worthiness of our counterparties. Our master netting arrangements reduce our exposure in that they permit outstanding receivables and payables with the counterparties to our derivative transactions to be offset in the event of default. We have not incurred such losses and consider the risk of counterparty default to be minimal. Inventory . If we are unable to obtain adequate quantities of the inventory we need to sell our products, we could face cost increases or delays or discontinuations in product shipments, which could have a material adverse effect on our results of operations. Many of the third parties that provide us with the instruments we sell and certain components, raw materials and consumables used in or with our products are obtained from sole or single source suppliers. Some of the products that we purchase from these sources are proprietary or complex in nature, and, therefore, cannot be readily or easily replaced by alternative sources.
New Accounting Pronouncements Not Yet Adopted	New Accounting Pronouncements Not Yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued an amendment which will replace most of the existing revenue recognition guidance within U.S. GAAP. The core principle of this guidance is that an entity should recognize revenue for the transfer of goods or services to customers in an amount that it expects to be entitled to receive for those goods or services. In doing so, companies will be required to make certain judgments and estimates, including identifying contract performance obligations, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price among separate performance obligations. Additionally, the amendment requires disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, significant judgments reached in the application of the guidance and assets recognized from the costs to obtain or fulfill a contract. In July 2015, the FASB voted to defer the effective date of the amendment to apply to public business entities for annual and interim periods ending after December 15, 2017. The amendment allows for two methods of adoption: a full retrospective method or a modified retrospective approach with the cumulative effect recognized at the date of initial application. We are in the process of determining the method of adoption and the impact of this amendment on our consolidated financial statements. In August 2014, the FASB issued an amendment that requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The amendments in this update provide guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for one year after the date that the financial statements are issued and to provide related footnote disclosures. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments in this update apply to all entities and are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. This amendment is not expected to have a material impact on our financial statements. In February 2015, the FASB issued amendments which change the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities, placing more emphasis on risk of loss when determining a controlling financial interest. The amendments in this update apply to all entities and are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. This amendment is not expected to have a material impact on our financial statements. In April 2015, the FASB issued amendments that require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. Under current guidance, our debt issuance costs are reflected as a deferred charge, within other current assets and other long-te rm assets on our consolidated balance sheets. This update is effective for the annual reporting periods beginning after December 15, 2015. In August 2015, the FASB confirmed that the aforementioned amendments did not address the presentation or subsequent measurement of debt issuance costs related to line-of-credit arrangements. For line-of-credit arrangements, borrowers have the option of presenting debt issuance costs as an asset which is subsequently amortized ratably over the term of the line-of-credit arrangement, regardless of whether there are any related outstanding borrowings. These amendments are not expected to have a material impact on our financial statements. In April 2015, the FASB issued amendments that provide guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The n ew guidance does not change a customer’s accounting for service contracts. The standard update is effective for fiscal years beginning after December 15, 2015 and interim periods within those years. Early adoption is permitted. The standard allows for adoption retrospectively or prospectively to all arrangements entered into or materially modified after the effective date. The amendment is not expected to have a material impact on our financial statements. In May 2015, the FASB issued amendments which remove the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value as a practical expedient for fair value. Removing investments measured using the practical expedient from the fair value hierarchy is intended to eliminate the diversity in practice that currently exists with respect to the categorization of these investments. The new guidance requires reporting entities to continue to disclose information on investments for which fair value is measured at net asset value (or its equivalent) as a practical expedient to help users understand the nature and risks of the investments and whether the investments, if sold, are probable of being sold at amounts different from net asset value. A reporting entity should apply the amendments retrospectively to all periods presented. This update is effective for public business entities during fiscal years beginning after December 15, 2015. Early adoption is permitted. This amendment is not expected to have a material impact on our financial statements. In July 2015, the FASB issued amendments which simplify the existing guidance which requires entities to subsequently measure inventory at the lower of cost or market value. Under the amendments, an entity should measure inventory valued using a first-in, first-out or average cost method at the lower of cost or net realizable value, which is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This update is effective for public business entities during fiscal years beginning after December 15, 2016. Early adoption is permitted. This amendment is not expected to have a material impact on our financial statements. In September 2015, the FASB issued amendments which eliminate the requirement for an acquirer in a business combination to retrospectively account for measurement-period adjustments. Under the amendments, an entity is required to record measurement-period adjustments during the period in which the amounts are determined, including changes in depreciation, amortization and any other income effects as if the accounting had been completed at the acquisition date. This update is effective for public business entities during fiscal years beginning after December 15, 2015. Early adoption is permitted. This amendment is not expected to have a material impact on our financial statements. In November 2015, the FASB issued amendments which simplify the existing guidance which requires an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in a classified statement of financial position. Under the amendments, an entity should classify all deferred tax liabilities and assets as noncurrent within the statement of financial position. The amendments apply to all entities that present a classified statem ent of financial position and are effective for public business entities for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted . In 2016, we intend to early adopt this amendment, which is not expected to have a material impact on our financial statements.

Summary Of Significant Accoun33

Summary Of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Summary Of Significant Accounting Policies [Abstract]
Schedule Of Estimated Useful Lives For Property And Equipment	Asset Classification Estimated Useful Life Land improvements 15 to 20 years Buildings and improvements 15 to 40 years Leasehold improvements Shorter of remaining lease term or useful life of improvements Machinery and equipment 3 to 8 years Office furniture and equipment 3 to 7 years Computer hardware and software 3 to 7 years
Schedule Of Estimated Useful Lives For Intangible Assets	Asset Classification Estimated Useful Life Patents 13 years Product rights (1) 5 to 15 years Customer-related intangible assets (2) 5 to 17 years Noncompete agreements 3 to 5 years (1) Product rights comprise certain technologies, intellectual property, licenses and trade names acquired from third parties. (2) Customer-related intangible assets comprise customer lists and customer relationships acquired from third parties.

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Share-Based Compensation [Abstract]
Schedule Of Selected Financial Impact Of Share-Based Compensation	For the Years Ended December 31, 2015 2014 2013 Share-based compensation expense included in cost of revenue $ 2,138 $ 1,937 $ 1,841 Share-based compensation expense included in operating expenses 17,746 16,162 14,733 Total share-based compensation expense included in consolidated statements of income 19,884 18,099 16,574 Income tax benefit resulting from share-based compensation arrangements (6,229 ) (6,107 ) (5,584 ) Net impact of share-based compensation on net income $ 13,655 $ 11,992 $ 10,990
Schedule Of Weighted Averages Of The Assumptions Used In Estimating The Fair Value Of Stock Option Awards	For the Years Ended December 31, 2015 2014 2013 Expected stock price volatility 23 % 28 % 32 % Expected term, in years 5.6 5.7 4.9 Risk-free interest rate 1.5 % 1.5 % 1.0 % Weighted average fair value of options granted $ 19.72 $ 18.07 $ 13.59
Schedule Of Stock Option Activity	Number of Options (000) Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value ($000) Outstanding as of December 31, 2014 3,560 $ 40.08 Granted 611 78.08 Exercised (675) 23.65 Forfeited (112) 53.64 Expired - Outstanding as of December 31, 2015 3,384 $ 49.76 4.8 $ 81,936 Fully vested as of December 31, 2015 1,748 $ 39.67 3.0 $ 58,132 Fully vested and expected to vest as of December 31, 2015 3,276 $ 49.41 4.7 $ 80,453
Schedule Of Restricted Stock Unit Activity	Number of Units (000) Weighted Average Grant-Date Fair Value Nonvested as of December 31, 2014 578 $ 47.98 Granted 153 78.46 Vested (196) 43.14 Forfeited (37) 56.01 Nonvested as of December 31, 2015 498 $ 58.94 Expected to vest as of December 31, 2015 456 $ 58.52

Marketable Securities (Tables)

Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2015
Marketable Securities [Abstract]
Amortized Cost And Fair Value Of Marketable Securities	As of December 31, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Corporate bonds $ 177,810 $ 24 $ (221) $ 177,613 U.S. government bonds 12,881 - (10) 12,871 Agency bonds 12,068 - (3) 12,065 Certificates of deposit 3,500 - - 3,500 Commercial paper 3,491 - - 3,491 International government bonds 1,462 - (3) 1,459 Municipal bonds 1,400 - (1) 1,399 Treasury bill 1,192 1 - 1,193 Total marketable securities $ 213,804 $ 25 $ (238) $ 213,591
Contractual Maturities Of Marketable Securities	As of December 31, 2015 Amortized Cost Fair Value Due in one year or less $ 147,735 $ 147,626 Due after one through two years 66,069 65,965 $ 213,804 $ 213,591

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2015
Inventories [Abstract]
Schedule Of Components Of Inventories	December 31, December 31, 2015 2014 Raw materials $ 31,184 $ 26,908 Work-in-process 18,698 16,859 Finished goods 138,951 116,575 Total inventories $ 188,833 $ 160,342

Property And Equipment, Net (Ta

Property And Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2015
Property And Equipment, Net [Abstract]
Schedule Of Property And Equipment	December 31, December 31, 2015 2014 Land and improvements $ 7,357 $ 7,417 Buildings and improvements 162,146 159,298 Leasehold improvements 40,526 45,655 Machinery and equipment 224,100 183,575 Office furniture and equipment 39,334 35,696 Computer hardware and software 169,615 151,404 Construction in progress 35,546 20,890 678,624 603,935 Less accumulated depreciation and amortization 345,598 300,348 Total property and equipment, net $ 333,026 $ 303,587

Other Current and Noncurrent 38

Other Current and Noncurrent Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Other Current and Noncurrent Assets [Abstract]
Schedule Of Other Current Assets	December 31, December 31, 2015 2014 Prepaid expenses $ 27,244 $ 32,672 Taxes receivable 11,792 28,926 Customer acquisition costs, net 16,412 11,262 Other assets 6,621 13,591 Total other current assets $ 62,069 $ 86,451
Schedule Of Other Noncurrent Assets	December 31, December 31, 2015 2014 Investment in long-term product supply arrangements $ 12,165 $ 10,765 Customer acquisition costs, net 43,570 28,165 Other assets 29,755 32,724 Total other long-term assets $ 85,490 $ 71,654

Goodwill And Intangible Asset39

Goodwill And Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets, Net [Abstract]
Schedule Of Intangible Assets Other Than Goodwill	December 31, 2015 December 31, 2014 Cost Accumulated Amortization Cost Accumulated Amortization Patents $ 2,192 $ 1,907 $ 4,871 $ 4,308 Product rights (1) 35,318 22,976 36,912 20,657 Customer-related intangible assets (2) 86,806 44,232 88,494 40,933 Noncompete agreements 1,413 705 1,125 382 $ 125,729 $ 69,820 $ 131,402 $ 66,280 (1) Product rights comprise certain technologies, licenses and trade names acquired from third parties. (2) Customer-related intangible assets are comprised of customer lists and customer relationships acquired from third parties.
Schedule Of Expected Amortization Expense	Amortization Expense 2016 $ 9,952 2017 9,144 2018 7,854 2019 6,541 2020 5,123 Thereafter 17,295 $ 55,909
Schedule Of Goodwill	CAG Water LPD Other Consolidated Total Balance as of December 31, 2012 $ 143,155 $ 14,179 $ 11,129 $ 6,531 $ 174,994 Business Combinations 250 - 6,491 - 6,741 Impact of Changes in Foreign Currency Exchange Rates (1,997) 336 447 - (1,214) Balance as of December 31, 2013 $ 141,408 $ 14,515 $ 18,067 $ 6,531 $ 180,521 Business Combinations 13,077 - - - 13,077 Impact of Changes in Foreign Currency Exchange Rates (6,334) (826) (1,988) - (9,148) Balance as of December 31, 2014 $ 148,151 $ 13,689 $ 16,079 $ 6,531 $ 184,450 Business Combinations 5,047 - - - 5,047 Impact of Changes in Foreign Currency Exchange Rates (8,007) (651) (1,905) - (10,563) Balance as of December 31, 2015 $ 145,191 $ 13,038 $ 14,174 $ 6,531 $ 178,934

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Accrued Liabilities [Abstract]
Schedule Of Accrued Liabilities	December 31, December 31, 2015 2014 Accrued expenses $ 65,665 $ 55,655 Accrued employee compensation and related expenses 77,027 75,232 Accrued taxes 18,963 28,439 Accrued customer programs 43,875 36,025 Total accrued liabilities $ 205,530 $ 195,351

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2015
Debt [Abstract]
Schedule Of Annual Principal Payments On Long-Term Debt	Years Ending December 31, Amount 2016 $ - 2017 - 2018 - 2019 - 2020 - Thereafter 597,085 $ 597,085

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Taxes [Abstract]
Schedule Of Earnings Before Income Taxes	For the Years Ended December 31, 2015 2014 2013 Domestic $ 187,200 $ 148,510 $ 184,086 International 85,941 98,045 79,175 $ 273,141 $ 246,555 $ 263,261
Schedule Of Components Of Provision (Benefit) For Income Taxes	For the Years Ended December 31, 2015 2014 2013 Current Federal $ 52,966 $ 39,713 $ 50,999 State 5,353 4,692 5,639 International 17,681 20,213 16,657 76,000 64,618 73,295 Deferred Federal 5,762 2,301 3,203 State 526 33 329 International (1,282) (2,348) (1,360) 5,006 (14) 2,172 $ 81,006 $ 64,604 $ 75,467
Schedule Of Effective Income Tax Rate Reconciliation	For the Years Ended December 31, 2015 2014 2013 U.S. federal statutory rate 35.0 % 35.0 % 35.0 % State income tax, net of federal tax benefit 1.6 1.5 1.5 International income taxes (5.3) (7.0) (4.6) Domestic manufacturing exclusions (1.5) (1.2) (1.4) Research and development credit (1.2) (1.3) (2.3) Other, net 1.1 (0.8) 0.5 Effective tax rate 29.7 % 26.2 % 28.7 %
Schedule Of Components Of Net Deferred Tax Assets And Liabilities	December 31, 2015 December 31, 2014 Current Long-Term Current Long-Term Assets Accrued expenses $ 23,298 $ 5,329 $ 20,377 $ 7,824 Accounts receivable reserves 2,973 - 2,591 - Deferred revenue 7,392 3,656 8,697 3,084 Inventory basis differences 3,292 293 3,154 347 Property-based differences - 1,524 - 1,601 Share-based compensation 2,565 10,580 2,490 8,936 Other 234 361 171 255 Net operating loss carryforwards 65 4,059 65 4,368 Unrealized losses on foreign currency exchange contracts, interest rate swaps and investments - 53 - - Total assets 39,819 25,855 37,545 26,415 Valuation allowance (507) (3,939) (457) (4,221) Total assets, net of valuation allowance 39,312 21,916 37,088 22,194 Liabilities Deferred instrument costs - (16,090) - (10,149) Property-based differences - (35,079) - (33,978) Intangible asset basis differences - (17,109) - (16,882) Other (550) (1,460) (610) (517) Unrealized gains on foreign currency exchange contracts, interest rate swaps and investments (882) - (2,603) - Total liabilities (1,432) (69,738) (3,213) (61,526) Net deferred tax assets (liabilities) $ 37,880 $ (47,822) $ 33,875 $ (39,332)
Schedule Of Changes In Unrecognized Tax Benefits	For the Years Ended December 31, 2015 2014 2013 Total amounts of unrecognized tax benefits, beginning of period $ 5,942 $ 6,325 $ 5,906 Gross increases in unrecognized tax benefits as a result of tax positions taken during a prior period 47 432 8 Gross increases in unrecognized tax benefits as a result of tax positions taken in the current period 1,569 1,789 1,954 Decreases in unrecognized tax benefits relating to settlements with taxing authorities - (2,242) (317) Decreases in unrecognized tax benefits as a result of a lapse of the applicable statutes of limitations (354) (362) (1,226) Total amounts of unrecognized tax benefits, end of period $ 7,204 $ 5,942 $ 6,325

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Schedule Of Reconciliation Of Shares Outstanding For Basic And Diluted Earnings Per Share	For the Years Ended December 31, 2015 2014 2013 Shares outstanding for basic earnings per share: 92,601 100,094 106,318 Shares outstanding for diluted earnings per share: Shares outstanding for basic earnings per share 92,601 100,094 106,318 Dilutive effect of share-based payment awards 1,048 1,409 1,652 93,649 101,503 107,970
Schedule Of Number Of Anti-Dilutive Stock Options	For the Years Ended December 31, 2015 2014 2013 Weighted average number of shares underlying anti-dilutive options 644 644 1,054

Commitments, Contingencies An44

Commitments, Contingencies And Guarantees (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments, Contingencies And Guarantees [Abstract]
Schedule Of Minimum Annual Rental Payments	Years Ending December 31, Amount 2016 $ 16,222 2017 14,005 2018 10,719 2019 7,321 2020 5,607 Thereafter 11,006 $ 64,880

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Summary Of Segment Performance	For the Years Ended December 31, CAG Water LPD Other Unallocated Amounts Consolidated Total 2015 Revenue $ 1,356,287 $ 96,884 $ 127,143 $ 21,578 $ - $ 1,601,892 Income (loss) from operations $ 231,642 $ 44,584 $ 24,397 $ 156 $ (867) $ 299,912 Interest expense, net (26,771) Income before provision for income taxes 273,141 Provision for income taxes 81,006 Net income 192,135 Less: Net income attributable to noncontrolling interest 57 Net income attributable to IDEXX Laboratories, Inc. stockholders $ 192,078 Depreciation and amortization $ 60,715 $ 3,188 $ 4,367 $ 686 $ - $ 68,956 Expenditures for long-lived assets (1) $ 69,371 $ 2,781 $ 9,110 $ 1,659 $ - $ 82,921 2014 Revenue $ 1,223,064 $ 94,725 $ 141,179 $ 26,839 $ - $ 1,485,807 Income (loss) from operations $ 203,536 $ 39,262 $ 33,788 $ 2,479 $ (18,810) $ 260,255 Interest expense, net (13,700) Income before provision for income taxes 246,555 Provision for income taxes 64,604 Net income 181,951 Less: Net income attributable to noncontrolling interest 45 Net income attributable to IDEXX Laboratories, Inc. stockholders $ 181,906 Depreciation and amortization $ 48,740 $ 2,553 $ 5,144 $ 2,451 $ - $ 58,888 Expenditures for long-lived assets (1) $ 49,270 $ 2,499 $ 4,025 $ 4,729 $ - $ 60,523 2013 Revenue $ 1,140,292 $ 87,959 $ 123,688 $ 25,119 $ - $ 1,377,058 Income (loss) from operations $ 212,558 $ 37,321 $ 20,246 $ 2,405 $ (5,768) $ 266,762 Interest expense, net (3,501) Income before provision for income taxes 263,261 Provision for income taxes 75,467 Net income 187,794 Less: Net loss attributable to noncontrolling interest (6) Net income attributable to IDEXX Laboratories, Inc. stockholders $ 187,800 Depreciation and amortization $ 45,079 $ 2,470 $ 4,906 $ 2,141 $ - $ 54,596 Expenditures for long-lived assets (1) $ 66,134 $ 3,254 $ 5,569 $ 2,655 $ - $ 77,612 __________ (1) Expenditures for long-lived assets exclude expenditures for intangible assets. See Note 3 for information regarding acquisitions of intangible assets during the years ended December 31, 2015, 2014 and 2013.
Summary Of Revenue By Product And Service Category	For the Years Ended December 31, 2015 2014 2013 CAG segment revenue: CAG Diagnostics recurring revenue: $ 1,146,527 $ 1,039,252 $ 964,009 VetLab consumables 396,526 341,407 312,457 VetLab service and accessories 55,176 53,006 50,675 Rapid assay products 182,670 165,647 169,547 Reference laboratory diagnostic and consulting services 512,155 479,192 431,330 CAG Diagnostics capital instruments 99,001 79,993 83,492 Customer information management and diagnostic imaging systems 110,759 103,819 92,791 CAG segment revenue 1,356,287 1,223,064 1,140,292 Water segment revenue 96,884 94,725 87,959 LPD segment revenue 127,143 141,179 123,688 Other segment revenue 21,578 26,839 25,119 Total revenue $ 1,601,892 $ 1,485,807 $ 1,377,058
Schedule Of Revenue By Principal Geographic Area	For the Years Ended December 31, 2015 2014 2013 Americas United States $ 980,281 $ 848,928 $ 802,345 Canada 69,303 69,743 69,947 Latin America 34,725 34,086 26,893 1,084,309 952,757 899,185 Europe, the Middle East and Africa Germany 73,395 85,189 78,109 United Kingdom 74,879 74,131 65,027 France 46,972 53,322 49,093 Italy 25,903 28,794 26,443 Spain 19,998 21,566 20,194 Switzerland 15,631 14,544 12,246 Netherlands 11,645 10,643 9,352 Other 79,910 78,201 66,221 348,333 366,390 326,685 Asia Pacific Region Australia 49,274 58,448 53,063 Japan 43,171 44,132 44,869 China 40,619 34,674 29,044 Other 36,186 29,406 24,212 169,250 166,660 151,188 Total $ 1,601,892 $ 1,485,807 $ 1,377,058
Schedule Of Net Long-Lived Assets By Principal Geographic Areas	December 31, December 31, 2015 2014 Americas United States $ 285,391 $ 262,475 Brazil 8,404 3,206 Canada 1,796 2,270 295,591 267,951 Europe, the Middle East and Africa United Kingdom 13,269 14,366 Germany 5,159 4,836 Netherlands 4,425 3,456 France 2,679 3,172 Switzerland 2,831 2,631 Other 2,047 1,674 30,410 30,135 Asia Pacific Region Japan 2,210 2,204 Australia 2,135 1,789 Other 2,680 1,508 7,025 5,501 Total $ 333,026 $ 303,587

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Measurements [Abstract]
Schedule Of Fair Value Of Assets And Liabilities Measured On Recurring Basis	Quoted Prices Significant in Active Other Significant Markets for Observable Unobservable Identical Assets Inputs Inputs Balance at As of December 31, 2015 (Level 1) (Level 2) (Level 3) December 31, 2015 Assets Money market funds (1) $ 15,490 $ - $ - $ 15,490 Agency bonds - 1,999 - 1,999 Commercial paper - 1,800 - 1,800 Marketable securities Corporate bonds - 177,613 - 177,613 U.S. government bonds - 12,871 - 12,871 Agency bonds - 12,065 - 12,065 Certificates of deposit - 3,500 - 3,500 Commercial paper - 3,491 - 3,491 International government bonds - 1,459 - 1,459 Municipal bonds - 1,399 - 1,399 Treasury bills - 1,193 - 1,193 Total marketable securities - 213,591 - 213,591 Equity mutual funds (2) 2,264 - - 2,264 Foreign currency exchange contracts (3) - 4,876 - 4,876 Liabilities Foreign currency exchange contracts (3) - 1,365 - 1,365 Deferred compensation (4) 2,264 - - 2,264 Interest rate swaps (5) - 384 - 384 Quoted Prices Significant in Active Other Significant Markets for Observable Unobservable Identical Assets Inputs Inputs Balance at As of December 31, 2014 (Level 1) (Level 2) (Level 3) December 31, 2014 Assets Money market funds (1) $ 204,743 $ - $ - $ 204,743 Equity mutual funds (2) 2,654 - - 2,654 Foreign currency exchange contracts (3) - 12,226 - 12,226 Liabilities Foreign currency exchange contracts (3) - 1,323 - 1,323 Deferred compensation (4) 2,654 - - 2,654 Interest rate swaps (5) - 1,117 - 1,117 __________ (1) Money market funds, agency bonds and commercial paper with an original maturity of less than ninety days are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of December 31, 2015 and December 31, 2014 consisted of demand deposits. Commercial paper with an original maturity of over ninety days is included within marketable securities. (2) Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other long-term assets, net. See number (4) below for a discussion of the related deferred compensation liability. (3) Foreign currency exchange contracts are included within other current assets, net; other long-term assets, net; accrued liabilities; or other long-term liabilities depending on the gain (loss) position and anticipated settlement date. (4) A deferred compensation plan assumed as part of a previous business combination is included within other long-term liabilities. The fair value of our deferred compensation plan is indexed to the performance of the underlying equity mutual funds discussed in number (2) above. (5) Interest rate swaps are included within accrued liabilities.

Hedging Instruments (Tables)

Hedging Instruments (Tables)	12 Months Ended
	Dec. 31, 2015
Derivative [Line Items]
Gain/(Loss) Recognized In Other Comprehensive Income On Derivative Instruments (Effective Portion)	Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion) For Year Ended December 31, Derivative instruments 2015 2014 2013 Foreign currency exchange contracts, net of tax $ (5,604) $ 7,098 $ 1,350 Interest rate swaps, net of tax 461 442 541 Total derivative instruments, net of tax $ (5,143) $ 7,540 $ 1,891
Assets [Member]
Derivative [Line Items]
Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments	Hedging Assets December 31, December 31, 2015 2014 Derivatives designated as hedging instruments Balance Sheet Classification Foreign currency exchange contracts Other current assets $ 4,876 $ 12,226 Gross amounts subject to master netting arrangements not offset on the balance sheet 1,268 1,323 Net amount $ 3,608 $ 10,903
Liabilities [Member]
Derivative [Line Items]
Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments	Hedging Liabilities December 31, December 31, 2015 2014 Derivatives designated as hedging instruments Balance Sheet Classification Foreign currency exchange contracts Accrued liabilities $ 1,365 $ 1,323 Interest rate swaps Accrued liabilities 384 1,117 Total derivative instruments presented as cash flow hedges on the balance sheet 1,749 2,440 Foreign currency borrowings designated as net investment hedge on the balance sheet Long-term debt 97,085 - Total hedging instruments presented on the balance sheet 98,834 2,440 Gross amounts subject to master netting arrangements not offset on the balance sheet 1,268 1,323 Net amount $ 97,566 $ 1,117

Repurchases Of Common Stock (Ta

Repurchases Of Common Stock (Tables)	12 Months Ended
	Dec. 31, 2015
Repurchases Of Common Stock [Abstract]
Schedule Of Common Stock Repurchases	For the Years Ended December 31, 2015 2014 2013 Share repurchases during the period (1) 5,659 9,761 7,903 Shares acquired through employee surrender (1) 69 92 99 Total shares repurchased (1) 5,728 9,853 8,002 Cost of share repurchases during the period $ 406,430 $ 618,158 $ 367,762 Cost of employee surrenders 5,457 5,809 4,548 Total cost of shares repurchased $ 411,887 $ 623,967 $ 372,310 Average cost per share $ 71.90 $ 63.32 $ 46.53 (1) Shares repurchased and acquired through employee surrender for payment of minimum required withholding taxes on and before June 15, 2015 and the associated average cost per share have been adjusted to reflect the June 2015 two-for-one stock split. Actual shares repurchased were approximately 4,313,000 , 4,927,000 and 4,001,000 for the years ended December 31, 2015, 2014, and 2013, respectively.

Accumulated Other Comprehensi49

Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2015
Accumulated Other Comprehensive Income [Abstract]
Schedule Of Accumulated Other Comprehensive Income	Unrealized gain (loss) on investments, net of tax Unrealized gain (loss) on derivatives instruments, net of tax Unrealized gain on net investment hedge, net of tax Cumulative translation adjustment Total Balance as of December 31, 2013 $ 108 $ (179) $ - $ 13,693 $ 13,622 Other comprehensive income (loss) before reclassifications (107) 9,542 - (29,126) (19,691) Gains reclassified from accumulated other comprehensive income - (2,002) - - (2,002) Balance as of December 31, 2014 1 7,361 - (15,433) (8,071) Other comprehensive income (loss) before reclassifications (226) 8,839 1,894 (30,718) (20,211) Gains reclassified from accumulated other comprehensive income - (13,983) - - (13,983) Balance as of December 31, 2015 $ (225) $ 2,217 $ 1,894 $ (46,151) $ (42,265)
Summary Of Reclassifications Out Of Accumulated Other Comprehensive Income	Amounts Reclassified from Accumulated Other Affected Line Item in the Comprehensive Income Details about Accumulated Other Statement Where For the Years Ended December 31, Comprehensive Income Components Net Income in Presented 2015 2014 2013 Gains (losses) on derivative instruments included in net income: Foreign currency exchange contracts Cost of revenue $ 20,878 $ 3,822 $ 3,469 Interest rate swaps Interest expense (1,042) (1,064) (900) Total gains before tax 19,836 2,758 2,569 Tax expense 5,853 756 679 Gains, net of tax $ 13,983 $ 2,002 $ 1,890

Summary Of Quarterly Data (Tabl

Summary Of Quarterly Data (Tables)	12 Months Ended
	Dec. 31, 2015
Summary Of Quarterly Data [Abstract]
Schedule Of Quarterly Data	For the Three Months Ended March 31, June 30, September 30, December 31, 2015 Revenue $ 382,477 $ 413,343 $ 406,387 $ 399,685 Gross profit 215,544 232,757 224,274 217,695 Operating income 72,803 88,303 71,895 66,911 Net income attributable to IDEXX Laboratories, Inc. stockholders 46,594 56,912 44,223 44,349 Earnings per share: Basic $ 0.49 $ 0.61 $ 0.48 $ 0.49 Diluted $ 0.49 $ 0.60 $ 0.48 $ 0.48 2014 Revenue $ 360,203 $ 390,122 $ 383,523 $ 351,959 Gross profit 202,097 218,518 213,336 182,165 Operating income 70,046 83,219 72,189 34,801 Net income attributable to IDEXX Laboratories, Inc. stockholders 46,585 57,218 52,142 25,961 Earnings per share: Basic $ 0.45 $ 0.56 $ 0.52 $ 0.27 Diluted $ 0.45 $ 0.55 $ 0.52 $ 0.27 (1) Amounts presented may not recalculate to full-year totals due to rounding.

Nature Of Business, Basis Of 51

Nature Of Business, Basis Of Presentation And Principles Of Consolidation (Details)	12 Months Ended
	Dec. 31, 2015
Nature Of Business, Basis Of Presentation And Principles Of Consolidation [Abstract]
Stock split	2

Summary Of Significant Accoun52

Summary Of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies [Abstract]
Restricted cash	$ 0	$ 0
Goodwill impairments	$ 0	0	$ 0
Revenue recognition, multiple-deliverable arrangements, years	one to six years
Advertising costs	$ 1,200		1,500
Foreign currency transaction losses	(200)	(2,000)	$ (100)
Fair value of long-term debt	593,700	367,300
Carrying value of long-term debt	$ 597,085	$ 350,000

Summary Of Significant Accoun53

Summary Of Significant Accounting Policies (Schedule Of Estimated Useful Lives For Property And Equipment) (Details)	12 Months Ended
	Dec. 31, 2015
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	Shorter of remaining lease term or useful life of improvements
Maximum [Member] | Land Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	20
Maximum [Member] | Building And Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	40
Maximum [Member] | Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	8
Maximum [Member] | Office Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7
Maximum [Member] | Computer Hardware And Software [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7
Minimum [Member] | Land Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	15
Minimum [Member] | Building And Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	15
Minimum [Member] | Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3
Minimum [Member] | Office Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3
Minimum [Member] | Computer Hardware And Software [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3

Summary Of Significant Accoun54

Summary Of Significant Accounting Policies (Schedule Of Estimated Useful Lives For Intangible Assets) (Details)	12 Months Ended
	Dec. 31, 2015
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Estimated Useful Life	13 years
Maximum [Member] | Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Estimated Useful Life	15 years	[1]
Maximum [Member] | Customer-Related Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Estimated Useful Life	17 years	[2]
Maximum [Member] | Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Estimated Useful Life	5 years
Minimum [Member] | Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Estimated Useful Life	5 years	[1]
Minimum [Member] | Customer-Related Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Estimated Useful Life	5 years	[2]
Minimum [Member] | Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Estimated Useful Life	3 years
[1]	Product rights comprise certain technologies, intellectual property, licenses and trade names acquired from third parties.Customer-related intangible assets comprise customer lists and customer relationships acquired from third parties.
[2]	Customer-related intangible assets comprise customer lists and customer relationships acquired from third parties.

Acquisitions And Disposition 55

Acquisitions And Disposition Of Strategic Investment (Details) $ in Thousands	1 Months Ended	12 Months Ended
	Jun. 30, 2014USD ($)	Dec. 31, 2015USD ($)entity	Dec. 31, 2014USD ($)item	Dec. 31, 2013USD ($)
Acquisitions And Strategic Investments [Line Items]
Acquisition of a business, net of cash acquired		$ 10,302	$ 25,115	$ 10,923
Number of businesses acquired | item			7
Business Combinations, goodwill		$ 5,047	$ 13,077	6,741
Proceeds from sale of equity investment			(5,400)
Reference Laboratory Diagnostic And Consulting Businesses [Member]
Acquisitions And Strategic Investments [Line Items]
Number of businesses acquired | entity		2
Contingent consideration		$ 3,200
Business Combinations, goodwill		5,000
Cash payments to acquire businesses		7,500
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets		1,100
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		300
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent		$ 900
Cloud-based Veterinary Practice Software Businesses [Member]
Acquisitions And Strategic Investments [Line Items]
Acquisition of a business, net of cash acquired			$ 18,700
Number of businesses acquired | item			3
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			$ 11,700
Business Combinations, goodwill			$ 12,400
Weighted average useful lives of amortizable intangible assets			11 years 4 months 24 days
Amortizable intangible assets deductible for income tax purposes			$ 5,600
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability			$ 4,200
Assets Of Cloud-based Veterinary Practice Software Businesses [Member]
Acquisitions And Strategic Investments [Line Items]
Number of businesses acquired | item			2
Cloud-based Veterinary Practice Software Businesses, Foreign [Member]
Acquisitions And Strategic Investments [Line Items]
Number of businesses acquired | item			2
Veterinary Reference Laboratory Testing Businesses [Member]
Acquisitions And Strategic Investments [Line Items]
Acquisition of a business, net of cash acquired			$ 6,200
Number of businesses acquired | item			2
Weighted average useful lives of amortizable intangible assets			13 years 3 months 18 days
Amortizable intangible assets deductible for income tax purposes			$ 4,900
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability			$ 1,500
Assets Of Veterinary Reference Laboratory Testing Businesses [Member]
Acquisitions And Strategic Investments [Line Items]
Number of businesses acquired | item			2
Company That Owns And Operates Veterinary Hospitals [Member]
Acquisitions And Strategic Investments [Line Items]
Proceeds from sale of equity investment	$ 5,400
Equity method investment, ownership percentage	11.00%
Gain on sale of equity investment	$ 700
Distributor Of Bovine And Dairy Test Products And Other Food Safety Testing Products [Member]
Acquisitions And Strategic Investments [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill				$ 4,800
Weighted average useful lives of amortizable intangible assets				9 years 10 months 24 days
Cash payments to acquire businesses				$ 10,800
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents				700
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets				1,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment				500
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets				2,100
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent				1,700
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability				$ 3,100
Computer Software, Intangible Asset [Member] | Cloud-based Veterinary Practice Software Businesses [Member]
Acquisitions And Strategic Investments [Line Items]
Weighted average useful lives of amortizable intangible assets			7 years
Customer Lists [Member] | Reference Laboratory Diagnostic And Consulting Businesses [Member]
Acquisitions And Strategic Investments [Line Items]
Useful life assigned to intangible asset, years		15 years
Intangibles acquired as result of business combination		$ 5,200
Customer Lists [Member] | Cloud-based Veterinary Practice Software Businesses [Member]
Acquisitions And Strategic Investments [Line Items]
Weighted average useful lives of amortizable intangible assets			16 years 4 months 24 days
Customer Lists [Member] | Distributor Of Bovine And Dairy Test Products And Other Food Safety Testing Products [Member]
Acquisitions And Strategic Investments [Line Items]
Useful life assigned to intangible asset, years				10 years
Noncompete Agreements [Member] | Distributor Of Bovine And Dairy Test Products And Other Food Safety Testing Products [Member]
Acquisitions And Strategic Investments [Line Items]
Useful life assigned to intangible asset, years				5 years
Trademarks [Member] | Distributor Of Bovine And Dairy Test Products And Other Food Safety Testing Products [Member]
Acquisitions And Strategic Investments [Line Items]
Useful life assigned to intangible asset, years				15 years

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensation awards outstanding	$ 37.8
Weighted average recognition period for unrecognized compensation expense, in years	1 year 7 months 6 days
Intrinsic value of stock options exercised	$ 35.1	$ 51.2	$ 49
Number of unissued shares of common stock each DSU represents right to receive	$ 1
Fair value of options vested during period	$ 8.7	$ 7.8	$ 8.4
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years	7 years
2009 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for grant under share-based incentive plans	19,900,000
Shares available for grant under share-based incentive plans	12,538,049
1997 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for grant under share-based incentive plans	4,700,000
Shares available for grant under share-based incentive plans	1,393,760
Common stock issued in connection with the Employee Stock Purchase Plan	105,000	93,000	110,000
Discount from market value for employee stock purchase rights	15.00%
Stock Options Granted To Non-Employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Restricted Stock Units Granted To Employees With Ratable Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years
Restricted Stock Units Granted To Non-Employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of unvested share-based awards to vest upon change in control	25%
Fair value of awards vested during period	$ 15.3	$ 15.4	$ 12.7
Stock Options And Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ratio of shares issued under share-based awards to shares authorized under stock plans	1 to 1
Awards Other Than Stock Options And Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ratio of shares issued under share-based awards to shares authorized under stock plans	2 to 1
Stock Options Granted To Employees With Ratable Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of unvested share-based awards to vest upon change in control	25%

Share-Based Compensation (Sched

Share-Based Compensation (Schedule Of Selected Financial Impact Of Share-Based Compensation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Income tax benefit resulting from share-based compensation arrangements	$ (6,229)	$ (6,107)	$ (5,584)
Net impact of share-based compensation on net income	13,655	11,992	10,990
Cost Of Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	2,138	1,937	1,841
Operating Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	17,746	16,162	14,733
Total Share-Based Compensation Expense Included In Consolidated Statements Of Income [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 19,884	$ 18,099	$ 16,574

Share-Based Compensation (Sch58

Share-Based Compensation (Schedule Of Weighted Averages Of The Assumptions Used In Estimating The Fair Value Of Stock Option Awards) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-Based Compensation [Abstract]
Expected stock price volatility	23.00%	28.00%	32.00%
Expected term, in years	5 years 7 months 6 days	5 years 8 months 12 days	4 years 10 months 24 days
Risk-free interest rate	1.50%	1.50%	1.00%
Weighted average fair value of options granted	$ 19.72	$ 18.07	$ 13.59

Share-Based Compensation (Sch59

Share-Based Compensation (Schedule Of Stock Option Activity) (Details) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Share-Based Compensation [Abstract]
Outstanding as of December 31, 2014 | shares	3,560
Granted | shares	611
Exercised | shares	(675)
Forfeited | shares	(112)
Outstanding as of December 31, 2015 | shares	3,384
Fully vested as of December 31, 2015 | shares	1,748
Fully vested and expected to vest as of December 31, 2015 | shares	3,276
Weighted average exercise price of beginning balance of options outstanding | $ / shares	$ 40.08
Weighted average exercise price of options granted | $ / shares	78.08
Weighted average exercise price of options exercised | $ / shares	23.65
Weighted average exercise price of options forfeited | $ / shares	53.64
Weighted average exercise price of ending balance of options outstanding | $ / shares	49.76
Weighted average exercise price of options fully vested | $ / shares	39.67
Weighted average exercise price of options fully vested and expected to vest | $ / shares	$ 49.41
Weighted average remaining contractual term of ending balance of options outstanding	4 years 9 months 18 days
Weighted average remaining contractual term of options fully vested	3 years
Weighted average remaining contractual term of options fully vested and expected to vest	4 years 8 months 12 days
Aggregate Intrinsic Value | $	$ 81,936
Aggregate intrinsic value of options fully vested | $	58,132
Aggregate intrinsic value of options expected to vest | $	$ 80,453

Share-Based Compensation (Sch60

Share-Based Compensation (Schedule Of Restricted Stock Unit Activity) (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs Outstanding as of December 31, 2014 | shares	578
Granted | shares	153
Vested | shares	(196)
Forfeited | shares	(37)
RSUs Outstanding as of December 31, 2015 | shares	498
Weighted Average Grant-Date Fair Value of Beginning Balance of Outstanding Awards as of December 31, 2014 | $ / shares	$ 47.98
Weighted Average Grant-Date Fair Value, Granted | $ / shares	78.46
Weighted Average Grant-Date Fair Value of Awards Vested | $ / shares	43.14
Weighted Average Grant-Date Fair Value of Awards Forfeited | $ / shares	56.01
Weighted Average Grant-Date Fair Value of Ending Balance of Outstanding Awards as of December 31, 2015 | $ / shares	$ 58.94
Restricted Stock Units Expected To Vest, Reduced For Estimated Forfeitures [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs Outstanding as of December 31, 2015 | shares	456
Weighted Average Grant-Date Fair Value of Ending Balance of Outstanding Awards as of December 31, 2015 | $ / shares	$ 58.52

Marketable Securities (Amortize

Marketable Securities (Amortized Cost And Fair Value Of Marketable Securities) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 213,804
Gross Unrealized Gains	25
Gross Unrealized Losses	(238)
Fair Value	213,591
Marketable securities have been in a continuous unrealized loss position for more than twelve months	0
Marketable securities that we consider to be other-than-temporarily impaired	0
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	177,810
Gross Unrealized Gains	24
Gross Unrealized Losses	(221)
Fair Value	177,613
U S Government Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	12,881
Gross Unrealized Losses	(10)
Fair Value	12,871
Agency Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	12,068
Gross Unrealized Losses	(3)
Fair Value	12,065
Certificates Of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	3,500
Fair Value	3,500
Markerable Securities - Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	3,491
Fair Value	3,491
International Government Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,462
Gross Unrealized Losses	(3)
Fair Value	1,459
Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,400
Gross Unrealized Losses	(1)
Fair Value	1,399
Treasury Bills [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,192
Gross Unrealized Gains	1
Fair Value	$ 1,193

Marketable Securities (Contract

Marketable Securities (Contractual Maturities Of Marketable Securities) (Details) $ in Thousands	Dec. 31, 2015USD ($)
Marketable Securities [Abstract]
Due in one year or less, Amortized Cost	$ 147,735
Due after one through two years, Amortized Cost	66,069
Total marketable securities, Amortized Cost	213,804
Due in one year or less, Fair Value	147,626
Due after one through two years, Fair Value	65,965
Total marketable securities, Fair Value	$ 213,591

Inventories (Schedule Of Compon

Inventories (Schedule Of Components Of Inventories) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventories [Abstract]
Raw materials	$ 31,184	$ 26,908
Work-in-process	18,698	16,859
Finished goods	138,951	116,575
Total inventories	$ 188,833	$ 160,342

Property And Equipment, Net (Na

Property And Equipment, Net (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense of property and equipment	$ 57,000	$ 48,800	$ 42,800
Impairment charge	8,212
Unpaid property and equipment purchases reflected within accounts payable and accrued liabilities of our consolidated balance sheets	8,500	6,500	2,200
Software Developed For Internal Use [Member]
Property, Plant and Equipment [Line Items]
Current year additions	$ 19,100	$ 11,900	$ 10,900

Property And Equipment, Net (Sc

Property And Equipment, Net (Schedule Of Property And Equipment) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Gross amount	$ 678,624	$ 603,935
Less accumulated depreciation and amortization	345,598	300,348
Total property and equipment, net	333,026	303,587
Land And Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross amount	7,357	7,417
Building And Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross amount	162,146	159,298
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross amount	40,526	45,655
Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross amount	224,100	183,575
Office Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross amount	39,334	35,696
Computer Hardware And Software [Member]
Property, Plant and Equipment [Line Items]
Gross amount	169,615	151,404
Construction In Progress [Member]
Property, Plant and Equipment [Line Items]
Gross amount	$ 35,546	$ 20,890

Other Current and Noncurrent 66

Other Current and Noncurrent Assets (Schedule Of Other Current Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Other Current and Noncurrent Assets [Abstract]
Prepaid expenses	$ 27,244	$ 32,672
Taxes receivable	11,792	28,926
Customer acquisition costs, net	16,412	11,262
Other assets	6,621	13,591
Total other current assets	$ 62,069	$ 86,451

Other Current and Noncurrent 67

Other Current and Noncurrent Assets (Schedule Of Other Noncurrent Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Other Current and Noncurrent Assets [Abstract]
Investment in long-term product supply arrangements	$ 12,165	$ 10,765
Customer acquisition costs, net	43,570	28,165
Other assets	29,755	32,724
Total other long-term assets, net	$ 85,490	$ 71,654

Goodwil And Intangible Assets,

Goodwil And Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Goodwill and Intangible Assets, Net [Abstract]
Aggregate amortization expense	$ 10.4	$ 9.8	$ 9.7

Goodwill And Intangible Asset69

Goodwill And Intangible Assets, Net (Schedule Of Intangible Assets Other Than Goodwill) (Details) - USD ($) $ in Thousands		Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Cost		$ 125,729	$ 131,402
Accumulated Amortization		69,820	66,280
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Cost		2,192	4,871
Accumulated Amortization		1,907	4,308
Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	[1]	35,318	36,912
Accumulated Amortization	[1]	22,976	20,657
Customer-Related Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	[2]	86,806	88,494
Accumulated Amortization	[2]	44,232	40,933
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Cost		1,413	1,125
Accumulated Amortization		$ 705	$ 382
[1]	Product rights comprise certain technologies, intellectual property, licenses and trade names acquired from third parties.Customer-related intangible assets comprise customer lists and customer relationships acquired from third parties.
[2]	Customer-related intangible assets comprise customer lists and customer relationships acquired from third parties.

Goodwill And Intangible Asset70

Goodwill And Intangible Assets, Net (Schedule Of Expected Amortization Expense) (Details) $ in Thousands	Dec. 31, 2015USD ($)
Goodwill and Intangible Assets, Net [Abstract]
2,016	$ 9,952
2,017	9,144
2,018	7,854
2,019	6,541
2,020	5,123
Thereafter	17,295
Total estimated amortization expense to be incurred after December 31, 2015	$ 55,909

Goodwill And Intangible Asset71

Goodwill And Intangible Assets, Net (Schedule Of Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segments Of Goodwill [Line Items]
Beginning balance	$ 184,450	$ 180,521	$ 174,994
Business Combinations	5,047	13,077	6,741
Impact of Changes in Foreign Currency Exchange Rates	(10,563)	(9,148)	(1,214)
Ending balance	178,934	184,450	180,521
CAG [Member]
Segments Of Goodwill [Line Items]
Beginning balance	148,151	141,408	143,155
Business Combinations	5,047	13,077	250
Impact of Changes in Foreign Currency Exchange Rates	(8,007)	(6,334)	(1,997)
Ending balance	145,191	148,151	141,408
Water Segment [Member]
Segments Of Goodwill [Line Items]
Beginning balance	13,689	14,515	14,179
Impact of Changes in Foreign Currency Exchange Rates	(651)	(826)	336
Ending balance	13,038	13,689	14,515
LPD [Member]
Segments Of Goodwill [Line Items]
Beginning balance	16,079	18,067	11,129
Business Combinations			6,491
Impact of Changes in Foreign Currency Exchange Rates	(1,905)	(1,988)	447
Ending balance	14,174	16,079	18,067
Other Segment [Member]
Segments Of Goodwill [Line Items]
Beginning balance	6,531	6,531	6,531
Ending balance	$ 6,531	$ 6,531	$ 6,531

Accrued Liabilities (Schedule O

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accrued Liabilities [Abstract]
Accrued expenses	$ 65,665	$ 55,655
Accrued employee compensation and related expenses	77,027	75,232
Accrued taxes	18,963	28,439
Accrued customer programs	43,875	36,025
Total accrued liabilities	$ 205,530	$ 195,351

Debt (Narrative) (Details)

Debt (Narrative) (Details) € in Millions	1 Months Ended	12 Months Ended
	Dec. 31, 2014USD ($)	Dec. 31, 2015EUR (€)	Dec. 31, 2015USD ($)	Sep. 30, 2014USD ($)	Jul. 31, 2014USD ($)	Dec. 31, 2013USD ($)	May. 09, 2013USD ($)	Jul. 26, 2011USD ($)
Line of Credit Facility [Line Items]
Outstanding Credit Facility balance	$ 549,000,000		$ 573,000,000
Credit Facility borrowings hedged			80,000,000
Consolidated Leverage Ratio Under Credit Facility & Note Payable, maximum		3.50%
Long-term Debt			597,085,000
Fair value of mortgage at inception	367,300,000		593,700,000
Maximum [Member]
Line of Credit Facility [Line Items]
Commitment fees		0.25%
Minimum [Member]
Line of Credit Facility [Line Items]
Commitment fees		0.075%
Senior Notes [Member]
Line of Credit Facility [Line Items]
Consolidated Leverage Ratio Under Credit Facility & Note Payable, maximum		3.50%
Notes Payable	150,000,000			$ 75,000,000	$ 125,000,000
Debt Instrument, Interest Rate, Stated Percentage				3.72%
Series A Senior Note [Member]
Line of Credit Facility [Line Items]
Notes Payable	$ 75,000,000				$ 50,000,000
Debt Instrument, Interest Rate, Stated Percentage	3.25%				3.32%	3.94%
Debt Instrument, Term	7 years
Series B Senior Note [Member]
Line of Credit Facility [Line Items]
Notes Payable	$ 75,000,000				$ 75,000,000	$ 75,000,000
Debt Instrument, Interest Rate, Stated Percentage	3.72%				3.76%	4.04%
Debt Instrument, Term	12 years
Series C Senior Note [Member]
Line of Credit Facility [Line Items]
Notes Payable		€ 88.9	$ 100,000,000
Debt Instrument, Interest Rate, Stated Percentage		1.785%	1.785%
Shelf Notes [Member]
Line of Credit Facility [Line Items]
Notes Payable			$ 75,000,000
Debt Instrument, Term		12 years
Outdated Unsecured Short Term Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Borrowing capacity								$ 700,000,000
Amended And Restated Unsecured Short Term Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Borrowing capacity							$ 850,000,000
Credit Facility maturity date		Dec. 4, 2020
Outstanding Credit Facility balance	$ 549,000,000		$ 573,000,000
Credit Facility weighted average interest rates on outstanding balance	1.50%	1.90%	1.90%
Reduction of Credit Facility Availability	$ 1,000,000		$ 1,000,000
Minimum Credit Spread On LIBOR Or CDOR Borrowings [Member]
Line of Credit Facility [Line Items]
Credit spread during period		0.875%
Maximum Credit Spread On LIBOR Or CDOR Borrowings [Member]
Line of Credit Facility [Line Items]
Credit spread during period		1.375%
Maximum Credit Spread On Prime Rate Borrowings [Member]
Line of Credit Facility [Line Items]
Credit spread during period		0.375%
Uncommitted Shelf Facility [Member]
Line of Credit Facility [Line Items]
Notes Payable	$ 50,000,000
Uncommitted Shelf Facility [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Term	15 years

Debt (Schedule Of Annual Princi

Debt (Schedule Of Annual Principal Payments On Long-Term Debt) (Details) $ in Thousands	Dec. 31, 2015USD ($)
Debt [Abstract]
Thereafter	$ 597,085
Annual Principal Payments on Long-Term Debt, Total	$ 597,085

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Effective Tax Rate	29.70%	26.20%	28.70%
Income tax ruling exemption	$ 8,500	$ 8,500	$ 6,500
Cumulative earnings of non-United States subsidiaries considered to be indefinitely invested outside of United States	493,300
Unrecognized tax benefits	7,204	5,942	6,325	$ 5,906
Unrecognized tax benefits that would impact effective tax rate if recognized	5,900	5,000
Interest expense and penalties related to unrecognized tax benefits	300	300	$ 300
Interest expense and penalties accrued	600	$ 500
Net operating loss carryforwards in certain state and international jurisdictions	31,500
Valuation allowance against certain deferred tax assets related to net operating loss carryforwards	$ 4,400
Tax years no longer subject to U.S. federal examination [Member]
Years before	2,013
With few exceptions, tax years no longer subject to state or local and international jurisdicition examination [Member]
Years before	2,007
Switzerland [Member]
Expiration date for tax holidays	December 31, 2015
Netherlands [Member]
Expiration date for tax holidays	December 31, 2022

Income Taxes (Schedule Of Earni

Income Taxes (Schedule Of Earnings Before Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Abstract]
Domestic	$ 187,200	$ 148,510	$ 184,086
International	85,941	98,045	79,175
Income before provision for income taxes	$ 273,141	$ 246,555	$ 263,261

Income Taxes (Schedule Of Compo

Income Taxes (Schedule Of Components Of Provision (Benefit) For Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Provision Benefit For Income Taxes [Line Items]
Provision (benefit) for deferred income taxes	$ 5,143	$ 830	$ 2,073
Provision for income taxes	81,006	64,604	75,467
Current [Member]
Provision Benefit For Income Taxes [Line Items]
Federal	52,966	39,713	50,999
State	5,353	4,692	5,639
International	17,681	20,213	16,657
Provision for current income taxes	76,000	64,618	73,295
Deferred [Member]
Provision Benefit For Income Taxes [Line Items]
Federal	5,762	2,301	3,203
State	526	33	329
International	(1,282)	(2,348)	(1,360)
Provision (benefit) for deferred income taxes	$ 5,006	$ (14)	$ 2,172

Income Taxes (Schedule Of Effec

Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Abstract]
U.S. federal statutory rate	35.00%	35.00%	35.00%
State income tax, net of federal tax benefit	1.60%	1.50%	1.50%
International income taxes	(5.30%)	(7.00%)	(4.60%)
Domestic manufacturing exclusions	(1.50%)	(1.20%)	(1.40%)
Research and development credit	(1.20%)	(1.30%)	(2.30%)
Other, net	1.10%	(0.80%)	0.50%
Effective tax rate	29.70%	26.20%	28.70%

Income Taxes (Schedule Of Com79

Income Taxes (Schedule Of Components Of Net Deferred Tax Assets And Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current [Member]
Assets:
Accrued expenses	$ 23,298	$ 20,377
Accounts receivable reserves	2,973	2,591
Deferred revenue	7,392	8,697
Inventory basis differences	3,292	3,154
Share-based compensation	2,565	2,490
Other	234	171
Net operating loss carryforwards	65	65
Total assets	39,819	37,545
Valuation allowance	(507)	(457)
Total assets, net of valuation allowance	39,312	37,088
Liabilities:
Other	(550)	(610)
Unrealized gains on foreign currency exchange contracts, interest rate swaps and investments	(882)	(2,603)
Total liabilities	(1,432)	(3,213)
Net deferred tax assets	37,880	33,875
Long-Term [Member]
Assets:
Accrued expenses	5,329	7,824
Deferred revenue	3,656	3,084
Inventory basis differences	293	347
Property-based differences	1,524	1,601
Share-based compensation	10,580	8,936
Other	361	255
Net operating loss carryforwards	4,059	4,368
Unrealized losses on foreign currency exchange contracts, interest rate swaps and investments	53
Total assets	25,855	26,415
Valuation allowance	(3,939)	(4,221)
Total assets, net of valuation allowance	21,916	22,194
Liabilities:
Deferred instrument costs	(16,090)	(10,149)
Property-based differences	(35,079)	(33,978)
Intangible assst basis differences	(17,109)	(16,882)
Other	(1,460)	(517)
Total liabilities	(69,738)	(61,526)
Net deferred tax (liabilities)	$ (47,822)	$ (39,332)

Income Taxes (Schedule Of Chang

Income Taxes (Schedule Of Changes In Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Abstract]
Total amounts of unrecognized tax benefits, beginning of period	$ 5,942	$ 6,325	$ 5,906
Gross increases in unrecognized tax benefits as a result of tax positions taken during a prior period	47	432	8
Gross increases in unrecognized tax benefits as a result of tax positions taken in the current period	1,569	1,789	1,954
Decreases in unrecognized tax benefits relating to settlements with taxing authorities		(2,242)	(317)
Decreases in unrecognized tax benefits as a result of a lapse of the applicable statutes of limitations	(354)	(362)	(1,226)
Total amounts of unrecognized tax benefits, end of period	$ 7,204	$ 5,942	$ 6,325

Earnings Per Share (Schedule Of

Earnings Per Share (Schedule Of Reconciliation Of Shares Outstanding For Basic And Diluted Earnings Per Share) (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Shares outstanding for basic earnings per share	92,601	100,094	106,318
Dilutive effect of share-based payment awards	1,048	1,409	1,652
Shares outstanding for diluted earnings per share	93,649	101,503	107,970

Earnings Per Share (Schedule 82

Earnings Per Share (Schedule Of Number Of Anti-Dilutive Stock Options) (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Weighted average number of shares underlying anti-dilutive options	644	644	1,054

Commitments, Contingencies An83

Commitments, Contingencies And Guarantees (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Payment Required Upon Termination Of Employment [Line Items]
Rent expense charged to operations	$ 20,500,000	$ 17,200,000	$ 15,800,000
Minimum royalty payments due through 2027	3,100,000
Contingent commitments, not accrued	5,500,000
Business Combination, Contingent Consideration, Liability	5,900,000	6,300,000
Total contingent liabilities	11,400,000
Purchase Obligation	15,200,000
Loss contingency, range of possible loss, maximum	3,500,000	2,300,000	2,000,000
Liabilities for indemnification obligations	0	0
Other Liabilities	1,400,000	2,500,000
Outstanding letters of credit to insurance company as security for workers' compensation claims	$ 1,300,000
Period for continued vesting of outstanding equity awards upon termination of CEO without cause other than following a change in control, years	two years
Payment Required To CEO Upon Termination Of Employment Without Cause Other Than Following Change In Control [Member]
Payment Required Upon Termination Of Employment [Line Items]
Employee agreement contingencies	$ 1,600,000
Payment Required To Officers Upon Termination Of Employment Following Change Of Control [Member]
Payment Required Upon Termination Of Employment [Line Items]
Employee agreement contingencies	26,400,000
Workers Compensation Insurance Policies [Member]
Payment Required Upon Termination Of Employment [Line Items]
Retained claim liability per incident	300,000	300,000	250,000
Employee Health Care Insurance Policy [Member]
Payment Required Upon Termination Of Employment [Line Items]
Retained claim liability per incident	425,000	375,000	325,000
General insurance expense	34,600,000	32,000,000	$ 29,200,000
Self Insurance Reserve	$ 4,800,000	$ 4,100,000

Commitments, Contingencies An84

Commitments, Contingencies And Guarantees (Schedule Of Minimum Annual Rental Payments) (Details) $ in Thousands	Dec. 31, 2015USD ($)
Commitments, Contingencies And Guarantees [Abstract]
2,016	$ 16,222
2,017	14,005
2,018	10,719
2,019	7,321
2,020	5,607
Thereafter	11,006
Total minimum annual rental payments	$ 64,880

Segment Reporting (Summary Of S

Segment Reporting (Summary Of Segment Performance) (Details) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2014USD ($)	Jun. 30, 2014USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2015USD ($)segment	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Segment Reporting Information [Line Items]
Number of business segments | segment									3
Revenue	$ 399,685	$ 406,387	$ 413,343	$ 382,477	$ 351,959	$ 383,523	$ 390,122	$ 360,203	$ 1,601,892	$ 1,485,807	$ 1,377,058
Income (loss) from operations	66,911	71,895	88,303	72,803	34,801	72,189	83,219	70,046	299,912	260,255	266,762
Interest expense, net									(26,771)	(13,700)	(3,501)
Income before provision for income taxes									273,141	246,555	263,261
Provision for income taxes									81,006	64,604	75,467
Net income									192,135	181,951	187,794
Less: Net income (loss) attributable to noncontrolling interest									57	45	(6)
Net income attributable to IDEXX Laboratories, Inc. stockholders	$ 44,349	$ 44,223	$ 56,912	$ 46,594	$ 25,961	$ 52,142	$ 57,218	$ 46,585	192,078	181,906	187,800
Depreciation and amortization									68,956	58,888	54,596
Expenditures for long-lived assets									82,921	60,523	77,612
CAG/LPD Segment Transition [Member]
Segment Reporting Information [Line Items]
Revenue										13,800	9,900
CAG Segment [Member]
Segment Reporting Information [Line Items]
Revenue									1,356,287	1,223,064	1,140,292
Income (loss) from operations									231,642	203,536	212,558
Depreciation and amortization									60,715	48,740	45,079
Expenditures for long-lived assets									69,371	49,270	66,134
Water Segment [Member]
Segment Reporting Information [Line Items]
Revenue									96,884	94,725	87,959
Income (loss) from operations									44,584	39,262	37,321
Depreciation and amortization									3,188	2,553	2,470
Expenditures for long-lived assets									2,781	2,499	3,254
LPD Segment [Member]
Segment Reporting Information [Line Items]
Revenue									127,143	141,179	123,688
Income (loss) from operations									24,397	33,788	20,246
Depreciation and amortization									4,367	5,144	4,906
Expenditures for long-lived assets									9,110	4,025	5,569
Other Segment [Member]
Segment Reporting Information [Line Items]
Revenue									21,578	26,839	25,119
Income (loss) from operations									156	2,479	2,405
Depreciation and amortization									686	2,451	2,141
Expenditures for long-lived assets									1,659	4,729	2,655
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Income (loss) from operations									$ (867)	$ (18,810)	$ (5,768)

Segment Reporting (Summary Of R

Segment Reporting (Summary Of Revenue By Product And Service Category) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Revenue	$ 399,685	$ 406,387	$ 413,343	$ 382,477	$ 351,959	$ 383,523	$ 390,122	$ 360,203	$ 1,601,892	$ 1,485,807	$ 1,377,058
CAG Segment [Member]
Segment Reporting Information [Line Items]
Revenue									1,356,287	1,223,064	1,140,292
CAG Segment [Member] | CAG Diagnostics Recurring Revenue [Member]
Segment Reporting Information [Line Items]
Revenue									1,146,527	1,039,252	964,009
CAG Segment [Member] | Vetlab Consumables [Member]
Segment Reporting Information [Line Items]
Revenue									396,526	341,407	312,457
CAG Segment [Member] | VetLab Service and Accessories [Member]
Segment Reporting Information [Line Items]
Revenue									55,176	53,006	50,675
CAG Segment [Member] | Rapid Assay Products [Member]
Segment Reporting Information [Line Items]
Revenue									182,670	165,647	169,547
CAG Segment [Member] | Reference Laboratory Diagnostic And Consulting Services [Member]
Segment Reporting Information [Line Items]
Revenue									512,155	479,192	431,330
CAG Segment [Member] | CAG Diagnostic Capital - Instruments [Member]
Segment Reporting Information [Line Items]
Revenue									99,001	79,993	83,492
CAG Segment [Member] | Customer Information Managment and Diagnostic Imaging Systems [Member]
Segment Reporting Information [Line Items]
Revenue									110,759	103,819	92,791
Water Segment [Member]
Segment Reporting Information [Line Items]
Revenue									96,884	94,725	87,959
LPD Segment [Member]
Segment Reporting Information [Line Items]
Revenue									127,143	141,179	123,688
Other Segment [Member]
Segment Reporting Information [Line Items]
Revenue									$ 21,578	$ 26,839	$ 25,119

Segment Reporting (Schedule Of

Segment Reporting (Schedule Of Revenue By Principal Geographic Area) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 399,685	$ 406,387	$ 413,343	$ 382,477	$ 351,959	$ 383,523	$ 390,122	$ 360,203	$ 1,601,892	$ 1,485,807	$ 1,377,058
Americas [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									1,084,309	952,757	899,185
Americas [Member] | United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									980,281	848,928	802,345
Americas [Member] | Canada [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									69,303	69,743	69,947
Americas [Member] | Latin America [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									34,725	34,086	26,893
Europe, The Middle East And Africa [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									348,333	366,390	326,685
Europe, The Middle East And Africa [Member] | Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									73,395	85,189	78,109
Europe, The Middle East And Africa [Member] | United Kingdom [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									74,879	74,131	65,027
Europe, The Middle East And Africa [Member] | France [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									46,972	53,322	49,093
Europe, The Middle East And Africa [Member] | Italy [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									25,903	28,794	26,443
Europe, The Middle East And Africa [Member] | Spain [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									19,998	21,566	20,194
Europe, The Middle East And Africa [Member] | Switzerland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									15,631	14,544	12,246
Europe, The Middle East And Africa [Member] | Netherlands [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									11,645	10,643	9,352
Europe, The Middle East And Africa [Member] | Other Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									79,910	78,201	66,221
Asia Pacific Region [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									169,250	166,660	151,188
Asia Pacific Region [Member] | Australia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									49,274	58,448	53,063
Asia Pacific Region [Member] | Japan [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									43,171	44,132	44,869
Asia Pacific Region [Member] | China [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									40,619	34,674	29,044
Asia Pacific Region [Member] | Other Asia Pacific [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									$ 36,186	$ 29,406	$ 24,212

Segment Reporting (Schedule O88

Segment Reporting (Schedule Of Net Long-Lived Assets By Principal Geographic Areas) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Assets	$ 333,026	$ 303,587
Americas [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Assets	295,591	267,951
Americas [Member] | United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Assets	285,391	262,475
Americas [Member] | Brazil [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Assets	8,404	3,206
Americas [Member] | Canada [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Assets	1,796	2,270
Europe, The Middle East And Africa [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Assets	30,410	30,135
Europe, The Middle East And Africa [Member] | United Kingdom [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Assets	13,269	14,366
Europe, The Middle East And Africa [Member] | Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Assets	5,159	4,836
Europe, The Middle East And Africa [Member] | Netherlands [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Assets	4,425	3,456
Europe, The Middle East And Africa [Member] | France [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Assets	2,679	3,172
Europe, The Middle East And Africa [Member] | Switzerland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Assets	2,831	2,631
Europe, The Middle East And Africa [Member] | Other Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Assets	2,047	1,674
Asia Pacific Region [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Assets	7,025	5,501
Asia Pacific Region [Member] | Japan [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Assets	2,210	2,204
Asia Pacific Region [Member] | Australia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Assets	2,135	1,789
Asia Pacific Region [Member] | Other Asia Pacific [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Assets	$ 2,680	$ 1,508

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule Of Fair Value Of Assets And Liabilities Measured On Recurring Basis) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	$ 213,591
Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	12,065
Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	177,613
U S Government Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	12,871
Certificates Of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	3,500
Markerable Securities - Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	3,491
International Government Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	1,459
Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	1,399
Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	1,193
Measured At Fair Value On Recurring Basis [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	213,591
Measured At Fair Value On Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	213,591
Measured At Fair Value On Recurring Basis [Member] | Equity Mutual Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,264	$ 2,654
Measured At Fair Value On Recurring Basis [Member] | Equity Mutual Funds [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,264	2,654
Measured At Fair Value On Recurring Basis [Member] | Foreign Currency Exchange Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	4,876	12,226
Fair value of Liabilities	1,365	1,323
Measured At Fair Value On Recurring Basis [Member] | Foreign Currency Exchange Contracts [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	4,876	12,226
Fair value of Liabilities	1,365	1,323
Measured At Fair Value On Recurring Basis [Member] | Deferred Compensation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Liabilities	2,264	2,654
Measured At Fair Value On Recurring Basis [Member] | Deferred Compensation [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Liabilities	2,264	2,654
Measured At Fair Value On Recurring Basis [Member] | Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Liabilities	384	1,117
Measured At Fair Value On Recurring Basis [Member] | Interest Rate Swaps [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Liabilities	384	1,117
Measured At Fair Value On Recurring Basis [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	15,490	204,743
Measured At Fair Value On Recurring Basis [Member] | Money Market Funds [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	15,490	$ 204,743
Measured At Fair Value On Recurring Basis [Member] | Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	1,999
Measured At Fair Value On Recurring Basis [Member] | Agency Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	1,999
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	1,800
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	1,800
Measured At Fair Value On Recurring Basis [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	177,613
Measured At Fair Value On Recurring Basis [Member] | Corporate Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	177,613
Measured At Fair Value On Recurring Basis [Member] | U S Government Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	12,871
Measured At Fair Value On Recurring Basis [Member] | U S Government Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	12,871
Measured At Fair Value On Recurring Basis [Member] | Marketable Securities Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	12,065
Measured At Fair Value On Recurring Basis [Member] | Marketable Securities Agency Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	12,065
Measured At Fair Value On Recurring Basis [Member] | Certificates Of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	3,500
Measured At Fair Value On Recurring Basis [Member] | Certificates Of Deposit [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	3,500
Measured At Fair Value On Recurring Basis [Member] | Markerable Securities - Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	3,491
Measured At Fair Value On Recurring Basis [Member] | Markerable Securities - Commercial Paper [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	3,491
Measured At Fair Value On Recurring Basis [Member] | International Government Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	1,459
Measured At Fair Value On Recurring Basis [Member] | International Government Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	1,459
Measured At Fair Value On Recurring Basis [Member] | Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	1,399
Measured At Fair Value On Recurring Basis [Member] | Municipal Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	1,399
Measured At Fair Value On Recurring Basis [Member] | Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	1,193
Measured At Fair Value On Recurring Basis [Member] | Treasury Bills [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	$ 1,193

Hedging Instruments (Narrative)

Hedging Instruments (Narrative) (Details) $ in Thousands, € in Millions	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2015EUR (€)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Derivative [Line Items]
Estimated net amount of gains expected to be reclassified out of accumulated other comprehensive income and into earnings within next 12 months	$ 2,300
Discussion of Foreign Currency Derivative Risk Management Policy	We hedge approximately 85% of the estimated exposure
Cash Flow Hedge, hedge percentage of Eetimated exposure from intercompany products purchases and sales	85.00%
General duration of foreign currency exchange contracts	24 months
Credit Facility borrowings hedged			$ 80,000
Notional Amount of Foreign Currency Exchange Contracts			176,100	$ 186,700
Unrealized gain on net investment hedge	$ 1,894
Series C Senior Note [Member]
Derivative [Line Items]
Notes Payable		€ 88.9	$ 100,000
Stated interest rate		1.785%	1.785%
Interest Rate Swap Effective On March 30, 2012 [Member]
Derivative [Line Items]
Fixed portion of interest rate associated with interest rate swap		1.36%	1.36%
Credit Facility borrowings hedged			$ 40,000
Interest Rate Swap Effective On March 28, 2013 [Member]
Derivative [Line Items]
Fixed portion of interest rate associated with interest rate swap		1.64%	1.64%
Credit Facility borrowings hedged			$ 40,000

Hedging Instruments (Schedule O

Hedging Instruments (Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments) (Details) - Derivatives Designated As Hedging Instruments [Member] - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Derivatives, Fair Value [Line Items]
Hedging Assets, Gross amounts subject to master netting arrangements not offset on the balance sheet	$ 1,268	$ 1,323
Hedging Assets, Net amount	3,608	10,903
Hedging Liabilities, Total hedging instruments presented on the balance sheet	98,834	2,440
Hedging Liabilities, Gross amounts subject to master netting arrangements not offset on the balance sheet	1,268	1,323
Hedging Liabilities, Net amount	97,566	1,117
Cash Flow Hedges [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	1,749	2,440
Foreign Currency Exchange Contracts [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Hedging Assets, Total derivative instruments presented as cash flow hedges on the balance sheet	4,876	12,226
Foreign Currency Exchange Contracts [Member] | Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	1,365	1,323
Interest Rate Swaps [Member] | Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	384	$ 1,117
Foreign Currency Borrowings Designated As Net Investment Hedge On The Balance Sheet [Member] | Long-term Debt [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	$ 97,085

Hedging Instruments (Gain (Loss

Hedging Instruments (Gain (Loss) Recognized In Other Comprehensive Income On Derivative Instruments (Effective Portion)) (Details) - Cash Flow Hedges [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in OCI on Derivative Instruments (Effective Portion), Net of Tax	$ (5,143)	$ 7,540	$ 1,891
Foreign Currency Exchange Contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in OCI on Derivative Instruments (Effective Portion), Net of Tax	(5,604)	7,098	1,350
Interest Rate Swaps [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in OCI on Derivative Instruments (Effective Portion), Net of Tax	$ 461	$ 442	$ 541

Repurchases Of Common Stock (De

Repurchases Of Common Stock (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares
Shares of common stock repurchases authorized	65,000,000
Remaining shares available for repurchase under authorization	6,806,152
Share repurchases during the period	5,659,000	9,761,000	7,903,000
Shares acquired through employee surrenders	69,000	92,000	99,000
Total shares repurchased	5,728,000	9,853,000	8,002,000
Cost of share repurchases during the period | $	$ 406,430	$ 618,158	$ 367,762
Cost of employee surrenders | $	5,457	5,809	4,548
Total cost of shares repurchased | $	$ 411,887	$ 623,967	$ 372,310
Average cost per share | $ / shares	$ 71.90	$ 63.32	$ 46.53
Stock split	2
Treasury Stock [Member]
Total shares repurchased	4,313,000	4,927,000	4,001,000

Accumulated Other Comprehensi94

Accumulated Other Comprehensive Income (Schedule Of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accumulated Other Comprehensive Income [Abstract]
Beginning balance, Unrealized Gain (Loss) on Investments, Net of Tax	$ 1	$ 108
Beginning balance, Unrealized Gain (Loss) on Derivative Instruments, Net of Tax	7,361	(179)
Beginning balance, Cumulative Translation Adjustment	(15,433)	13,693
Other comprehensive income (loss) before reclassifications, Unrealized Gain (Loss) on Investments, Net of Tax	(226)	(107)	$ 279
Other comprehensive income (loss) before reclassifications, Unrealized Gain (Loss) on Derivative Instruments, Net of Tax	8,839	9,542	3,781
Other comprehensive income (loss) before reclassifications, Unrealized Gain On Net Investment Hedge, Net Of Tax	1,894
Other comprehensive income (loss) before reclassifications, Cumulative Translation Adjustment	(30,718)	(29,126)	(4,502)
Gains reclassified from accumulated other comprehensive income, Unrealized Gain (Loss) on Derivative Instruments, Net of Tax	(13,983)	(2,002)	(1,890)
Ending balance, Unrealized Gain (Loss) on Investments, Net of Tax	(225)	1	108
Ending balance, Unrealized Gain (Loss) on Derivative Instruments, Net of Tax	2,217	7,361	(179)
Ending balance, Unrealized Gain On Net Investment Hedge, Net Of Tax	1,894
Ending balance, Cumulative Translation Adjustment	(46,151)	(15,433)	13,693
Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning Balance	(8,071)	13,622
Accumulated Other Comprehensive Income, before Tax	(20,211)	(19,691)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(13,983)	(2,002)
Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending Balance	$ (42,265)	$ (8,071)	$ 13,622

Accumulated Other Comprehensi95

Accumulated Other Comprehensive Income (Schedule of Reclassifications out of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Provision for income taxes	$ 81,006	$ 64,604	$ 75,467
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	13,983	2,002
Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	19,836	2,758	2,569
Provision for income taxes	5,853	756	679
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	13,983	2,002	1,890
Interest Rate Swaps [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	(1,042)	(1,064)	(900)
Foreign Currency Exchange Contracts [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	$ 20,878	$ 3,822	$ 3,469

Preferred Stock (Details)

Preferred Stock (Details)	Dec. 31, 2015$ / sharesshares
Preferred Stock [Abstract]
Shares of preferred stock authorized	500,000
Par value per share | $ / shares	$ 1
Preferred Stock outstanding	0

IDEXX Retirement And Incentiv97

IDEXX Retirement And Incentive Savings Plan (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
401(k) Plan [Member]
Retirement And Incentive Savings Plan [Line Items]
Contribution match, maximum percent of participants' eligible compensation	4.00%
Employer contributions	$ 11.5	$ 8.8	$ 7.8
Discretionary contributions	0	0	0
European And Canadian Based Defined Contribution Plan [Member]
Retirement And Incentive Savings Plan [Line Items]
Employer contributions	$ 3.5	$ 3.7	$ 3.1

Summary Of Quarterly Data (Deta

Summary Of Quarterly Data (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Summary Of Quarterly Data [Abstract]
Revenue	$ 399,685	$ 406,387	$ 413,343	$ 382,477	$ 351,959	$ 383,523	$ 390,122	$ 360,203	$ 1,601,892	$ 1,485,807	$ 1,377,058
Gross profit	217,695	224,274	232,757	215,544	182,165	213,336	218,518	202,097	890,270	816,116	756,118
Operating income	66,911	71,895	88,303	72,803	34,801	72,189	83,219	70,046	299,912	260,255	266,762
Net income attributable to stockholders	$ 44,349	$ 44,223	$ 56,912	$ 46,594	$ 25,961	$ 52,142	$ 57,218	$ 46,585	$ 192,078	$ 181,906	$ 187,800
Earnings per Share:
Basic	$ 0.49	$ 0.48	$ 0.61	$ 0.49	$ 0.27	$ 0.52	$ 0.56	$ 0.45	$ 2.07	$ 1.82	$ 1.77
Diluted	$ 0.48	$ 0.48	$ 0.60	$ 0.49	$ 0.27	$ 0.52	$ 0.55	$ 0.45	$ 2.05	$ 1.79	$ 1.74

Valuation And Qualifying Acco99

Valuation And Qualifying Accounts (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Reserves For Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year		$ 4,306	$ 3,533	$ 2,632
Charges to Costs and Expenses		2,200	2,035	1,601
Write-Offs/Cash Payments		(817)	(1,146)	(762)
Foreign Currency Translation		(561)	(116)	62
Balance at End of Year		5,128	4,306	3,533
Valuation Allowance For Deferred Tax [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year		4,678	5,201	4,547
Charges to Costs and Expenses		634	799	735
Charges to Other Accounts	[1]			742
Write-Offs/Cash Payments		(468)	(1,042)	(701)
Foreign Currency Translation		(398)	(280)	(122)
Balance at End of Year		$ 4,446	$ 4,678	$ 5,201
[1]	Amount relates to net operating losses obtained through acquisitions where uncertainty exists as to our ability to use the tax attribute.